

INFORMAZIONI PERSONALI

DELIA GOLETTI

 Via Portuense 292, Roma 00149, Italy (LAVORO)

 +39 0655170906;

 delia.goletti@inmi.it

Sesso F | Nazionalità ITALIANA | Coniugata, 2 figli

POSIZIONE RICOPERTA

Dirigente medico II Livello, Direttrice della Unità Operativa Complessa di Ricerca Traslazionale dal 01/02/2024

Principali mansioni e responsabilità

Da Febbraio 2024

Dirigente medico II Livello - Direttrice UOC Ricerca Traslazionale

Da Giugno 1999

Dirigente medico I Livello - Responsabile UOSD Ricerca Traslazionale

Dirigente medico infettivologo Day Service della Divisione di Malattie Infettive dell'Apparato Respiratorio (MIAR), Istituto Nazionale per le Malattie Infettive L. Spallanzani I.R.C.C.S. – Roma

Principali mansioni e responsabilità

1. Coordinamento dell'attività di ricerca sulla risposta immunologica a *M. tuberculosis*, *Echinococco granulosus* e SARS-CoV-2.
2. Attività clinica presso L'ambulatorio presa in carico della UOC di malattie infettive dell'apparato respiratorio di cui il responsabile è il primario dr Fabrizio Palmieri.

Da Novembre 1996 a Maggio 1999

Medico contrattista (Primo Ricercatore) Istituto di Virologia (Resp.le Dr. B. Ensoli)

Istituto Superiore di Sanità - Roma

Attività di ricerca sul ruolo dell'HHV-8 nello sviluppo del Sarcoma di Kaposi, sull'uso di "tat" come approccio vaccinale per l'infezione da SHIV nel modello dei primati

Settembre 1992 a settembre 1996

Visiting Associate

Laboratory of Immunoregulation (LIR) - National Institute of Allergy and Infectious Diseases (NIAID) presso i National Institutes of Health (NIH) di Bethesda, Maryland USA (responsabile dott. A. S. Fauci)

Attività di ricerca nel campo della regolazione delle citochine e chemiochine nell'infezione da HIV. Studio dell'interazione immunologica e virologica tra *M. tuberculosis* e HIV

ESPERIENZA PROFESSIONALE

ISTRUZIONE E FORMAZIONE
1994-1997

Specializzazione in Malattie Infettive
Università Cattolica del Sacro Cuore (UCSC) di Roma
votazione di 70/70 e lode

1991-1994

Dottorato in Infettivologia
Università Cattolica del Sacro Cuore (UCSC) di Roma
Votazione : Ottimo

1984-1990

Laurea in Medicina e Chirurgia
Università Cattolica del Sacro Cuore (UCSC) di Roma
Votazione di 110/110 con lode

Lingua madre	ITALIANA				
Altre lingue	COMPRENSIONE		PARLATO		PRODUZIONE SCRITTA
	Ascolto	Lettura	Interazione	Produzione orale	
INGLESE	C2	C2	C2	C2	C2
FRANCESE	C1	C1	C1	C1	C1
SPAGNOLO	A2	A2	A2	A2	A1

Livelli: A1/2 Livello base - B1/2 Livello intermedio - C1/2 Livello avanzato
Quadro Comune Europeo di Riferimento delle Lingue

INTERVISTE TELEVISIVE

2017: Medicina 33. Giornalista: Laura Berti, trasmissione andata in onda: 29 novembre.

2018: Medicina 33. Giornalista: Laura Berti, trasmissione andata in onda: 27 novembre. Replica il 21 febbraio, 2019.

INTERNATIONAL WEBINAR

Management of TB infection in HIV co-infected patients, WEBINAR sponsored by QIAGEN, July 3rd, 2018

**INSEGNAMENTO
UNIVERSITARIO**

Visiting Professor in the Centre for Immunobiology within the Blizard Institute, Queen Mary University of London has been approved (September 2019-ongoing)

Professore di Patologia Generale a contratto presso la Facoltà di Medicina di UniCamillus, Università Medica Internazionale dal 2019 al 2022.

Lezione presso l'Università Cattolica del Sacro Cuore su "Biomarkers in infectious diseases", 7 maggio 2020.

Competenze organizzative e gestionali

Direttrice dell'Unità Operativa Complessa di Ricerca Traslazionale che si occupa principalmente dello studio della risposta immunologica a *M. tuberculosis*, *Echinococcus granulosus* e SARS-CoV-2. L'incarico è dal 01/02/2024.

Collaborazione con World Health Organization (WHO) e European Respiratory Society (ERS) per la stesura del documento programmatico sull'eliminazione della tubercolosi nei paesi a bassa endemia di tubercolosi: Framework for tuberculosis elimination in low incidence countries – adaptation of the post-2015 global TB strategy

Partecipazione come esperto sulla tubercolosi al meeting organizzato dal Global Tuberculosis Programme (GTB) of the World Health Organization (WHO) e dallo Scientific Development Group for Target Product Profiles (TPP) for Test for Tuberculosis Treatment Monitoring and Optimisation (27-29 March 2023) and the Scientific Development Group for Target Regimen Profiles (TRP) for Tuberculosis Treatment (29-31 March 2023), Istanbul, Turkey, 2023

Collaborazione con eCDC per la revisione del documento : Framework Action Plan to Fight Tuberculosis in the European Union: Gaps and Options analysis

Presidente del gruppo di MICOBATTERIOLOGIA (ESGMYC) dell'ESCMID (dal 2017 al 2022)

Presidente del gruppo regionale europeo dell'Union against Tuberculosis and Lung Diseases (dal 2025)

Vice presidente del gruppo regionale europeo dell'Union against Tuberculosis and Lung Diseases (dal 2021)

Secretary del gruppo regionale europeo dell'Union against Tuberculosis and Lung Diseases (dal 2017)

Secretary del gruppo di Advocay della tubercolosi dell'European Respiratory Society (Società Europea delle Malattie Respiratorie) (2014-2018)

Ex-Membro dello Steering Committee del TBNET (settore diagnostico) che è una rete europea di ricercatori clinici e di base sulla tubercolosi in Europa (novembre 2006-Settembre 2012)

Secretary dell'European Respiratory Society (Società Europea delle Malattie Respiratorie) per l'Assembly 10 (Malattie Infettive Respiratorie, sottogruppo "Tubercolosi") (2012-2015)

Membro dello Steering Committee di "GABRIEL (Global Approach for Biological Research on Infectious Epidemics in Low income countries)", network della Fondation Mérieux per lo studio delle Malattie Infettive e Tropicali nei Paesi in Via di Sviluppo (da dicembre 2010)

Esperienza di conduzione di trail in India, Africa ed in Europa (attraverso il TBNET) per la valutazione di test sperimentali per la diagnosi di infezione tubercolare latente

Collaborazione con il Dr Fabrizio Palmieri [primario del reparto di Malattie Infettive dell'apparato respiratorio dell'INMI (MIAR)] per la cura dei pazienti con tubercolosi nell'ambulatorio presa in carico del MIAR

Abilitazione universitaria

Abilitazione a Professore Ordinario e professore Associato per:

1. Malattie Infettive (aprile 2017) : 06/D4-MED/35 MALATTIE CUTANEE, MALATTIE INFETTIVE E MALATTIE DELL'APPARATO DIGERENTE
2. Patologia generale (gennaio 2017): 06/A2-MED/02.

Premi/riconoscimenti

"Premio Arnaldo Curcio Editore", Roma 10 ottobre 2025

"Premio Polimnia 2025", Settore Ricerca Scientifica, Cortona 16 maggio, 2025

"Premio semplicemente donna 2023", Castiglion Fiorentino, 25 novembre 2023

"She made a difference 2021" da parte della associazione "European Women's Development Menagement " al Senato della Repubblica italiana, 19 novembre, 2021

"Top Italian Women Scientist", dal 2019

"Excellence in contributions to research, education and clinical leadership in respiratory medicine at the European Respiratory Society", 2006

"Certificate of excellence for the work done at the Laboratory of Immune regulation" from Anthony Fauci, National Institute dor Infectious Diseases, National Institute of Health, 1996

FERS. The Fellow of the European Respiratory Society (ERS) title, 2016.

Consulenze Svolge attività di consulenza con varie aziende nazionali ed internazionali per lo sviluppo di nuovi test diagnostici e per la formazione nell'ambito della malattie infettive (Astrazeneca, Amgen, Beckman Coulter, Biogen, Biomerieux, Celgene, Danaher, Diasorin, Janssen, PBD, Qiagen, Quidel,).

Membro di Board Scientifici Internazionali Membro del Scientific Advisory Board of Deutsches Zentrum für Infektionsforschung (DZIF) <https://www.dzif.de/en> per l'argomento tubercolosi

Membro di società scientifiche ERS, ESCMID, SIMIT, UNION against tuberculosis and lung diseases.

Referee per tesi di dottorato internazionali:

1. **Dominique Justin Pepper thesis for a PHD at the University of Cape Town, South Africa, Faculty of Health Science** of on "Clinical deterioration during antituberculosis treatment in a high HIV-1 prevalence setting", April 2010.
2. **Alicia Lacoma, thesis for a PHD at the University of Barcelona, Spain.** Thesis on "Biomarkers for the management of the respiratory diseases", May 20th, 2011.
3. **Marc Oliver Tebruegge thesis for a PHD at the Department of Paediatrics, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Australia.** Thesis on "Novel approaches for the immune diagnosis of childhood tuberculosis", September, 2012.
4. **Malika Davids thesis for a PHD at the University of Cape Town, South Africa,** on "Immunological studies in patients with extensively drug resistant tuberculosis", November 2012.
5. **Anil Pooran, thesis for a PHD at the University of Cape Town, South Africa,** on "The role of IL-4 and Th2-like cytokines in pulmonary tuberculosis, July 2015
6. **Jonathan Hoffman, thesis for a PHD at the Ecole Normale Supérieure de Lyon, France,** on "Etude translationnelle sur les interactions hôte-pathogène : étiologie des infections respiratoires aiguës et impact des co-infections sur la modulation de la réponse immunitaire innée", Lyon, France, October 10th, 2015
7. **Ida Wergeland, thesis for PhD, at the Department of Clinical Science, Faculty of Medicine and Dentistry, University of Bergen, Norway** on "Immune cells and soluble immune markers in different stages of tuberculosis. Potential biomarkers for diagnosis and treatment efficacy", Bergen, Norway, March 30th, 2017
8. **Emilie Wahren Borgström thesis for a PhD, at the Karolinska Institute, Stockholm, Sweden** entitled "Evaluation of immunological markers for the diagnosis of active and latent tuberculosis", Stockholm, January 25th, 2019
9. **Raquel Villar Hernández, thesis for a PhD for Universitat Autònoma de Barcelona,** entitled "Towards a better diagnosis of mycobacterial infections. IGRAs and beyond", Badalona, Spain, December 13th, 2019.
10. **Melissa Davidsen Jørstad for a PhD University of Bergen, Norway** entitled: "Diagnosis and management of extrapulmonary tuberculosis in low-resource settings, a study from Zanzibar, Tanzania", January 11, 2021. Webinar
11. **Cheleka Anne-Marie Mpande,** PhD University of Cape Town, Department of Pathology Faculty of Health Sciences, South Africa. "Characterisation of T cell specificity, functional, activation and memory profiles associated with QuantiFERON TB Gold conversion and reversion. Thesis Presented for the Degree of DOCTOR OF PHILOSOPHY in the Department of Pathology Faculty of Health Sciences, UNIVERSITY OF CAPE TOWN.
12. **Fregenet Tesfaye,** PhD: "Immunology aspect of latent tuberculosis infection during pregnancy", Thesis Presented for the Degree of DOCTOR OF PHILOSOPHY in the Department of Pathology Faculty of Health Sciences, UNIVERSITY OF Lund, Sweden, webinar February 15th, 2022.
13. **Jonathan Uzorka,** PhD. "Diagnosis of tuberculosis infection before immunosuppression: from better use of existing tools to better tools", webinar October 6th, 2022.
14. **Rolanda Sabrina Londt,** Development of an Autologous Human Dendritic Cell Vaccine against Mycobacterium tuberculosis in Patients with Extensively Drug-Resistant Tuberculosis, Department of Medicine, Faculty of Health Science, University of Cape Town, thesis dissertation reviewed on July 2022
15. **Kristin Grotle Nore, MD,** "The Eicosanoid system – effects on pathogenesis and potential as targets for host directed therapy in tuberculosis", Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, & Department of Infectious Diseases, Oslo University Hospital, thesis dissertation reviewed and opponent on May 27, 2023 in remote
16. **Komal Umashankat Rao,** PhD, Antimicrobial peptide therapy for tuberculosis infection, Faculty of Medicine, Lund University, Svezia, in remote

- Pubblicazioni** Autrice **di piu di 400 articoli pubblicati** su riviste internazionali indicizzate sullo studio delle modificazioni immunologiche in corso di infezioni da tubercolosi, HIV-1, HHV-8, HCV, Echinococcosi cistica, COVID-19. <https://pubmed.ncbi.nlm.nih.gov/?term=GOLETTI+D&sort=date&size=100>
- Progetti** Finanziamenti in corso per ricerca su COVID-19, tubercolosi, echinococchi
- Conferenze** Esperta a livello internazionale sull'argomento della diagnosi immunologica della tubercolosi sul quale ha pubblicato 231 articoli e su COVID-19 su cui ha pubblicato 69 articoli. Invitata in numerosi paesi a tenere seminari sull'argomento: in Austria, Brasile, Bulgaria, Francia, Germania, Giappone, Gran Bretagna, India, Iran, Laos, Mali, Romania, Russia, Svezia, Stati Uniti, Singapore, Svizzera, Tanzania
- Riconoscimenti e citazioni** **TOP ITALIAN SCIENTIST (H index>30) Inserita nella lista da gennaio 2014**
http://www.topitalianscientists.org/top_italian_scientists.aspx
TOP ITALIAN WOMEN SCIENTIST (H index>50): Inserita nella lista nel 2019
Citation Index: H-index 92 (Google Scholar), 80 (Scopus), 82 (Web of Science)
- Brevetto** **Brevetto europeo:** European patent N. 1723426 on T-cell assay based on selected RD1 peptides
- Academic Editor:** PLOS ONE, PloS Neglected Tropical Diseases, BMC Infectious Diseases, Journal of Infection, ISRN Pulmonology, Translational Medicine, Peer J, Dataset International, Dataset Papers in Medicine, Autoimmune Diseases and Therapeutic Approaches, Frontiers in Immunology, International Journal of Infectious Diseases.
- AD HOC REVIEWER**
American Journal Of Critical Care Medicine, Archives of Medical Research, BMC Infectious Diseases, Cell Death and Differentiation, Clinical and Infectious Diseases, Clinical Experimental Immunology, Diseases Markers, Drugs, Emerging Infectious Diseases, European Respiratory Journal, European Journal of Clinical Microbiology & Infectious Diseases, Expert Review of Molecular Diagnostics, Infection, International Journal of Antimicrobial Agents, International Journal of Infectious Diseases, Journal of Infections, Journal of Laboratory Clinical Medicine, Journal of Immunological Methods, Journal of Infectious Diseases, Journal of Tuberculosis and Lung Diseases, Infectious Diseases, Lancet, Lancet ID, NEJM, Lancet Infectious Diseases, Molecular Diagnostics, Open Journal of Infectious Diseases, Lancet, PloS Medicine, PLoS ONE, PLoS Pathogen, Plos Medicine, Respiratory Medicine, Reviews in Infections, Scandinavian Journal of Rheumatology, Scandinavian Journal of Immunology, Scandinavian Journal of Infectious Diseases, The Pediatric Journal Of Infectious Diseases, Trends in Microbiology, Tuberculosis, Tuberculosis Research and Treatment

Presentazioni a meeting nazionali ed internazionali

1. Tuberculosis in the era of biological and targeted immunomodulatory therapies, iCube Università Federico II Napoli, July 6, 2026
2. New drugs and old infections. Prophylaxis and vaccination in immunocompromised patients. GISEA/OEG International Symposium, TRANI 2026 • May 20th - 21st - 22nd, 2026
3. Tuberculosis and Immunodepression (anti-TNF therapy). ESOR special focus on tuberculosis, April 14th, 2026, remotely
4. Biomarkers for tuberculosis infection, TB day 2026. Rome, March 11, 2026
5. Biomarkers for tuberculosis infection: From the host to the pathogen, Workshop on Innovations in Tuberculosis 2025: research perspectives for Europe, WHO UN Copenhagen, Denmark, May 22, 2025
6. Il contributo della terapia diretta dall'ospite (HDT) nel trattamento della tubercolosi, AMCLI, 52 congresso, national meeting, Rimini, March 27th, 2025
7. TBVAC, Les Diablerets, Switzerland, February 1, 2025
8. Dalla ricerca alle prospettive diagnostiche nella infezione tubercolare, SIMIT national meeting, Napoli, Italy, December 4th, 2024
9. New biomarkers for tuberculosis infection diagnosis, Waidid (World Association of Infectious Diseases and immunological disorders) Meeting, Milan, Italy, November 28-30, 2024
10. Il ruolo della ricerca traslazionale nel COVID-19 e nella tubercolosi, Congresso Regionale della SIMIT, Viterbo, 8 novembre 2024
11. Biomarkers for tuberculosis infection: from the host to the pathogen, Karolinska Institute, Sweden, October 24, 2024
12. Tuberculosis infection and management, 41st congress of the Brazilian Society of Pneumology and Tisiology, October 9th, 2024, remotely
13. Cysteamine as a host-directed therapy for infectious diseases, EUSTM, September 7th, 2024, remotely
14. The infectious risk in rheumatology in the era of biological and targeted synthetic DMARDs, GISEA meeting, Roma, May 24, 2024
15. Biomarkers for tuberculosis infection: from the host to the pathogen, ECCMID 33RD, Barcelona, April 28th, 2024
16. Il ruolo della ricerca traslazionale nel COVID-19 e nella tubercolosi, Congresso Regionale della SIMIT, Viterbo, 8 novembre 2024
17. Il rischio infettivo e la tubercolosi latente in Artrite Reumatoide, La gestione appropriata del paziente con Malattia Reumatica e l'importanza dell'approccio multidisciplinare, Prato, May 17th, 2024
18. Biomarkers for tuberculosis infection: from the host to the pathogen, ECCMID 33RD, Barcelona, 28 aprile 2024
19. Protecting from tuberculosis the most vulnerable patients: Are all the immunosuppressive drugs similar? ISPUP, Istitute Salud Publica Universitate Porto, March 9, in remote, 2024
20. Echinococcosis: pathogenesis and clinical management, Roma, INMI, January 30th, in remote, 2024
21. Immunologia delle malattie infettive e medicina di genere, Roma, INMI, Malattie Infettive e Medicina di Genere, 11 dicembre, 2023
22. Rischio infettivo e farmaci biologici" Quali sono i farmaci a maggiore pericolo di riattivazione della tubercolosi, 22 congresso SIMIT, Firenze, 5 dicembre, 2023
23. Protecting the most vulnerable tuberculosis in the Immunocompromised patient: Are all the immunosuppressive drugs similar? 38 Congress of the Society of Portugal Pneumologists, November 11th, 2023
24. Le infezioni nel paziente in terapia immunosoppressiva. X congresso SIGR, 6 ottobre, 2023, Università Europea di Roma
25. Diagnosi di malattia infettiva basata sulla risposta dell'ospite: attualità e prospettive. Congresso Nazionale della Società Italiana di Microbiologia (SIM), September 25th, 2023
26. Paziente con storia di pregressa infezione tubercolare di epatite B/C: come gestire la terapia biotecnologica. Civitareuma. Tarquinia, September 16th, 2023
27. Nuovi schemi terapeutici nell'infezione tubercolare, corso FAD: La tubercolosi come malattia eliminabile: obiettivo possibile? 19 maggio, 2023, in remote
28. L'impatto delle malattie infettive nel nostro quotidiano, Cerimonia di Premiazione delle Topi Italian Women Scientists, Palazzo Pirelli, sede della Regione Lombardia, Milano, 10 maggio, 2023
29. Update on the management of TB infection, AMIT International Congress, Topics in Infectious Diseases and Tropical Medicine, 17 marzo, 2023
30. The new concept of latent tuberculosis infection and its future implications Attualità nella diagnostica della tubercolosi, Service de pneumologie Hôpitaux Universitaires Genève, Webinar, February 6th, 2023
31. Attualità nella diagnostica della tubercolosi, Simposio al 21 congresso SIMIT, Roma 23 novembre, 2022
32. Immunomodulanti come approccio terapeutico per le infezioni gravi, Simposio al 21 congresso SIMIT, Roma 21 novembre, 2022
33. Cosa può insegnare la ricerca sul COVID-19 in tema di immunologia della TB, Novità in tema di gestione clinica della tubercolosi multifarmaco resistente e 9 a revisione 2022 pda del paziente con infezione/malattia tubercolare, webinar 15 novembre, 2022
34. The new concept of latent tuberculosis infection and its future implications, 38 Congresso di Pneumologia Portoghese e 8 congresso della Union against Tuberculosis and Lung Diseases, Algarde, Portugal, November 10th, 2022
35. Risposta immunologica ai vaccini anti-COVID-19 nei pazienti con malattie immune-mediate, Corso di virologia sulla biosicurezza, 27 ottobre, 2022
36. Rilevanza della infezione tubercolare in gastro-reumatologia: dalla diagnosi differenziale alla terapia biologica, congresso SIGR

- (Società Italiana di gastroenterologia e Reumatologia), Roma, 9 ottobre, 2022
37. Whole blood tests to measure T cell specific response in infectious diseases, International conference of European Society of Translational Medicine (ESTM), webinar, October 3, 2022
 38. Farmaci biologici in reumatologia: il punto di vista dell'infettivologo, Civitarema IX, Tarquinia, 24 settembre
 39. TB immunology and host - pathogen interactions: "From biomarkers to host - directed therapy in TB", Karolinska Institutet, Stocholm, Sweden, September 9, 2022
 40. "The future for treatment of latent tuberculosis infection", Lisbona, 15 Luglio 2022. Webinar.
 41. "Cysteamine: a new antiviral and immuno-modulating treatment for COVID-19", Evento di brokerage: la ricerca sanitaria incontra l'industria. Ministero della Salute, Roma 13 luglio, 2022.
 42. "Rischio infettivo nel paziente reumatologico", IRCCS Humanitas Research Hospital, Roma, 11 Luglio 2022. Webinar.
 43. "Challenges in tuberculosis treatment" 20th ESCMID Summer School, Rome, 4 Luglio 2022.
 44. "Biomarkers for TB infection: past, present and future", Annual Meeting European Society of Mycobacteriology, Bologna, 26 Giugno 2022.
 45. "Le infezioni nell'era dei Biologici e dei tDMARDs", "La gestione clinica dell'artrite reumatoide, artrite psoriasica e spondiloartriti assiali", Prato, 17 Giugno 2022.
 46. "La vaccinazione nei pazienti con malattie reumatologiche infiammatorie/autoimmuni", "Incontri Reumatologici Romani 2022", Rome, 27 maggio 2022.
 47. "La risposta ai vaccini del COVID-19", Ordine dei Medici "Prevenzione, ricerca, ambiente e innovazione tecnologica nell'era post Covid: aspetti multidisciplinari per la salute e il benessere generale", Rome, 14 Maggio 2022. Webinar.
 48. Latent tuberculosis in migrants and travelers during COVID times, 32 ECCMID, Lisbon, April 26, 2022
 49. "COVID-19: from therapies to vaccination in the fragile population", Consulate general of Italy in Miami, V giornata della ricerca Italiana nel mondo, webinar, 12 aprile, 2022
 50. "Latent TB risk stratification and screening", ESCMID course 2022 on "Diagnosis and treatment of mycobacterial infections", 24-25 marzo, 2022, Nijmegen, The Netherland
 51. "Women in science, Italian excellence through research in infectious diseases", Unicamillus, March 9th, 2022
 52. "Current knowledge on T-cell testing for SARS-CoV-2", webinar supported by Qiagen, presented on February 24th, 2022.
 53. "From bench to bed side to propose new therapies and diagnostic tools for COVID-19", presentation within the meeting "A women's eye in Immunology", organizzato dalla Ambasciata Italiana a Washington, 15 febbraio, 2022. Webinar.
 54. Risposta immunologica ai vaccini anti-COVID-19 nei pazienti con malattie immune-mediate, corso di accreditamento per l'accesso ai laboratori P3 dell'Istituto Nazionale per le Malattie Infettive L. Spallanzani, Edizione 2021, 16 dicembre 2021. Webinar.
 55. Immunodeficienze e predisposizione a malattie da Micobatteri: prevenzione e cura", corso pregressuale, SIMIT 2021, Milano, 28, november, 2021.
 56. Vaccini anti-SARS-CoV-2 nei pazienti con malattie immunitarie: risposta specifica umorale e cellulo-mediate a SARS-CoV-2, "Ruolo dei farmaci inibitori di JAK per la terapia di COVID-19: incontro tra reumatologi e infettivologi", 23 novembre, 2021. Webinar.
 57. "Efficacia e sicurezza dei vaccini anti-Covid: dagli RCT agli studi post-marketing", Istituto Superiore di Sanità, "14 convegno, Il contributo dei centri per i disturbi cognitivi e le demenze per la gestione integrata dei pazienti" October 18th, 2021
 58. Vaccinazione anti SARS-CoV-2 nelle malattie sistemiche Immunomediate: come, quando e perché, 8 congresso SIGR, Ergife, Roma 4 ottobre, 2021.
 59. Cronicità e malattie infettive, TIWS Meeting, October 2nd, 2021. Webinar.
 60. "IMMUNOLOGIA E MICOBATTERI", secondo seminario su TB, NTM e malattie polmonari ostruttive, Milano, 2 ottobre, 2021. webinar.
 61. Characterization of CD4 and CD8 T-cell response in the VIDAS® TB-IGRA for tuberculosis infection diagnosis, 52 Union world conference on Lung Health, Characterization of CD4 and CD8 T-cell response in the VIDAS® TB-IGRA for tuberculosis infection diagnosis, October 19th, 2021. Webinar.
 62. "Beyond COVID-19, from the dark to the light", TED. invited by the EWMD, October 4th, 2021
 63. "Biological screening update", 2021 Global TB Clinical and Educational Summit, September 29th, 2021, webinar
 64. "Vaccinazione anti-SARS-CoV-2 e pazienti fragili", Civitarema VIII, Tarquinia, September 4th, 2021
 65. Vaccini anti-COVID-19 nei pazienti in terapia per reumatismi infiammatori", "La terapia personalizzata in reumatologia alla luce delle nuove possibilità terapeutiche", Prato, 2 luglio, 2021
 66. The potential clinical utility of measuring COVID-19 T-cell responses, pre-ECCMID, June 16th, 2021
 67. Vaccinazione anti-SARS CoV-2, Incontri Reumatologici romani, 29 maggio, 2021
 68. Precision medicine based on host-markers for tuberculosis, Pre-ECCMID, May 19, 2021 (online)
 69. LTBI diagnosis: caveats from the laboratory perspective. Update in TB and NTM mycobacterial diagnosis and clinical management. ESCMID-supported online course, April 15-17, 2021 (online)
 70. TB pathogenesis: does latent TB really exist? Update in TB and NTM mycobacterial diagnosis and clinical management. ESCMID-supported online course, April 15-17, 2021 (online)
 71. Infezioni latenti e farmaci biologici: aspetti gestionali. Pandora ID 2021, April 7th, 2021 (online)
 72. COVID-19 vaccines: updates, FAD meeting on SM, April 6th, 2021 (online)
 73. Diagnosi di infezione tubercolare latente, TB day meeting organized by SOPT TB Italia, 25 marzo, 2021 (online)
 74. Impatto della infezione da HIV sulla risposta al QuantiFERON TB Plus. 30 Marzo 2021, <https://micomfad.it>
 75. IGRAs and other TB infection tests in children, Saudi Pediatric Pulmonology Association (SPPA), February 26th, 2021, webinar.
 76. IGRAs and other TB infection test Tuberculosis – 9th Edition", webinar organized by the Institute of Public Health University of Porto (ISPUP), January 30th, 2021
 77. GRAs and other TB infection tests, ERS-organized webinar, January 12, 2021
 78. COVID-19: ricerca di nuovi approcci terapeutici e diagnostici, Corso di formazione per gli operatori dei laboratori di Biosicurezza dell'INMI, webinar, Roma December 16th, 2020

79. Gestione dello screening nei pazienti candidati a farmaci a piccole molecole: è necessario? Corso di malattie infettive associato all'uso di farmaci inibitori di JAK per la terapia delle malattie reumatologiche", webinar, Roma December 2, 2020
80. Vaccinazioni consigliate nei pazienti candidati a farmaci a piccole molecole. Corso di malattie infettive associato all'uso di farmaci inibitori di JAK per la terapia delle malattie reumatologiche", Roma December 2, 2020
81. Which is the best approach to screen HIV-infected individuals for latent tuberculosis infection in Italy? ICAR 2020, October 15th, 2020
82. COVID-19 pathogenesis and status of art of the clinical aspects, Sfide ed innovazioni terapeutiche in reumatologia, Prato October 2, 2020
83. COVID-19: Il punto di vista dell'infettivologo, A better PSO: the future is now, Bologna October 3rd, 2020
84. Ruolo degli inibitori di JAK 1 e JAK2 nella terapia di COVID-19, INCONTRO TOP ITALIAN WOMEN SCIENTISTS TIWS, EWMD e ONDA Centro Internazionale Loris Malaguzzi, Reggio Emilia, October 2, 2020
85. Rischio di riattivazione di tubercolosi associata all'uso di farmaci biologici e indicazioni per la pratica clinica, SIMIT, Hot topics in infettivologia, October 1st, 2020
86. C'è un ruolo per le terapie dirette all'ospite nelle NTM? NTM DARE DEBATE AWARENESS ON NTM, September 25th, 2020
87. Il punto di vista dell'infettivologo ai tempi del COVID-19, in Optimize psoriasis treatment and modify diseases history, Rome, September 23rd, 2020
88. Baricitinib as a potential drug for COVID-19: evidence from a multicenter trial and translational research studies, 7th Annual congress of the European Society For Translational Medicine on COVID-19, September 21st, 2020
89. SARS 2-Cov e Covid-19: strategie di un Virus e Strategie contro il Virus. European Womens Management Development «EWMD», Italia On AIR. Scenari di ripresa Post Covid: area Medica. June 11th, 2020
90. Gestione delle malattie infettive nei pazienti in terapia con biologico, "Incontri reumatologici romani", 22 febbraio 2020
91. Update on the research on TB biomarkers, TBVAC, Les Diablerets, 27 gennaio 2020
92. Echinococco e cibo: dobbiamo ancora avere paura? CONVEGNO ALIMENTAZIONE MULTIDISCIPLINARE in collaborazione con «Poster in Itinere» - patrocinato da OMCeO Roma, Casa Dell'Aviatore, Roma, 25 gennaio 2020
Revisione del protocollo di gestione clinica della tubercolosi. Revisione N. 8, INMI. Roma, 10 dicembre, 2019
93. Screening della infezione tubercolare latente in persone con infezione da HIV, 18esimo congresso SIMIT, Palermo 24 novembre 2019
94. Abbiamo bisogno di nuovi cut-off per la diagnosi di infezione tubercolare latente? 18esimo congresso SIMIT, Palermo 24 novembre 2019
95. Screening della infezione tubercolare e terapia preventiva, Modelli di gestione clinica per identificare il rischio di malattie infettive associate ai farmaci biologici, Corso INMI, 7 novembre, 2019
96. Overview sulla tubercolosi. Tubercolosi: Update and Prevention. Ospedale Bamino Gesu', Roma, 29 ottobre, 2019
97. La tubercolosi nel paziente anziano, 120 Congresso della Società Italiana di Medicina Interna (SIMI), 20 ottobre, 2019
98. Understanding the use of interferon assays for latent tuberculosis infection diagnosis. Tuberculosis and Mycobacterial Infections; an educational update supported by ESCMID and WHO. Singapore, Settembre 26-28, 2019
99. HIV-TB coinfection management. Tuberculosis and Mycobacterial Infections; an educational update supported by ESCMID and WHO. Singapore, Settembre 26-28, 2019
100. Biomarkers for tuberculosis. Tuberculosis and Mycobacterial Infections; an educational update supported by ESCMID and WHO. Singapore, Settembre 26-28, 2019
101. Gestione della tubercolosi nei pazienti trattati con farmaci biologici, Roma, 47 congresso nazionale SIM, Roma, 19 settembre 2019
102. How to test for latent tuberculosis infection. TB Elimination in Low-Incidence Countries How to approach the pool of latent TB infections? Muscat, Oman, 5 Settembre 2019
103. Prevenzione e terapia della tubercolosi, IBD&infections, Milano, 28 giugno, 2019
104. Can we really diagnose LTBI? 1st International Blizard/QMUL Tuberculosis Symposium, 26-27th Giugno 2019, London 26 Giugno, 2019
105. Conventional T cell group: activities. Seattle, USA, 20 Giugno, 2019.
106. Latent Tuberculosis Prevalence at HIV Diagnosis: a Multicenter SIMIT Study, ICAR 2019, Milano, 6 giugno, 2019
107. Echinococcosi cistica: aspetti epidemiologici e clinici, incontri inter-dipartimentali INMI, Roma 29 maggio, 2019
108. "It's time to test and treat latent TB infection", EUROMEDLAB, Barcelona, 22 maggio, 2019
109. "Innovative markers in the fight against tuberculosis", Tests for the future, Torino, 14-15 maggio, 2019
110. "Lo screening per la TB latente: è necessario per tutti i biologici? Auditorium della Camera di Commercio-Prato, evento scientifico.
111. "La Reumatologia dal 1400 ai giorni nostri". Prato, 9 maggio, 2019
112. "Host-related markers of response to TB treatment", ESCMID, 14 Aprile, 2019
113. "TB research at INMI", Bilateral Workshop on Transmissible Diseases: HIV/AIDS, Tuberculosis and Malaria Italy-South Africa Collaborative Workshop on the occasion of the Italian Research Day in the world, Pretoria, 5 Aprile 2019
114. Confronto clinico con l'infettivologo, Congresso di Reumatologia della Campania: COMUNICARE OGGI, Napoli, 28 marzo, 2019
115. Il rischio di tubercolosi nella popolazione generale, TB day organizzato da STOP TB, Palermo, Palazzo dei Normanni, 21 marzo, 2019
116. Vaccini e farmaci biologici, Giornate reumatologiche romane, centro congressi AROMA, Roma 22 febbraio, 2019
117. "Final update on TB biomarkers from the INMI team", presentation at the TBVAC, EU funded project, 30 Gennaio, 2019, Les Diableret, Switzerland.
118. Il trattamento dell'infezione latente nei pazienti candidati a farmaci biologici, XVII SIMIT, Torino, 4 Dicembre, 2018
119. LE MALATTIE BOLLOSE AUTOIMMUNI: DALLA GENESI ALLA CURA DEL PAZIENTE
120. Rischio infettivo in pazienti affetti da pemfigo e pemfigoide, LE MALATTIE BOLLOSE AUTOIMMUNI: DALLA GENESI ALLA CURA DEL PAZIENTE, Roma, dicembre 1st, 2018
121. Biomarkers in tuberculosis, IV SYMPOSIUM ON RESEARCH, DEVELOPMENT AND INNOVATION IN BACTERIAL AND

- FUNGAL DISEASES, Improvements In Biomarkers, Host Interaction, and Life Quality", Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, Novembre 22 - 23, 2018
122. Overview sui nuovi test per la diagnosi di infezione latente, XLVII AMCLI 2018, Rimini, 12 novembre, 2018
 123. Impatto dei farmaci biologici anti-TNF sulla tubercolosi, epatiti e malattie opportunistiche, INMI, Impatto dei farmaci biologici sullo sviluppo delle malattie infettive, Roma 9 novembre 2018
 124. Quantiferon-TB Gold Plus -an update on performance and comparing the 'new' with the 'old', UK TB Educational Symposium 2018, London, 19 Ottobre, 2018
 125. Il rischio tubercolare nella terapia con farmaci biologici, XXV riunione annuale, SIRS Puglia, 5 Ottobre, 2018
 126. Screening for Latent TB among Migrants in Italy, International Conference on Migration Health, Rome, 2 Ottobre, 2018
 127. Biomarkers of latent tuberculosis infection and predictors of active disease, Management of Mycobacterial diseases and associated comorbidities, ESCMID course held in Rome, 27-28 Settembre, 2018
 128. Practical issues of the treatment of tuberculosis in immunocompromised patients (IRIS and drug Interactions). Management of Mycobacterial diseases and associated comorbidities, ESCMID course held in Rome, Settembre 27-28, 2018
 129. TB biomarkers and studies on TB pathogenesis, University of Medicine, Southampton, 14 Settembre, 2018.
 130. Infezione latente tubercolare, corso INMI, 25 Settembre, 2018
 131. T cell based tests for cystic echinococcosis, Final meeting of the EU funded project Heracles, Istituto Superiore di Sanità, Rome, 17 Settembre, 2018
 132. Management of TB infection in HIV co-infected patients, WEBINAR sponsored by QIAGEN, 3 Luglio, 2018
 133. Scelta del biologico in pazienti con tubercolosi latente, Prato, 8 Giugno, 2018
 134. Il rischio infettivologico ed il trattamento con biologici, "Passato, Presente e Futuro delle ricerca sulla psoriasi", 11 Maggio, 2018
 135. La diagnosi della infezione tubercolare latente, Corso sulla diagnostica delle "Immagini della tubercolosi", INMI, Rome 3 Maggio, 2018.
 136. Issues in screening for latent tuberculosis, ECCMID, Madrid, 21 Aprile 2018
 137. Rischio infettivo nel paziente con artrite psoriasica, Paziente 23, Workshop e Real life, Roma, 24 marzo, 2018
 138. Il test QuantiFERON Plus e la gestione diagnostica della infezione latente tubercolare, "La Tubercolosi e il test QuantiFERON: dal paziente nefropatico agli operatori sanitari", Napoli, 22 marzo, 2018
 139. Nouvelles études QuantiFERON®-TB Gold Plus, Infection Tuberculeuse Latente et IGRA: Etat des lieux en 2018, Institut Pasteur, Paris, 15 Mars, 2018
 140. Rischio infettivo nel paziente con artrite psoriasica, Paziente 23, Workshop e Real life, Milano 2 marzo, 2018
 141. "TB biomarkers: organization of the work at INMI", presentation at the TBVAC, EU funded project, 30 Gennaio, 2018, Les Diableret, Switzerland.
 142. "Biomarkers for diagnosis and treatment efficacy in tuberculosis", Fondation Merieux, Annecy, 14 dicembre, 2017
 143. "Presentation of the multicenters study on the use of the in vitro response to HBHA as a tool to monitor therapy efficacy", Fondation Merieux, Annecy, 14 dicembre, 2017
 144. "Nuovi potenziali test diagnostici per l'Echinococcosi", Aggiornamento sull'Echinococcosi: aspetti epidemiologici, clinici, diagnostici e terapeutici, INMI, 6 dicembre, 2017.
 145. "Update on biomarkers for tuberculosis in HIV-TB coinfecting patients" All-Russian scientific practical conference with international participation «an interdisciplinary approach to solve the problem of tuberculosis», Moscow, 15 novembre, 2017
 146. "Update on biomarkers for tuberculosis" at the Federal State Budgetary Scientific Institution Central Tuberculosis Research Institute, Moscow, 13 novembre, 2017
 147. "Diagnosi immunologica di echinococcosi cistica", CORSO SOIPA-SIM PER I GIOVANI MICROBIOLOGI su "La parassitologia, dalle basi alla pratica diagnostica. Micro-Young-Group: Advancement in Parasitology. Eboli, 25 ottobre, 2017.
 148. "L'utilizzo di biomarcatori per predire lo sviluppo di TB attiva", Meeting INMI sull' "Appropriatezza nella presa in carico e nella gestione del paziente con TB-MDR. Roma, 24 ottobre, 2017
 149. QuantiFERON TB Plus: nuova generazione di IGRA per la diagnosi di infezione tubercolare latente, Congresso SIMIT, Salerno, 17 ottobre, 2017.
 150. "Peptidi multiepitopici dell'antigene B per la diagnosi dell'echinococcosi cistica", Congresso SIMIT, Salerno, 17 ottobre, 2017. Evaluation of the impact of M. tuberculosis on the autophagic flux. Kick-off meeting PRINN on Ubiquitin E3 ligases as critical sensors in physiological and pathological conditions, Roma, 7 Luglio, 2017
 151. Conventional T Cell Research Community report: CTVD Annual Meeting 2017, Bill and Melissa Gates Foundation, Washington Seattle, 23 Giugno, 2017
 152. "Diagnostica immunologica della tubercolosi: stato corrente e prospettive", Università di Tor Vergata, Roma 23 maggio, 2017
 153. "Sospetto clinico e diagnosi di complicità infettiva in pazienti trattati con terapia biologica", La gestione dei pazienti in terapia con farmaci biologici e small molecules: monitoraggio clinico e valutazioni farmaco-economiche, Prato 19-20 maggio, 2017.
 154. "Recommendations for vaccine and testing immune response in tuberculosis", ECCMID, Vienna, 22 aprile, 2017
 155. "Analytical evaluation of Quantiferon Plus and Quantiferon In-tube assays in subjects with or without tuberculosis", ECCMID, Vienna, 23 aprile, 2017
 156. Recommendations for vaccine and testing immune response in tuberculosis, ECCMID, Vienna, 22 aprile, 2017
 157. Analytical evaluation of Quantiferon Plus and Quantiferon In-tube assays in subjects with or without tuberculosis, ECCMID, Vienna, 23 aprile, 2017
 158. "Novità in tema di infezione tubercolare latente", Revisione del protocollo interno, National Institute for Infectious Diseases, Rome Italy, 28 Marzo, 2017
 159. "Prospettive dell'impiego di test immunologici per lo studio della tubercolosi latente", Word TB day 2017, National Institute for Infectious Diseases, Rome Italy, 20 Marzo, 2017
 160. "Characterization of the CD4 and CD8 T cell response in the QuantiFERON-TB-Plus kit", Second African Asian Society of Microbiology (AASM), Isfahan, Iran, Febbraio 26th, 2017

161. "TB biomarkers: organization of the work at INMI", presentation at the TBVAC, EU funded project, 1 Febbraio, 2017, Les Diableret, Switzerland.
162. "IGRA ed infezione tubercolare latente", INMI, Roma, 24 Novembre, 2016
163. "Tubercolosi e Screening tra i Migranti", Ferrara 18 Novembre, 2016
164. "Are there immunological tools for assessing TB cure?" PG course: Difficult to treat Mycobacterial infections. Organized by ECCMID, 30 Settembre, 2016, Brac, Croatia
165. "Clinical aspects of TB, microbiological diagnosis of TB, HIV-TB and IRIS", elective course at the Medical School of Leiden, 22 Settembre, 2016, Medical School of Leiden, Netherland
166. "Research for tuberculosis biomarkers", Invited Seminar, 23 Settembre, 2016, University of Leiden, Netherland
167. "First experiences with QFT-Plus. Assessing performance and exploring CD8+ T-cell response". SEIMC, the Spanish Society of Infectious Diseases and Clinical Microbiology, 28 Maggio, 2016, Barcelona, Spain.
168. "TB biomarkers: organization of the work at INMI", presentation at the TBVAC, EU funded project, 3 Febbraio, 2016, Les Diableret, Switzerland.
169. "Assays to predict active tuberculosis development from latent tuberculosis infection", 3 Dicembre, 2015, Union Meeting, Cape Town, South Africa
170. "Immune response to M. tuberculosis and search for new TB biomarkers", 30 Novembre 2015, Cape Town University, Cape Town, South Africa
171. "Nuovi test IGRA: oltre il quantiFERON?", 13 novembre 2015, Università di Padova, Italy
172. "Toward an immune diagnostic test for CE diagnosis based on IL-4 specific response", 12 Novembre 2015, Istituto Superiore di Sanità, Roma, Italy
173. "IGRA for tuberculosis diagnosis", 30 Ottobre, Istituto san Raffaele, Milan, Italy
174. "Algoritmo diagnostico dell'infezione tubercolare latente", 27-28 ottobre, 2015, INMI, Rome, Italy
175. "Evaluation of the accuracy of several immune experimental diagnostic tools to distinguish active tuberculosis from latent infection", European Respiratory Society Conference, 2015, Amsterdam, The Netherland.
176. "Quantiferon-TB Gold: criteri di interpretazione, accuratezza diagnostica, nuovi approcci diagnostici per la diagnosi di infezione tubercolare latente", 3 Luglio, 2015, Firenze, Italy.
177. Biologici e rischio infettivo: individualizzazione del rischio e scelta ragionata del biologico, 26 giugno, 2015, Prato, Italy.
178. Nuovi approcci diagnostici nell'infezione tubercolare, Università di Torvergata, 23 Giugno, 2015
179. "Migrants and infectious diseases", invited lecture at the Cystinet meeting, 13 Maggio 2015, Rome, Italy
180. "CD27 expression as a new tool to distinguish active tuberculosis (TB) from latent TB infection", ECCMID 2015, 26 aprile, 2015, Copenhagen, Denmark
181. "Ruolo degli IGRA nella pratica clinica e nuovi test sperimentali per la diagnosi immunologica della tubercolosi", Ordine dei Medici di Roma, 17 Aprile, 2015, Roma, Italy
182. "Immune response to M. tuberculosis and search for new biomarkers", University of Palermo, Marzo 26th, 2015, Palermo, Italy
183. "TB biomarkers from diagnosis to protection", TB day celebration, INMI, Roma, 23 Marzo, 2015, Rome, Italy.
184. "TB biomarkers: organization of the work at INMI", presentation at the Kickoff meeting of TBVAC, EU funded project, 12 Febbraio, 2015, IJmuiden, The Netherland.
185. "Can blood or urine IP-10 discriminate between active and no active tuberculosis in children from high endemic areas?" Keystone meeting on Tuberculosis, 26 Gennaio, 2015, Rockville, MD, USA
186. "Immune response to M. tuberculosis and search of new TB biomarkers", AERAS, 21 Gennaio, 2015, Rockville, MD, USA
187. IGRA ed infezione tubercolare latente, Corso "Micobatteri e malattia tubercolare", INMI, Roma, 26 Novembre, 2014, Rome, Italy.
188. Polyfunctional T cells and an effector memory phenotype are associated with active TB in HIV-infected patients, ERS meeting, 9 Settembre, Munich, Germany, 2014
189. Identification and clinical management of LTBI in children versus adults, post graduate course at the ERS meeting (PG20 Global evaluation of tuberculosis from children to adults), 6 Settembre, Munich, Germany, 2014
190. Polyfunctional T cells and an effector memory phenotype are associated with active TB in HIV-infected patients, 9th International Conference on the pathogenesis of Mycobacterial Infections, 27 Giugno, 2014, Salsjobaden, Sweden.
191. Anti-TNF ed infezioni: il ruolo dei fattori di rischio correlati all'ospite, Artimino (Prato), 6 Giugno, 2014
192. Diagnosi immunologica della tubercolosi: presente e futuro, Ospedale Pediatrico Bambino Gesù, TB day, 24 Marzo, 2014, Rome, Italy
193. Immune diagnostic tests for tuberculosis: the present and the future, Department of Infectious Diseases, 13 Febbraio, 2014, San Gallen, Switzerland.
194. Nuovi approcci per la diagnosi immunologica della tubercolosi, Dipartimento di Malattie Infettive e Tropicali, Università di Pavia, 27 Gennaio, 2014, Pavia Italy.
195. Use of IGRAs in HIV-infected individuals in comparison to experimental tests, Pan European Symposium on the use of IGRA in HIV-infected individuals, 17 Dicembre, 2013, Paris, France.
196. Restitution of the boarding research committee of GABRIEL, 13 Dicembre, 2013, Annecy, France.
197. Rendicontazione progetto europeo IDEA, Dar Es Salam, Tanzania, 26 settembre 2013.
198. IP-10 urinario correla con la citolisi epatica nei pazienti con epatopatia HCV-correlata, Congresso SIMIT, 27-30 Ottobre, 2013, Milano, Italy.
199. IGRA ed infezione tubercolare latente, Sesto corso di Micobatteriologia avanzata, Milano 16-20 settembre, Ospedale San Raffaele, 2013 IFN-gamma Release Assays: advantages, limitations, new advances. Lecture. Annual congress of European Society of Mycobacteriology, Luglio 3, 2013, Florence, Italy.
200. Infezione tubercolare latente: definizione, e nuovi approcci sperimentali diagnostici, Corso aziendale sulla tubercolosi, INMI, 27 giugno, 2013, Roma, Italy.
201. Sospetto clinico e diagnosi di tubercolosi attiva in pazienti trattati con farmaci biotecnologici, 7-8 Giugno, 2013, Artimino (Prato),

Italy.

202. Sensibilità e specificità del TST e IGRA per la diagnosi di infezione tubercolare latente, 7-8 Giugno, 2013, Artimino (Prato), Italy.
203. Gestione del paziente con insorgenza di malattia tubercolare attiva durante il trattamento con farmaco biologico, 7-8 Giugno, 2013, Artimino (Prato), Italy.
204. "Le Linee Guida Ministeriali 2013 sulla prevenzione della tubercolosi negli operatori sanitari", all'interno del meeting: "Il medico competente e la gestione del rischio TUBERCOLOSI in ospedale alla luce delle Linee Guida 2013 del Ministero della Salute" 15 maggio, 2013, Roma, Italy.
205. Corso annuale sulla "gestione della tubercolosi" organizzato dall'Università di Brescia, Diagnosi immunologica della tubercolosi e dell'infezione tubercolare latente: stato dell'arte e nuove prospettive, 15 Aprile 2013, Sondalo, Italy.
206. Rendicontazione progetto europeo "Biomarkers for tuberculosis in urine", TB CHILD European grant 2010-2013, 16 Marzo 2013, Bagamoyo, Tanzania.
207. A toolbox for tuberculosis diagnosis: an Indian multicentric study (2006-2008), the 5th GABRIEL meeting, Les Pensières, 10 Dicembre, 2012, Annecy, France.
208. TB biomarkers and the role of autophagy in TB, Max Plank Institute, Berlin, Germany, 15 Novembre, 2012
209. Tubercolosi: cross-road immigrato-viaggiatore, corso "Le Malattie Infettive del migrante e del viaggiatore, III edizione, 9 novembre 2012, Ferrara, Italy.
210. L'infezione tubercolare latente, corso "Tubercolosi: malattia riemergente, Percorsi clinici, diagnostici e terapeutici", 5 novembre, 2012, Lamezia Terme, Italy.
211. Il ruolo degli IGRA nella diagnosi di infezione tubercolare, SIMIT 2012, 20 Ottobre, 2012, Pescara, Italy.
212. Corso ECM, La diagnostica della tubercolosi, Presentazione su: Laboratorio, diagnostica immunologica, Istituto Nazionale per le Malattie Infettive L. Spallanzani, 11 Ottobre, 2012, Rome, Italy.
213. Corsi di Formazione ed aggiornamento professionale previsti dal programma di interventi urgenti per la prevenzione e la lotta contro l'AIDS (legge 135/1990), corso per il comparto dell'INMI, "Gestione dei contatti di caso", May, 2012, Rome, Italy.
214. What are the optimal approaches to discover correlates of protective immunity to tuberculosis? Emory Conference Center, 14 Aprile, 2012, Atlanta, Georgia, USA.
215. Corsi di Formazione ed aggiornamento professionale previsti dal programma di interventi urgenti per la prevenzione e la lotta contro l'AIDS (legge 135/1990), corso per Medici della Regione Lazio, 27-28 Febbraio, 2012, Rome, Italy.
216. Approaches on tuberculosis for developing countries, 4th international meeting. Report on the studies conducted by the GABRIEL network, Fondation Merieux, 5 Dicembre 2011, Bamako, Mali.
217. Infezione tubercolare latente: definizione, diagnosi e indicazioni alla profilassi secondo le linee guida. Attualità in tema di diagnosi, clinica e profilassi della tubercolosi, Confederazione ANTEL-ASSIATEL-AITIC, Sede provinciale della Croce Rossa a Villa Marelli, 26 Novembre, 2011, Rome, Italy.
218. Diagnosi immunologica della tubercolosi e dell'infezione tubercolare latente: stato dell'arte e nuove prospettive. Congresso AMCLI, invited lecture, 10 Novembre, 2011, Rimini, Italy.
219. Diagnosi e profilassi dell'infezione tubercolare latente in ambito occupazionale, Università di Tor Vergata, Istituto di Medicina del Lavoro, 21 Ottobre, 2011, Rome, Italy.
220. Methylated HBHA produced in *M. smegmatis* discriminates between active and non-active TB disease among the QFT-IT-responders, ERS meeting, 26 Settembre, 2011, Amsterdam, The Netherlands.
221. Autophagy modulation by *Mycobacterium tuberculosis* after in vitro infection of human primary macrophages, Eight International conference on the pathogenesis of Mycobacterial Infection, 2 Luglio 2011, Saltjbaden, Sweden.
222. Immunodiagnosis of tuberculosis, CHUV, 15 Giugno, 2011, Losanne, Suisse.
223. La diagnosi di infezione e malattia tubercolare: stato dell'arte e nuove prospettive, TB day, Università Cattolica del Sacro Cuore, 24 Marzo, 2011, Rome, Italy.
224. La diagnosi di tubercolosi polmonare latente. I test tubercolinici: utilità e limiti. Corso di aggiornamento teorico-pratico: la malattia tubercolare: attualità e prospettive diagnostiche e terapeutiche. 19 Febbraio, 2011, Crotone, Italy.
225. Approaches on tuberculosis for developing countries, 16 Dicembre, 2010, Veyrier du Lac, France.
226. La diagnosi di infezione e malattia tubercolare: oltre gli IGRA, Congresso della Società Italiana di Malattie Infettive e Tropicali, Hotel Ergife, 25 novembre, 2010, Rome, Italy.
227. Diagnosi immunologica della tubercolosi: stato dell'arte e nuove prospettive, Riccione, Palazzo dei Congressi, Congresso della Società Italiana di Microbiologia, 18 Ottobre 2010, Rome, Italy.
228. Come migliorare gli IGRA? Valutazioni di nuovi approcci sperimentali, Meeting di costituzione della rete romana per la tubercolosi, INMI, 6 settembre, 2010, Rome, Italy.
229. In HIV+ subjects IP-10 is a marker for *M. tuberculosis*-specific response independent of CD4+ T cell counts, ERS meeting, 21 Settembre, 2010, Barcelona, Spain.
230. Biomarkers for tuberculosis in urine, 4th TBNET meeting, 17 Settembre, 2010, Barcelona, Spain.
231. Tuberculosis in immunocompromised patients, "Tuberculosis in HIV-infected patients", Congress of the Romanian Society of Pulmonology, Giugno 10-12, 2010, Bucharest, Romania.
232. Immunodiagnosis of Tuberculosis, ERS School Course on Tuberculosis at times of emerging drug resistance, 27-29, Maggio 2010, Borstel, Germany.
233. Constrains and common mistakes in TB/MDR-TB clinical trials, ERS School Course on Tuberculosis at times of emerging drug resistance, Maggio 27-29, 2010, Borstel, Germany.
234. Identification of antigens and antibodies in body fluids, Commemoration for the TB day, 25 Marzo, 2010, Münchenwiler, Suisse.
235. Impact of Hemithiasis in HIV and TB diseases, Kick-off meeting of the European project IDEA, Marzo 20-21, 2010, Amsterdam, the Netherlands.
236. Experimental immune assays for the diagnosis of latent tuberculosis infection and active disease, University of Torvergata, Biology Department, 19 Febbraio, 2010, Roma, Italy.

237. LTBI treatment in subjects with autoimmune diseases and T-cell IFN- γ responses, ERS 2009, 15 Settembre, 2009, Vienna, Austria.
238. New tools to discriminate active from past tuberculosis: comparison of the response to RD1 antigens vs latency antigens, ERS 2009, 15 Settembre, 2009, Vienna, Austria.
239. New tools to discriminate active tuberculosis disease from latent tuberculosis infection, 30 Maggio, 2009, Dubrovnik, Croatia.
240. Immune diagnosis of active tuberculosis and latent tuberculosis infection, Corso di Perfezionamento TB; aspetti clinici, diagnostici, terapeutici, 17 Marzo, 2009, Brescia, Italy.
241. Specificities of tuberculosis in HIV disease, organized by Merieux Fondation, held as "Les Cent Gardes" meeting, 4 Marzo, 2009, Delhi, India.
242. Tuberculosis in Children, Department of Pediatrics, Medical College, Agra, India, invited by Department of Pediatrics, Medical College, 3 Marzo, 2009, Agra, India.
243. Report on the activity to the evaluation on a test for the discrimination of active TB from LTBI based on the RD1 selected peptides, organized by Merieux Fondation, Dicembre 2nd, 2008, New Delhi, India.
244. Symposium lecture, RD1-selected peptides for the immunodiagnosis of active tuberculosis, ERS meeting, 6 Ottobre, 2008, Berlin, Germany.
245. Post-graduate course: Future developments for the diagnosis M. tuberculosis-infection", ERS meeting, 4 Ottobre, 2008, Berlin, Germany.
246. An assay based on RD1 selected peptides for the diagnosis of extra-pulmonary and smear negative tuberculosis, ERS meeting, 8 Ottobre, 2008, Berlin, Germany.
247. Use of QuantiFERON TB Gold In Tube to detect LTBI and to monitor prophylaxis in children recently exposed to M. tuberculosis, ERS meeting, 7 Ottobre, 2008, Berlin, Germany.
248. Memory response to RD1 antigens in TST+ subjects: a better tool to detect LTBI?, ERS meeting, 7 Ottobre, 2008, Berlin, Germany.
249. Test per discriminare l'infezione latente tubercolare dalla malattia tubercolosi attiva, invited by Istituto di Patologia Generale, Università Facoltà di Medicina, 16 Giugno, 2008, Palermo, Italy.
250. An assay based on RD1 selected peptides for the diagnosis of extra-pulmonary and smear negative tuberculosis, ATS 2008, 18 Maggio, 2008, Toronto, Canada.
251. RD1-selected peptides for the immunodiagnosis of active tuberculosis: results from a multicenter TB-NET study, National Pneumology Congress, 10 Aprile, 2008, Lubeck, Germany.
252. RD1-epitopes response for the immune diagnosis of tuberculosis, National Microbiologic Congress, 6 Aprileh, 2008, Plovdiv, Bulgaria.
253. Commemoration for Fabrizio Poccia, TB-VAC meeting, Gennaio 29th, 2008, Les Diablerets, Suisse.
254. RD1-epitopes response correlates with the time since first exposure in close contacts recently exposed to M. tuberculosis. European Respiratory Society, 13-14 Settembre, 2007, Stockholm, Sweden.
255. Response to RD1-selected epitopes is associated to active tuberculosis. Results of a european multicenter hospital based study: interim analysis of a european tuberculosis network (TBnet) study. European Respiratory Society, 13-14 Settembre, 2007, Stockholm, Sweden.
256. The clinical management of tuberculosis in HIV-coinfection, 17th ERS Annual Congress. European Respiratory Society, Settembre 13th-14th, 2007, Stockholm, Sweden.
257. Priorities of Tuberculosis Research, Second annual meeting of the TBNET, 13-14 Settembre, 2007, Stockholm, Sweden.
258. Response to RD1-selected epitopes is associated to active tuberculosis. Results of a european multicenter hospital based study: interim analysis of a european tuberculosis network (TBnet) study. Second annual meeting of the TBNET, 13-14 Settembre, 2007, Stockholm, Sweden.
259. Immune diagnostic assays for the diagnosis of active tuberculosis and latent infection. National Annual Meeting of the Japanese Union against Tuberculosis. 4 Giugno, 2007. Osaka, Japan.
260. Immune diagnostic assays for the diagnosis of latent tuberculosis infection and active disease, Research Center Ottobre 2nd, 2007, Borstel, Germany.
261. Diagnosi immunologica della tubercolosi, Istituto di Microbiologia, Università Cattolica del Sacro Cuore, 20 novembre 2006, Rome, Italy.
262. The role of a new immune diagnostic assay based on RD1 selected peptides in the evaluation of subjects with active M. tuberculosis replication. Tuberculosis Research Center (TBRC), 30 Ottobre, 2006, Chennai, India.
263. The role of a new immune diagnostic assay based on RD1 selected peptides in the evaluation of subjects with active M. tuberculosis replication. Department of Microbiology, Hinduja Hospital, 2 Novembre, 2006, Mumbai, India.
264. Response to ESAT-6/CFP-10 selected peptides response in the course of prophylaxis in individuals exposed to M. tuberculosis. ERS meeting, 14 Settembre, 2006, Munich, Germany.
265. Dynamics of ESAT-6/CFP-10 selected peptides response in the course of prophylaxis in individuals exposed to M. tuberculosis. ATS meeting, 22 Maggio, 2006, San Diego, USA.
266. The role of a new immune diagnostic assay based on RD1 selected peptides in the evaluation of subjects with active M. tuberculosis replication. Department of Microbiology and Immunology, Georgetown University, Maggio 19th, 2006, Washington DC, USA.
267. A new diagnostic immune assay for tuberculosis diagnosis. Clinical evaluation of tool box for tuberculosis diagnosis, Foundation Mérieux and Indian Council of Medical Research. Delhi (India), Dicembre 22th, 2005.
268. Detection of M. tuberculosis transrenal DNA from urine samples of patients with pulmonary TB: proof of concept study. IUTLD. Ottobre 18-22, 2005, Paris, France.
269. Comparison of an assay based on RD1 selected peptides with commercially available assays based on RD1 overlapping peptides to identify subjects with active TB. 15th ERS Annual Congress. 17-21 Settembre, 2005, Copenhagen, Denmark.
270. A T-cell-based assay for rapid diagnosis of difficult cases of tuberculosis (TB): smear negative pulmonary and extra-pulmonary TB. 15th ERS Annual Congress. 17-21 Settembre, 2005, Copenhagen, Denmark.

271. Immune diagnosis of tuberculosis. Case Western Reserve University, 25 Maggio, 2005, Cleveland, Ohio, USA.
272. Comparison of ELISPOT and whole blood assay for IFN-gamma in the immune diagnostic of tuberculosis using ESAT-6 and CFP-10 selected peptides, 14th ERS congress, 4-8 Settembre, 2004, Glasgow, UK.
273. Use of immunological assays based on selected ESAT-6 e CFP-10 peptides in the diagnosis of active TB, GISTA meeting, INMI, 21 Maggio, 2004, Roma, Italy.
274. Immuno-diagnosis of active and latent tuberculosis, Department of Parasitology and immuno-mediated diseases, Istituto Superiore di Sanità, 12 Maggio, 2004, Rome, Italy.
275. Clinical presentation and outcome of HIV-associated tuberculosis in the HAART era in Rome, 14th ECCMID congress, ECCMID, 1-4 Maggio, 2004, Prague, Czech Republic.
276. The role of new immune diagnostic test based on ESAT-6 epitopes in the evaluation of subjects with a clinical suspicion of active tuberculosis, 14th ECCMID congress, ECCMID, 1-4 Maggio, 2004, Prague, Czech Republic.
277. Immune diagnosis of tuberculosis. TB-VAC meeting, 6th Framework Programme, Febbraio 19-20, 2004, Leiden, The Netherland.
278. Immuno-diagnosis of tuberculosis, Division of Preventive Medicine, Azienda Sanitaria Locale San Camillo-Forlanini, Marzo 10st, 2004, Viterbo, Italy.
279. Clinical-diagnostic issues of tuberculosis in patients with immuno-deficiencies, Giornate pneumologiche laziali, AIPO, sezione laziale, 11 Dicembre, 2003, Rome, Italy.
280. Identification of ESAT-6 epitopes for the development of an immunodiagnostic assay for the diagnosis of active and latent tuberculosis, Division of Infectious Diseases, Ospedale del Bambino Gesù, 7 Ottobre, 2003, Rome, Italy.
281. The role of new immune diagnostic test based on ESAT-6 epitopes in the screening of subjects with a clinical suspicion of active tuberculosis. 13 st ERS congress, ERS, Vienna, Austria, 27 Settembre -1 Ottobre, 2003
282. Immuno-diagnosis of tuberculosis, Division of Infectious Diseases, Ospedale Belcolle, 7 Marzo, Viterbo, Italy.
283. Identification of ESAT-6 epitopes for the development of an immunodiagnostic assay for the diagnosis of active and latent tuberculosis, INMI meeting with the Laboratory of Allergy and Infectious diseases of University "La Sapienza", 10 Ottobre, 2002, Rome, Italy.
284. Evaluation of cell population of the immune system susceptible to HHV-8 infection. Annual Congress of Istituto di Virologia, Istituto Superiore di Sanità, 12 Maggio 1997, Roma, Italy.
285. Effect of tuberculosis in the pathogenesis of HIV infection, DIBIT, Istituto San Raffaele, 14 Aprile 1997, Milano, Italy.
286. Role of tuberculosis in the pathogenesis of HIV disease, Istituto di Patologia Generale, Università La Sapienza di Roma, 11 Febbraio, 1997, Roma, Italy.
287. Role of anti-inflammatory cytokines and chemokines in the modulation of tuberculosis-induced HIV replication, Department of Health and Human Services, USA, Settembre 25th , 1996, Washington D.C., USA.
288. Effect of tuberculosis in the pathogenesis of HIV infection, Johns Hopkins University, School of Hygiene and Public Health, department of Molecular Microbiology and Immunology, 19 Settembre, 1996, Baltimore, Maryland, USA.
289. Impact of opportunistic infections in the pathogenesis of HIV infection, Washington D.C. General Hospital, Tuberculosis and Chest Clinic, 11 Luglio, 1996, Washington D.C., USA.
290. Role of immune activation in tuberculosis-induced HIV replication, Institute de Recherche de Montreal, Institute d'Immunologie, 14 Luglio, 1996, Montreal, Canada.
291. Role of tuberculosis in the pathogenesis of HIV infection, 3th National Meeting on AIDS, 29 Gennaio, 1996, Washington, USA.
292. Role of tuberculosis in HIV infection, 9th International Congress in Immunology, 23-29 Luglio, 1995, San Francisco, USA.
293. Expression of LFA-1 antigen in AIDS patients. 5th National Meeting on AIDS, 1991, Cagliari, Italy.

Bibliografia

1. Walzl G, McHugh TD, Chakaya J, Sahu S, Ditiu L, Huggett JF, Mwaba P, Asogun D, Ahmed R, Zumla A, Nyasulu PS, Hui DS, Marais BJ, **Goletti D**, Zumla A. Advances in tuberculosis diagnostics and biomarkers, 2020-26: scientific evidence, recommendations, gaps, and developmental priorities. *Lancet Microbe*. 2027 Apr 27:101435. doi: 10.1016/j.lanmic.2026.101435. Epub ahead of print. PMID: 42526490.
2. Marais BJ, **Goletti D**, McHugh TD, Tiberi S, Aklillu E, Yeboah-Manu D, Mfinanga S, Zumla A, Ahmed R, Hasan T, Nyasulu PS, Chakaya J, Ntouni F, Walzl G, Hui DS, Zumla A. Advances in tuberculosis treatment: novel regimens, new drug pipelines, host-directed therapies, and updated management guidelines. *Lancet Microbe*. 2027 Apr 26:101442. doi: 10.1016/j.lanmic.2026.101442. Epub ahead of print. PMID: 42526491.
3. da Costa C, Marais BJ, **Goletti D**, Onyebujoh P, Chakaya J, Walzl G, Zumla A. Advances in development of tuberculosis vaccines and preventive drug therapies: current pipeline, evidence, and access. *Lancet Microbe*. 2027 Apr 26:101443. doi: 10.1016/j.lanmic.2026.101443. Epub ahead of print. PMID: 42526489.
4. Zenner D, Hui DS, Sahu S, Ditiu L, Yeboah-Manu D, Ntouni F, Mfinanga S, Chakaya J, Zumla A, Ahmed R, Tiberi S, **Goletti D**, Walzl G, Marais BJ, Zumla A. State of the global tuberculosis epidemic: burden, progress towards WHO End TB Strategy targets and systemic challenges. *Lancet Microbe*. 2027 Apr 26:101433. doi: 10.1016/j.lanmic.2026.101433. Epub ahead of print. PMID: 42526488.
5. Calcagno A, Zaffagnini A, Pontali E, Bertonazzi C, Del Puente F, Codecasa LR, Piccioni P, Piccioni D, Riccardi N; MYGRO Study Group. Treating tuberculosis without rifampicin: an open dilemma. *Respir Med*. 2026 Sep;261:109002. doi: 10.1016/j.rmed.2026.109002. Epub 2026 Jun 25. PMID: 42349725.
6. Silva T, Aiello A, Alonzi T, Carvalho MA, Finger V, **Goletti D**, Hoffner S, Kherabi Y, Korabecny J, Kulczyńska J, Kyzioł A, Lacoma A, Martins F, Nanovic Z, Hosseini-porgham S, Rambaher MH, Sechi LA, Smalchuk D, Stochel G, Tabernero L, Tateosian NL, Valcheva V, Zega A, Sarraguça M. Advancing Therapies for Mycobacterial Diseases: From Small Molecules to Host-Directed Strategies. *Med Res Rev*. 2026 Aug 4. doi: 10.1002/med.70096. Epub ahead of print. PMID: 42552751.
7. Alonzi T, Navarra A, Durodoye R, Bartlett J, Garbuglia AR, Lapa D, Vanini V, Cuzzi G, Capri A, Santoro A, Puro V, Girardi E, Gualano G, Palmieri F, Fimia GM, Piacentini M, Verma A, Williams SM, Sirugo G, **Goletti D**. IRGM genetic variants associate with tuberculosis disease in a European population. *Int J Infect Dis*. 2026 Jul 31:109024. doi: 10.1016/j.ijid.2026.109024. Epub ahead of print. PMID: 42537778.
8. Albin A, Vercesi E, Negri E, **Goletti D**, Gandini S, Corso G, Levi S. Challenges and barriers to women's leadership in medical research and how to prevent and overcome them. *Eur J Cancer Prev*. 2026 Jul 21. doi: 10.1097/CEJ.0000000000001031. Epub ahead of print. PMID: 42478873.
9. Pipitò L, Giacchino I, Mazzola CV, Nicastri E, Fasciana TMA, Puoti M, Malagnino V, Iannetta M, **Goletti D**, Bocci MG, Minutolo A, Cocuzza C, Merli M, Carla P, Velardo M, Campione M, Damiano M, Spinicci M, Tassone B, Grelli S, Falcone M, Rindi L, Russo A, Quirino A, Zammarchi L, Limongi D, Rossolini GM, Sarmati L, Giammanco GM, Giarratano A, Cascio A; SIS-NET Working Group. Community-acquired pneumonia outside the intensive care unit: Clinical characteristics and impact of rapid molecular diagnostics in the Italian SIS-NET study. *Int J Infect Dis*. 2026 Jul 17;171:108988. doi: 10.1016/j.ijid.2026.108988. Epub ahead of print. PMID: 42468735.
10. Ritz N, Tebruegge M, Aiello A, **Goletti D**. Extracting added value from existing tests-use of quantitative results from tuberculosis infection tests to improve the ability to predict progression to TB disease. *Clin Microbiol Infect*. 2026 Jul 10:S1198-743X(26)00370-8. doi: 10.1016/j.cmi.2026.07.004. Epub ahead of print. PMID: 42431398.
11. **Goletti D**, Andrade BB, Esmail H, Friedland JS, Martin C, Ng DHL, Migliori GB, Ong CW, Zumla A, Petersen E. World TB Day 2026: Scientific innovation across the tuberculosis continuum must now translate into global impact. *Int J Infect Dis*. 2026 Jun;167:108571. doi: 10.1016/j.ijid.2026.108571. Epub 2026 Mar 19. PMID: 41864268.
12. Petrone L, Aiello A, Najafi-Fard S, **Goletti D**. Impact of diabetes on TB infection diagnosis. *Int J Infect Dis*. 2026 Jun;167:108486. doi: 10.1016/j.ijid.2026.108486. Epub 2026 Feb 17. PMID: 41713694.
13. **Goletti D**, Aiello A, Chandran S, Martineau AR. Diagnosing Tuberculosis Infection: From the Host to the Pathogen. *Cold Spring Harb Perspect Med*. 2026 Jun 1;16(6):a041955. doi: 10.1101/cshperspect.a041955. PMID: 41558830; PMCID: PMC13224861.
14. Minosse C, Spezia PG, Belladonna S, Bettini A, Matusali G, Colavita F, Notari S, Petrone L, Tiberi M, Cavasio AR, Mazzotta V, Rosa L, Cimini E, Focosi D, **Goletti D**, Nicastri E, Antinori A, Maggi F. TTV Viremia and Immune Responses Following Vaccination Against Mpox and Dengue Viruses. *Vaccines (Basel)*. 2026 May 15;14(5):441. doi: 10.3390/vaccines14050441. PMID: 42188811; PMCID: PMC13211524.
15. van Meijgaarden KE, **Goletti D**, Palmieri F, Petrone L, Ottenhoff TH, Joosten SA. Mycobacterial growth control is heterogeneous but maintained during treatment in patients with tuberculosis disease. *Tuberculosis (Edinb)*. 2026 May;158:102761. doi: 10.1016/j.tube.2026.102761. Epub 2026 Apr 2. PMID: 41950542.
16. Walzl G, **Goletti D**, Zumla A. The Global Epidemiology of Tuberculosis: Burden, Trends, and Determinants. *Cold Spring Harb Perspect Med*. 2026 Apr 27:a041982. doi: 10.1101/cshperspect.a041982. Epub ahead of print. PMID: 42045066.
17. van Meijgaarden KE, **Goletti D**, Palmieri F, Petrone L, Ottenhoff TH, Joosten SA. Mycobacterial growth control is heterogeneous but maintained during treatment in patients with tuberculosis disease. *Tuberculosis (Edinb)*. 2026 Apr 2;158:102761. doi: 10.1016/j.tube.2026.102761. Epub ahead of print. PMID: 41950542.
18. **Goletti D**, Andrade BB, Esmail H, Friedland JS, Martin C, Ng DHL, Migliori GB, Ong CW, Zumla A, Petersen E. World TB Day 2026: Scientific innovation across the tuberculosis continuum must now translate into global impact. *Int J Infect Dis*. 2026 Mar 19:108571. doi: 10.1016/j.ijid.2026.108571. Epub ahead of print. PMID: 41864268.
19. Ferriero AM, Di Lella R, Farroni C, Aiello A, Giarratano A, Todaro M, Bocci MG, Nicastri E, **Goletti D**. Host-pathogen interaction in community-acquired pneumonia: a focus on the immune response. *Front Cell Infect Microbiol*. 2026 Feb 11;16:1731074. doi: 10.3389/fcimb.2026.1731074. PMID: 41756780; PMCID: PMC12932565.

20. D'Abramo A, Colavita F, Ponzetta L, De Marco P, Vita S, Rosa L, Cammisà S, Tartaglia E, Scorzolini L, Lalle E, Cimini E, Notari S, Tiberi M, Grifoni A, Weiskopf D, Sette A, Petrone L, Maggi F, **Goletti D**, Nicastri E; DENG-VAC study group. The DENG-VAC study: Preliminary findings on the immunogenicity of the TAK-003 dengue vaccine. *J Infect.* 2026 Mar;92(3):106707. doi: 10.1016/j.jinf.2026.106707. Epub 2026 Feb 18. PMID: 41720307.
21. Petrone L, Aiello A, Najafi-Fard S, **Goletti D**. Impact of diabetes on TB infection diagnosis. *Int J Infect Dis.* 2026 Feb 17:108486. doi: 10.1016/j.ijid.2026.108486. Epub ahead of print. PMID: 41713694.
22. Petersen E, Marais B, Koopmans M, Mwaba P, Asogun D, Bockarie MJ, Blumberg L, **Goletti D**, Abri SA, Scagliarini A, Simonsen L, Ntoumi F, Nyasulu PS, Hui DS, Durrheim DN, Grobusch MP, Zumla A. "Things Fall Apart": The Unravelling of Global Health Governance and the Imperative for Action Preserving Infectious Disease Prevention and Control. *Int J Infect Dis.* 2026 Apr;165:108472. doi: 10.1016/j.ijid.2026.108472. Epub 2026 Feb 12. PMID: 41690507.
23. Tiberi M, Petrone L, Salmi A, Vanini V, Cuzzi G, D'Abramo A, De Marco P, Grifoni A, Weiskopf D, Sette A, Nicastri E, **Goletti D**. Peptide MegaPools Approach to Evaluate the Dengue-Specific CD4 and CD8 T-Cell Response. *Pathogens.* 2025 Dec 20;15(1):5. doi: 10.3390/pathogens15010005. PMID: 41598989; PMCID: PMC12845116.
24. Vita S, Morlino G, D'Abramo A, Scorzolini L, Maffongelli G, **Goletti D**, Vairo F, Girardi E, Ciccozzi M, Nicastri E. Faster than Virus: The Physics of Pandemic Prediction. *Infect Dis Rep.* 2026 Jan 9;18(1):7. doi: 10.3390/idr18010007. PMID: 41562662; PMCID: PMC12821524.
25. **Goletti D**, Aiello A, Chandran S, Martineau AR. Diagnosing Tuberculosis Infection: From the Host to the Pathogen. *Cold Spring Harb Perspect Med.* 2026 Jan 20:a041955. doi: 10.1101/cshperspect.a041955. Epub ahead of print. PMID: 41558830.
26. Pinheiro M, Aguiar A, Moreira DN, Akkerman OW, Al-Suwaidi Z, Alfenaar JC, Arandjelović I, Brito U, de Colombani P, Curcic R, Garcia-Basteiro AL, **Goletti D**, Günther G, Ibrahim E, Kapata N, Lange C, Lipman M, Jankovic Makek M, Marais BJ, Mariandyshev A, Magis-Escurrea C, Migliori GB, Sánchez Montalvá A, Nanovic Z, Palmero DJ, Priwitzer M, Raviglione MCB, Silva DR, Salzer HJF, Schwarzbach C,
27. Spruijt I, Winthrop KL, Udwadia Z, Vasankari T, Vilaplana C, Duarte R. A multinational Delphi consensus on tuberculosis screening of migrants in Europe. *ERJ Open Res.* 2025 Dec 22;11(6):00574-2025. doi: 10.1183/23120541.00574-2025. PMID: 41438856; PMCID: PMC12720149.
28. **Goletti D**, Banaei N, Batra R, Berger AE, Blazevec A, Botelho-Nevers E, Breen R, Bruiners N, Cambau E, Carbonnelle E, Daley CL, Descotes-Genon C, Gennaro FD, Doucet-Populaire F, Esmail A, Guzman JDE, Fontana L, Gennaro ML, Handler D, Torres RMH, Hoft D, Ismail N, Isnard M, Kenny J, Lardizabal A, Lesage FX, Lopes A, Vidal WLL, Contreras RM, Manivet P, Marotte H, Méchaï F, Medjahed-Artebasse A, Meldau R, Mérieux Y, Morel J, Mougari F, Oelofse S, Palmieri F, Perrot JL, Petruccioli E, Pride DT, Tuailon E, Upton C, Vanker N, Dheda K. Accuracy of VIDAS[®] TB-IGRA in TB patients and individuals with different thresholds of exposure. *Int J Infect Dis.* 2026 Mar;164:108318. doi: 10.1016/j.ijid.2025.108318. Epub 2025 Dec 19. PMID: 41422942.
29. Hui D, Sahu S, Ditiu L, Marais BJ, Yeboah-Manu D, **Goletti D**, Walzl G, Zumla A. Global tuberculosis response off track: urgent priorities to end the world's top infectious killer. *Lancet.* 2026 Mar 21;407(10534):1126-1129. doi: 10.1016/S0140-6736(25)02433-X. Epub 2025 Dec 11. PMID: 41391466.
30. Petruccioli E, Alonzi T, Navarra A, Altera AMG, Cuzzi G, Farroni C, Repele F, Gualano G, Lindestam Arlehamn CS, Palmieri F, Salmi A, Vanini V, **Goletti D**. 3-Genes-TB-SCORE Accuracy for Tuberculosis Disease Diagnosis Is Not Affected by Immune-Mediated Inflammatory Disease Comorbidity. *Int J Mol Sci.* 2025 Nov 12;26(22):10931. doi: 10.3390/ijms262210931. PMID: 41303416; PMCID: PMC12652831.
31. Mortensen R, Arlehamn CSL, Coler RN, Gerner MY, **Goletti D**, Lewinsohn DA, Modlin RL, Musvosvi M, Rengarajan J, Urdahl KB, Walzl G, Behar SM, Barber DL; Collaboration for Tuberculosis Vaccine Discovery – Conventional T cells Research Community, Gates Foundation. T cell-macrophage interactions in tuberculosis: What we've got here is failure to communicate. *J Intern Med.* 2026 Jan;299(1):44-65. doi: 10.1111/joim.70028. Epub 2025 Nov 22. PMID: 41273222.
32. Aiello A, Navarra A, Haggiag S, Ruggieri S, Cuzzi G, Vanini V, Salmi A, Notari S, Altera AMG, Meschi S, Colavita F, Cimini E, Tortorella C, Prosperini L, Quartuccio ME, Galgani S, Puro V, Maggi F, Grifoni A, Sette A, Nicastri E, Gasperini C, **Goletti D**. Minimal association between Th1-specific responses to COVID-19 vaccines and SARS-CoV-2 breakthrough infections in multiple sclerosis patients receiving disease-modifying therapies. *Front Immunol.* 2025 Oct 30;16:1682049. doi: 10.3389/fimmu.2025.1682049. PMID: 41246331; PMCID: PMC12611814.
33. Chihab LY, Cheng C, Hillman H, Khan N, Kearns K, Mondal M, Wang A, Seumois G, Vijayanand P, Drake WP, Velkamp M, Janssen Bonás M, van Moorsel CHM, Joosten SA, van Meijgaarden KE, Palmieri F, Petrone L, Aiello A, **Goletti D**, De Silva AD, Tennekoon R, Dilani D, Scriba T, Fisher M, Luabeya AK, Lindestam Arlehamn CS, Peters B, Burel JG. Mycobacterium tuberculosis-specific blood immune signatures distinguish sarcoidosis from tuberculosis disease. *J Immunol.* 2025 Oct 17:vka274. doi: 10.1093/jimmun/vka274. Epub ahead of print. PMID: 41105206; PMCID: PMC12585110.
34. Ngiam JN, Koh MCY, D'Ambrosio L, **Goletti D**, Denholm JT, Akkerman OW, Centis R, Dinh-Xuan AT, Pontali E, Torrico MM, Garcia-Basteiro AL, Schaaf HS, Migliori GB, Ong CWM. Artificial intelligence for TB education and counselling: a modified Delphi consensus. *Int J Tuberc Lung Dis.* 2025 Aug 29;29(9):390-396. doi: 10.5588/ijtld.25.0086. PMID: 40883885.
35. Petruccioli E, Prosperini L, Ruggieri S, Vanini V, Salmi A, Cuzzi G, Galgani S, Haggiag S, Tortorella C, Parisi G, D'Agostino A, Gualano G, Palmieri F, Gasperini C, **Goletti D**. Characterization of QuantiFERON-TB-Plus Results in Patients with Tuberculosis Infection and Multiple Sclerosis. *Neurol Int.* 2025 Aug 2;17(8):119. doi: 10.3390/neurolint17080119. PMID: 40863988; PMCID: PMC12389123.

37. 3: Goletti D, Cirillo DM, Lange C, Tiberi S, Günther G, Petrone L, Kuksa L, Opota O, Akkerman O, Podlekareva D, Guglielmetti L, Duarte R. The Empty Medicine Cabinet: Urgent Action Needed to Resolve TB Drug Shortages in Europe. *Int J Infect Dis*. 2025 Oct;159:108022. doi: 10.1016/j.ijid.2025.108022. Epub 2025 Aug 16. PMID: 40825462.
38. Sester M, Altet-Gomez N, Andersen ÅB, Arias-Guillén M, Avars K, Bakken Kran AM, Bothamley G, Nordholm Breschel AC, Brown J, Chesov D, Ciobanu N, Cirillo DM, Crudu V, de Souza Galvao M, Dilektasli AG, Dominguez J, Duarte R, Dyrhol-Riise AM, **Goletti D**, Hoffmann H, Ibraim E, Kalsdorf B, Krawczyk M, Kunst H, Lange B, Lipman M, Matteelli A, Milkiewicz P, Neyer D, Nitschke M, Oral HB, Palacios- Gutiérrez JJ, Petruccioli E, Raszeja-Wyszomirska J, Ravn P, Rupp J, Spohn HE, Toader C, Villar-Hernandez R, Wagner D, van Leth F, Martinez L, Pedersen OS, Lange C. Diagnostic accuracy and predictive value of the QuantiFERON-TB gold plus assay for tuberculosis in immunocompromised individuals: a prospective TBnet study. *Lancet Reg Health Eur*. 2025 Aug 6;57:101416. doi: 10.1016/j.lanepe.2025.101416. PMID: 40823191; PMCID: PMC12355092.
39. Visca D, Centis R, D'Ambrosio L, Spanevello A, Petrone L, Migliori GB, Goletti D. Evaluating the impact of COVID-19 or SARS-CoV-2 vaccination on TB infection testing in the context of TB elimination. *Int J Tuberc Lung Dis*. 2025 Jun 27;29(7):293-298. doi: 10.5588/ijtld.25.0034. PMID: 40579764.
40. van Meijgaarden KE, Grace PS, Wang W, Goletti D, Palmieri F, Wuhler M, Ottenhoff THM, Joosten SA. Sera contributing to mycobacterial growth restriction in vitro display enhanced Fc-mediated phagocytosis. *iScience*. 2025 Apr 23;28(5):112504. doi: 10.1016/j.isci.2025.112504. PMID: 40458184; PMCID: PMC12127566.
41. Ratnakumar S, Hayward SE, Denneny EK, Goldsmith LP, Evans R, Checkley W, **Goletti D**, Ong CWM, Gotowiec M, Zhu J, Friedland JS, Porter JC. Post-pulmonary tuberculosis lung function: a systematic review and meta-analysis. *Lancet Glob Health*. 2025 Jun;13(6):e1020-e1029. doi: 10.1016/S2214-109X(25)00105-6. Erratum in: *Lancet Glob Health*. 2025 Aug;13(8):e1348. doi: 10.1016/S2214-109X(25)00224-4. PMID: 40412395; PMCID: PMC12287636. Sbarra S, Vola A, Tamarozzi F, Najafi-Fard S, Ludovisi A, Teggi A, Nicastrì E, Albarello F, Brunetti E, **Goletti D**, Petrone L. Stage-Specific Immune Responses to AgB T-Peptides in Patients with Cystic Echinococcosis. *Infect Dis Rep*. 2025 May 7;17(3):51. doi: 10.3390/idr17030051. PMID: 40407653.
42. 8. Sbarra S, Vola A, Tamarozzi F, Najafi-Fard S, Ludovisi A, Teggi A, Nicastrì E, Albarello F, Brunetti E, **Goletti D**, Petrone L. Stage-Specific Immune Responses to AgB T-Peptides in Patients with Cystic Echinococcosis. *Infect Dis Rep*. 2025 May 7;17(3):51. doi: 10.3390/idr17030051. PMID: 40407653; PMCID: PMC12101248.
43. Musso M, Gualano G, Mencarini P, Mastrobattista A, Licata MA, Pareo C, Cerva C, Mosti S, Di Bari V, Libertone R, Nisii C, Cannas A, Navarra A, **Goletti D**, Palmieri F. Diagnostic yield of induced sputum and Bronchoalveolar lavage in suspected pulmonary tuberculosis. *BMC Infect Dis*. 2025 May 8;25(1):680. doi: 10.1186/s12879-025-11020-3. PMID: 40340781; PMCID: PMC12063213.
44. Ferraioli M, Aiello A, Prevete I, Chimenti MS, De Marco L, Meschi S, Mariotti D, Vanini V, Cuzzi G, Salmi A, Notari S, Mellini V, Puro V, Maggi F, **Goletti D**, Sebastiani GD. Anti-SARS-CoV-2 B and T-Cell Immune Responses Persist 12 Months After mRNA Vaccination with BNT162b2 in Systemic Lupus Erythematosus Patients Independently of Immunosuppressive Therapies. *Vaccines (Basel)*. 2025 Apr 9;13(4):396. doi: 10.3390/vaccines13040396. PMID: 40333295; PMCID: PMC12031101.
45. Thong PM, Wong YH, Kornfeld H, **Goletti D**, Ong CWM. Immune dysregulation of diabetes in tuberculosis. *Semin Immunol*. 2025 Apr 22;78:101959. doi: 10.1016/j.smim.2025.101959. Epub ahead of print. PMID: 40267700.
46. Zumla A, Sahu S, Difu L, Singh U, Park YJ, Yeboah-Manu D, Osei-Wusu S, Asogun D, Nyasulu P, Tembo J, Kapata N, Alyaqoubi F, Maani AA, Blumberg L, Zumla A, Ahmed R, Go U, Hui DS, **Goletti D**, Petersen E. Inequities underlie the alarming resurgence of Tuberculosis as the world's top cause of death from an Infectious Disease - Breaking the silence and addressing the underlying root causes. *IJID Reg*. 2025 Mar 19;14(Suppl 2):100587. doi: 10.1016/j.ijregi.2025.100587. PMID: 40201557; PMCID: PMC11973691.
47. Nyasulu PS, Hui DS, Mwaba P, Tamuzi JL, Sakala DY, Ntouni F, Maeurer M, **Goletti D**, Petersen E, Zumla A. Global perspectives on tuberculosis in prisons and incarceration centers - Risk factors, priority needs, challenges for control and the way forward. *IJID Reg*. 2025 Mar 19;14(Suppl 2):100621. doi: 10.1016/j.ijregi.2025.100621. PMID: 40201555; PMCID: PMC11973647.
48. **Goletti D**, Matteelli A, Cliff JM, Meintjes G, Graham S, Esmail H, Shan Lee S. World TB Day 2025 Theme "Yes! We Can End TB: Commit, Invest, Deliver" can be made a reality through concerted global efforts to advance diagnosis, treatment and research of tuberculosis infection and disease. *Int J Infect Dis*. 2025 Jun;155:107892. doi: 10.1016/j.ijid.2025.107892. Epub 2025 Mar 17. PMID: 40107343.
49. Alonzi T, Petruccioli E, Aiello A, Repele F, **Goletti D**. Diagnostic tests for tuberculosis infection and predictive indicators of disease progression: Utilizing host and pathogen biomarkers to enhance the tuberculosis elimination strategies. *Int J Infect Dis*. 2025 Jun;155:107880. doi: 10.1016/j.ijid.2025.107880. Epub 2025 Mar 12. PMID: 40086617.
50. Zumla A, Sahu S, Yeboah-Manu D, **Goletti D**, Nyasulu PS, Mfinanga S, Shilalukey-Ngoma M, Ntouni F, Rodriguez-Morales AJ, Everett DB, Kamarulzaman A, Hui DS. Breaking dependency: strengthening the global tuberculosis response in the face of USAID cuts. *Lancet*. 2025 Mar 22;405(10483):958-961. doi: 10.1016/S0140-6736(25)00335-6. Epub 2025 Feb 26. PMID: 40023179.
51. Di Bari V, Cerva C, Libertone R, Carli SM, Musso M, **Goletti D**, Aiello A, Mazzarelli A, Cannas A, Matusali G, Palmieri F, Gualano G, On Behalf Of The Tb- Inmi Working Group. Impact of Severity of COVID-19 in TB Disease Patients: Experience from an Italian Infectious Disease Referral Hospital. *Infect Dis Rep*. 2025 Feb 5;17(1):11. doi: 10.3390/idr17010011. PMID: 39997463; PMCID: PMC11855733.
52. Picchianti-Diamanti A, Aiello A, De Lorenzo C, Migliori GB, **Goletti D**. Management of tuberculosis risk, screening and preventive therapy in patients with chronic autoimmune arthritis undergoing biotechnological and targeted immunosuppressive agents. *Front Immunol*. 2025 Feb 3;16:1494283. doi: 10.3389/fimmu.2025.1494283. PMID: 39963138; PMCID: PMC11830708.
53. Farroni C, Altera AMG, Salmi A, Vanini V, Cuzzi G, Lindestam Arlehamn CS, Sette A, Delogu G, Palucci I, Sbarra S, Aiello A, Picchianti-Diamanti A, Gualano G, Palmieri F, **Goletti D**, Petruccioli E. Specific immune response to M. tuberculosis and ability to in vitro control

- mycobacterial replication are not impaired in subjects with immune-mediated inflammatory disease and tuberculosis infection. **Front Immunol.** 2025 Jan 13;15:1484143. doi: 10.3389/fimmu.2024.1484143. PMID: 39872515; PMCID: PMC11770028.
54. Licata MA, Mencarini P, Mastrobattista A, Carli SM, Cerva C, Mosti S, Libertone R, Zolezzi A, Vittozzi P, Nisii C, Mazzarelli A, Cannas A, Navarra A, Ianniello S, Trisolini R, **Goletti D**, Palmieri F, Gualano G. Clinical Utility of Induced Sputum and Bronchoalveolar Lavage Cultures in Diagnosing Nontuberculous Mycobacterial Pulmonary Disease. **Pathogens.** 2024 Dec 3;13(12):1064. doi: 10.3390/pathogens13121064. PMID: 39770324; PMCID: PMC11728528.
 55. Khelghati F, Rahmanian M, Eghbal E, Seghatoleslami ZS, Goudarzi M, Keramatinia A, Ong CW, **Goletti D**, D'Ambrosio L, Centis R, Nasiri MJ, Migliori GB. Risk of tuberculosis disease in patients receiving TNF- α antagonist therapy: A meta-analysis of randomized controlled trials. **New Microbes New Infect.** 2024 Nov 16;62:101533. doi: 10.1016/j.nmni.2024.101533. PMID: 39639969; PMCID: PMC11617757.
 56. **Goletti D**, Meintjes G, Andrade BB, Zumla A, Shan Lee S. Insights from the 2024 WHO Global Tuberculosis Report - More Comprehensive Action, Innovation, and Investments required for achieving WHO End TB goals. **Int J Infect Dis.** 2025 Jan;150:107325. doi: 10.1016/j.ijid.2024.107325. Epub 2024 Dec 2. PMID: 39631498.
 57. Najafi-Fard S, Farroni C, Petrone L, Altera AMG, Salmi A, Vanini V, Cuzzi G, Alonzi T, Nicastrì E, Gualano G, Palmieri F, Piacentini M, **Goletti D**. Immunomodulatory effects of cysteamine and its potential use as a host-directed therapy for tuberculosis. **Front Immunol.** 2024 Oct 28;15:1411827. doi: 10.3389/fimmu.2024.1411827. PMID: 39530101; PMCID: PMC11550979.
 58. Matteelli A, Formenti B, Cimaglia C, Visconti M, di Rosario G, Russo G, Calcagno A, Gori A, Coppola N, Francisci D, Andreoni M, Foti G, Cristini F, Bassi P, Luzzati R, Scaggiante R, Torti C, Lapadula G, Cuzzi G, Antinori A, Gagliardini R, Navarra A, Girardi E, **Goletti D**. Cascade of care for TB infection in persons newly diagnosed with HIV in Italy. **Int J Tuberc Lung Dis.** 2024 Nov 1;28(11):557-559. doi: 10.5588/ijtld.24.0209. PMID: 39468021.
 59. **Goletti D**, Matteelli A, Cliff JM, Meintjes G, Graham S, Esmail H, Shan Lee S. World TB Day 2025 Theme "Yes! We Can End TB: Commit, Invest, Deliver" can be made a reality through concerted global efforts to advance diagnosis, treatment and research of tuberculosis infection and disease. **Int J Infect Dis.** 2025 Mar 17:107892. doi: 10.1016/j.ijid.2025.107892. Epub ahead of print. PMID: 40107343.
 60. Alonzi T, Petruccioli E, Aiello A, Repele F, **Goletti D**. Diagnostic tests for tuberculosis infection and predictive indicators of disease progression: utilizing host and pathogen biomarkers to enhance the TB elimination strategies. **Int J Infect Dis.** 2025 Mar 12:107880. doi: 10.1016/j.ijid.2025.107880. Epub ahead of print. PMID: 40086617.
 61. Zumla A, Sahu S, Yeboah-Manu D, **Goletti D**, Nyasulu PS, Mfinanga S, Shilalukey-Ngoma M, Ntoumi F, Rodriguez-Morales AJ, Everett DB, Kamarulzaman A, Hui DS. Breaking dependency: strengthening the global tuberculosis response in the face of USAID cuts. **Lancet.** 2025 Mar 22;405(10483):958-961. doi: 10.1016/S0140-6736(25)00335-6. Epub 2025 Feb 26. PMID: 40023179.
 62. Di Bari V, Cerva C, Libertone R, Carli SM, Musso M, **Goletti D**, Aiello A, Mazzarelli A, Cannas A, Matusali G, Palmieri F, Gualano G, On Behalf Of The Tb- Inmi Working Group. Impact of Severity of COVID-19 in TB Disease Patients: Experience from an Italian Infectious Disease Referral Hospital. **Infect Dis Rep.** 2025 Feb 5;17(1):11. doi: 10.3390/idr17010011. PMID: 39997463; PMCID: PMC11855733.
 63. Picchianti-Diamanti A, Aiello A, De Lorenzo C, Migliori GB, **Goletti D**. Management of tuberculosis risk, screening and preventive therapy in patients with chronic autoimmune arthritis undergoing biotechnological and targeted immunosuppressive agents. **Front Immunol.** 2025 Feb 3;16:1494283. doi: 10.3389/fimmu.2025.1494283. PMID: 39963138; PMCID: PMC11830708
 64. Farroni C, Altera AMG, Salmi A, Vanini V, Cuzzi G, Lindestam Arlehamn CS, Sette A, Delogu G, Palucci I, Sbarra S, Aiello A, Picchianti-Diamanti A, Gualano G, Palmieri F, **Goletti D**, Petruccioli E. Specific immune response to M. tuberculosis and ability to in vitro control mycobacterial replication are not impaired in subjects with immune-mediated inflammatory disease and tuberculosis infection. **Front Immunol.** 2025 Jan 13;15:1484143. doi: 10.3389/fimmu.2024.1484143. PMID: 39872515; PMCID: PMC11770028.
 65. Licata MA, Mencarini P, Mastrobattista A, Carli SM, Cerva C, Mosti S, Libertone R, Zolezzi A, Vittozzi P, Nisii C, Mazzarelli A, Cannas A, Navarra A, Ianniello S, Trisolini R, **Goletti D**, Palmieri F, Gualano G. Clinical Utility of Induced Sputum and Bronchoalveolar Lavage Cultures in Diagnosing Nontuberculous Mycobacterial Pulmonary Disease. **Pathogens.** 2024 Dec 3;13(12):1064. doi: 10.3390/pathogens13121064. PMID: 39770324; PMCID: PMC11728528. Khelghati F, Rahmanian M, Eghbal E, Seghatoleslami ZS, Goudarzi M, Keramatinia A, Ong CW, **Goletti D**, D'Ambrosio L, Centis R, Nasiri MJ, Migliori GB. Risk of tuberculosis disease in patients receiving TNF- α antagonist therapy: A meta-analysis of randomized controlled trials. **New Microbes New Infect.** 2024 Nov 16;62:101533. doi: 10.1016/j.nmni.2024.101533. PMID: 39639969; PMCID: PMC11617757.
 66. **Goletti D**, Meintjes G, Andrade BB, Zumla A, Shan Lee S. Insights from the 2024 WHO Global Tuberculosis Report - More Comprehensive Action, Innovation, and Investments required for achieving WHO End TB goals. **Int J Infect Dis.** 2025 Jan;150:107325. doi: 10.1016/j.ijid.2024.107325. Epub 2024 Dec 2. PMID: 39631498.
 67. Najafi-Fard S, Farroni C, Petrone L, Altera AMG, Salmi A, Vanini V, Cuzzi G, Alonzi T, Nicastrì E, Gualano G, Palmieri F, Piacentini M, **Goletti D**. Immunomodulatory effects of cysteamine and its potential use as a host-directed therapy for tuberculosis. **Front Immunol.** 2024 Oct 28;15:1411827. doi: 10.3389/fimmu.2024.1411827. PMID: 39530101; PMCID: PMC11550979.
 68. Matteelli A, Formenti B, Cimaglia C, Visconti M, di Rosario G, Russo G, Calcagno A, Gori A, Coppola N, Francisci D, Andreoni M, Foti G, Cristini F, Bassi P, Luzzati R, Scaggiante R, Torti C, Lapadula G, Cuzzi G, Antinori A, Gagliardini R, Navarra A, Girardi E, **Goletti D**. Cascade of care for TB infection in persons newly diagnosed with HIV in Italy. **Int J Tuberc Lung Dis.** 2024 Nov 1;28(11):557-559. doi: 10.5588/ijtld.24.0209. PMID: 39468021.

69. Prosperini L, Arrambide G, Celius EG, **Goletti D**, Killestein J, Kos D, Lavorgna L, Louapre C, Sormani MP, Stastna D, Ziemssen T, Di Filippo M. COVID-19 and multiple sclerosis: challenges and lessons for patient care. **Lancet Reg Health Eur.** 2024 Aug 22;44:100979. doi: 10.1016/j.lanepe.2024.100979. PMID: 39429966; PMCID: PMC11486927.
70. Petrone L, Peruzzo D, Altera AMG, Salmi A, Vanini V, Cuzzi G, Coppola A, Mellini V, Gualano G, Palmieri F, Panda S, Peters B, Sette A, Arlehamn CSL, **Goletti D**. Therapy modulates the response to T cell epitopes over the spectrum of tuberculosis infection. **J Infect.** 2024 Sep 27;89(6):106295. doi: 10.1016/j.jinf.2024.106295. Epub ahead of print. PMID: 39343243.
71. Petruccioli E, Sbarra S, Vita S, Salmi A, Cuzzi G, De Marco P, Matusali G, Navarra A, Pierelli L, Grifoni A, Sette A, Maggi F, Nicastrì E, **Goletti D**. Characterization of the Monkeypox Virus [MPX]-Specific Immune Response in MPX- Cured Individuals Using Whole Blood to Monitor Memory Response. **Vaccines (Basel).** 2024 Aug 26;12(9):964. doi: 10.3390/vaccines12090964. PMID: 39339995; PMCID: PMC11436000.
72. Riccardi N, Monari C, Antonello RM, Saderi L, Occhineri S, Pontarelli A, Zucchi P, Buonsenso D, Falbo E, Faverio P, Aliberti S, Parrella R, Falcone M, Besozzi G, Calcagno A, **Goletti D**, Gualano G, Sotgiu G, Tadolini M, Codecasa L. TB outpatient care in a high-income, low-incidence country. **Int J Tuberc Lung Dis.** 2024 Oct 1;28(10):513-515. doi: 10.5588/ijtld.24.0059. PMID: 39334547.
73. Aiello A, Ruggieri S, Navarra A, Tortorella C, Vanini V, Haggag S, Prosperini L, Cuzzi G, Salmi A, Quartuccio ME, Altera AMG, Meschi S, Matusali G, Vita S, Galgani S, Maggi F, Nicastrì E, Gasperini C, **Goletti D**. Anti-RBD Antibody Levels and IFN- γ -Specific T Cell Response Are Associated with a More Rapid Swab Reversion in Patients with Multiple Sclerosis after the Booster Dose of COVID-19 Vaccination. **Vaccines (Basel).** 2024 Aug 19;12(8):926. doi: 10.3390/vaccines12080926. PMID: 39204049; PMCID: PMC11359508.
74. Torres T, Brembilla NC, Langley RG, Warren RB, Thaçi D, Kolios AGA, Prinz JC, Londono-Garcia A, Nast A, Santin M, **Goletti D**, Abreu M, Spuls P, Boehncke WH, Puig L. Treatment of psoriasis with biologic and non-biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: Recommendations from a SPIN-FRT expert consensus. **J Eur Acad Dermatol Venereol.** 2024 Aug 16. doi: 10.1111/jdv.20287. Epub ahead of print. PMID: 39149807.
75. Alonzi T, Aiello A, Sali M, Delogu G, Vilella VR, Raia V, Nicastrì E, Piacentini M, **Goletti D**. Multiple antimicrobial and immune-modulating activities of cysteamine in infectious diseases. **Biomed Pharmacother.** 2024 Jul 17;178:117153. doi: 10.1016/j.biopha.2024.117153. Epub ahead of print. PMID: 39024833.
76. Petrone L, Najafi-Fard S, Falasca L, Sbarra S, Teggi A, Nicastrì E, Grillo LR, Burocchi M, Ettore GM, Ludovisi A, Colombo D, Del Nonno F, **Goletti D**. Evaluation of the Local and Peripheral Immune Responses in Patients with Cystic Echinococcosis. **Pathogens.** 2024 Jun 4;13(6):477. doi: 10.3390/pathogens13060477. PMID: 38921775; PMCID: PMC11206897.
77. Santin M, Trajman A, **Goletti D**, Anibarro L. Editorial: Addressing tuberculosis infection: an essential step in the fight against tuberculosis. **Front Med (Lausanne).** 2024 Jun 7;11:1428677. doi: 10.3389/fmed.2024.1428677. PMID: 38912341; PMCID: PMC11190313.
78. **Goletti D**, Ong CWM, Friedland JS. Host-directed therapies: old and new approaches for the treatment of infections. **Int J Infect Dis.** 2024 Jun 9;146:107130. doi: 10.1016/j.ijid.2024.107130. Epub ahead of print. PMID: 38857650.
79. Paulowski L, Filip R, Jankovic Makek M, Guglielmetti L, **Goletti D**, van Ingen J, Kranzer K, Maurer FP, ESGMYC. Impact of the COVID-19 pandemic on the real- world diagnostic infrastructure for tuberculosis-An ESGMYC collaborative study. **PLoS One.** 2024 Apr 16;19(4):e0291404. doi: 10.1371/journal.pone.0291404. PMID: 38626036; PMCID: PMC11020973.
80. Russomando G, Sanabria D, Díaz Acosta CC, Rojas L, Franco L, Arenas R, Delogu G, Ndiaye MDB, Bayaa R, Rakotosamimanana N, **Goletti D**, Hoffmann J. C1q and HBHA- specific IL-13 levels as surrogate plasma biomarkers for monitoring tuberculosis treatment efficacy: a cross-sectional cohort study in Paraguay. **Front Immunol.** 2024 Mar 13;15:1308015. doi: 10.3389/fimmu.2024.1308015. PMID: 38545118; PMCID: PMC10967656.
81. D'Abramo A, Vita S, Beccacece A, Navarra A, Pisapia R, Fusco FM, Matusali G, Girardi E, Maggi F, **Goletti D**, Nicastrì E. B-cell-depleted patients with persistent SARS-CoV-2 infection: combination therapy or monotherapy? A real- world experience. **Front Med (Lausanne).** 2024 Feb 29;11:1344267. doi: 10.3389/fmed.2024.1344267. PMID: 38487021; PMCID: PMC10937561.
82. Repele F, Alonzi T, Navarra A, Farroni C, Salmi A, Cuzzi G, Delogu G, Gualano G, Puro V, De Carli G, Girardi E, Palmieri F, Martineau AR, **Goletti D**. Detection of Mycobacterium tuberculosis DNA in CD34+ peripheral blood mononuclear cells of adults with tuberculosis infection and disease. **Int J Infect Dis.** 2024 Apr;141S:106999. doi: 10.1016/j.ijid.2024.106999. Epub 2024 Mar 7. PMID: 38458427.
83. **Goletti D**, Al-Abri S, Migliori GB, Arlehamn CL, Haldar P, Sundling C, da Costa C, To KW, Martineau AR, Petersen E, Zumla A, Shan Lee S. World Tuberculosis Day 2024 theme "Yes! We can end TB" can be made a reality through concerted global efforts that advance detection, diagnosis, and treatment of tuberculosis infection and disease. **Int J Infect Dis.** 2024 Apr;141S:106993. doi: 10.1016/j.ijid.2024.106993. Epub 2024 Mar 7. PMID: 38458422.
84. da Costa C, Benn CS, Nyirenda T, Mpabawani E, Grewal HMS, Ahmed R, Kapata N, Nyasulu PS, Maeurer M, Hui DS, **Goletti D**, Zumla A. Perspectives on development and advancement of new tuberculosis vaccines. **Int J Infect Dis.** 2024 Apr;141S:106987. doi: 10.1016/j.ijid.2024.106987. Epub 2024 Feb 26. PMID: 38417616.
85. Vita S, D'Abramo A, Coppola A, Farroni C, Iori AP, Faraglia F, Sette A, Grifoni A, Lindestam Arlehamn C, Bibas M, **Goletti D**, Nicastrì E. Combined antiviral therapy as effective and feasible option in allogeneic hematopoietic stem cell transplantation during SARS-COV-2 infection: a case report. **Front Oncol.** 2024 Feb 13;14:1290614. doi: 10.3389/fonc.2024.1290614. PMID: 38414746; PMCID: PMC10896944.
86. Calcagno A, Coppola N, Sarmati L, Tadolini M, Parrella R, Matteelli A, Riccardi N, Trezzi M, Di Biagio A, Piriatore V, Russo A, Gualano G, Pontali E, Surace L, Falbo E, Mencarini J, Palmieri F, Gori A, Schiuma M, Lapadula G, **Goletti D**; Study Group on Mycobacteria (MYGRO) of the Italian Society of Infectious Diseases and Tropical Medicine (SIMIT).. Drugs for treating infections caused by non-tubercular mycobacteria: a narrative review from the study group on mycobacteria of the Italian Society of Infectious Diseases and Tropical Medicine. **Infection.** 2024 Jun;52(3):737-765. doi: 10.1007/s15010-024-02183-3. Epub 2024 Feb 8. PMID: 38329686; PMCID: PMC11142973.

87. Trionfetti F, Alonzi T, Bontempi G, Terri M, Battistelli C, Montaldo C, Repele F, Rotili D, Valente S, Zwergel C, Matusali G, Maggi F, **Goletti D**, Tripodi M, Mai A, Strippoli R. HDAC1-3 inhibition increases SARS-CoV-2 replication and productive infection in lung mesothelial and epithelial cells. **Front Cell Infect Microbiol.** **2023** Dec 13;13:1257683. doi: 10.3389/fcimb.2023.1257683. PMID: 38162580; PMCID: PMC10757821.
88. Gualano G, Zace D, Mosti S, Mencarini P, Musso M, Libertone R, Cerva C, Goletti D, Rianda A, Del Nonno F, Falasca L, Palmieri F. Utility of Liver Biopsy in the Diagnosis and Management of Possible Drug-Induced Liver Injury in Patients Receiving Antituberculosis Therapy: A Retrospective Study. **Infect Dis Rep.** **2023** Nov 28;15(6):735-746. doi: 10.3390/idr15060066. PMID: 38131879; PMCID: PMC10742487.
89. Petruccioli E, Petrone L, Najafi-Fard S, Navarra A, Vanini V, Cuzzi G, Cantini F, Gualano G, Palmieri F, **Goletti D**. Alternative biomarkers of tuberculosis infection in patients with immune-mediated inflammatory diseases. **Front Med (Lausanne).** **2023** Nov 23;10:1271632. doi: 10.3389/fmed.2023.1271632. PMID: 38076244; PMCID: PMC10704032.
90. **Goletti D**, Al-Abri S, Migliori GB, Coler R, Ong CWM, Esposito SMR, Tadolini M, Matteelli A, Cirillo D, Nemes E, Zumla A, Petersen E. World Tuberculosis Day 2023 theme "Yes! We Can End TB!". **Int J Infect Dis.** **2023** May;130 Suppl 1:S1-S3. doi: 10.1016/j.ijid.2023.04.006. Epub 2023 Apr 7. PMID: 38039194; PMCID: PMC10186916.
91. Picchianti-Diamanti A, Navarra A, Aiello A, Laganà B, Cuzzi G, Salmi A, Vanini V, Maggi F, Meschi S, Matusali G, Notari S, Agrati C, Salemi S, Di Rosa R, Passarini D, Di Gioia V, Sesti G, Conti G, Spinelli FR, Corpolongo A, Chimenti MS, Ferraioli M, Sebastiani GD, Benucci M, Li Gobbi F, Santoro AP, Capri A, Puro V, Nicastri E, **Goletti D**. Older Age, a High Titre of Neutralising Antibodies and Therapy with Conventional DMARDs Are Associated with Protection from Breakthrough Infection in Rheumatoid Arthritis Patients after the Booster Dose of Anti-SARS-CoV-2 Vaccine. **Vaccines (Basel).** **2023** Nov 2;11(11):1684. doi: 10.3390/vaccines11111684. PMID: 38006015; PMCID: PMC10675674.
92. Gupta-Wright A, den Boon S, MacLean EL, Cirillo D, Cobelens F, Gillespie SH, Kohli M, Ruhwald M, Savic R, Brigden G, Gidado M, **Goletti D**, Hanna D, Hasan R, Hewison C, Koura KG, Lienhardt C, Lungu P, McHugh TD, McKenna L, Scott C, Scriba T, Sekaggya-Wiltshire C, Kasaeva T, Zignol M, Denkinger CM, Falzon D. Target product profiles: tests for tuberculosis treatment monitoring and optimization. **Bull World Health Organ.** **2023** Nov 1;101(11):730-737. doi: 10.2471/BLT.23.290901. Epub 2023 Oct 4. PMID: 37961060; PMCID: PMC10630735.
93. Matusali G, Petruccioli E, Cimini E, Colavita F, Bettini A, Tartaglia E, Sbarra S, Meschi S, Lapa D, Francalancia M, Bordini L, Mazzotta V, Coen S, Mizzoni K, Beccacece A, Nicastri E, Pierelli L, Antinori A, Girardi E, Vaia F, Sette A, Grifoni A, **Goletti D**, Puro V, Maggi F. Evaluation of Cross-Immunity to the Mpox Virus Due to Historic Smallpox Vaccination. **Vaccines (Basel).** **2023** Sep 28;11(10):1541. doi: 10.3390/vaccines11101541. PMID: 37896943; PMCID: PMC10610801.
94. Global Tuberculosis Network and TB/COVID-19 Global Study Group; Casco N, Jorge AL, Palmero DJ, Alfenaar JW, Fox GJ, Ezz W, Cho JG, Denholm J, Skrahina A, Solodovnikova V, Arbex MA, Alves T, Rabahi MF, Pereira GR, Sales R, Silva DR, Saffie MM, Salinas NE, Miranda RC, Cisterna C, Concha C, Fernandez I, Villalón C, Vera CG, Tapia PG, Cancino V, Carbonell M, Cruz A, Muñoz E, Muñoz C, Navarro I, Pizarro R, Cristina Sánchez GP, Vergara Riquelme MS, Vilca E, Soto A, Flores X, Garavagno A, Bahamondes MH, Merino LM, Pradenas AM, Revillat ME, Rodriguez P, Salinas AS, Taiba C, Valdés JF, Subiabre JN, Ortega C, Palma S, Castillo PP, Pinto M, Bidegain FR, Venegas M, Yucra E, Li Y, Cruz A, Guelvez B, Victoria Plaza R, Tello Hoyos KY, Cardoso-Landivar J, Van Den Boom M, Andréjak C, Blanc FX, Dourmane S, Froissart A, Izadifar A, Rivière F, Schlemmer F, Manika K, Diallo BD, Hassane-Harouna S, Artiles N, Mejia LA, Gupta N, Ish P, Mishra G, Patel JM, Singla R, Udawadia ZF, Alladio F, Angeli F, Calcagno A, Centis R, Codecasa LR, De Lauretis A, Esposito SMR, Formenti B, Gaviraghi A, Giacomet V, **Goletti D**, Gualano G, Matteelli A, Migliori GB, Motta I, Palmieri F, Pontali E, Prestileo T, Riccardi N, Saderi L, Saporiti M, Sotgiu G, Spanevello A, Stochino C, Tadolini M, Torre A, Villa S, Visca D, Kurhasani X, Furjani M, Rasheed N, Danila E, Diktanas S, Ridaura RL, Luna López FL, Torrico MM, Rendon A, Akkerman OW, Chizaram O, Al-Abri S, Alyaqubi F, Althohli K, Aguirre S, Teixeira RC, De Egea V, Irala S, Medina A, Sequera G, Sosa N, Vázquez F, Llanos-Tejada FK, Manga S, Villanueva-Villegas R, Araujo D, Sales Marques RD, Socaci A, Barkanova O, Bogorodskaya M, Borisov S, Mariandyshev A, Kaluzhenina A, Vukicevic TA, Stosic M, Beh D, Ng D, Ong CWM, Solovic I, Dheda K, Gina P, Caminero JA, De Souza Galvão ML, Dominguez-Castellano A, García-García JM, Pinargote IM, Fernandez SQ, Sánchez-Montalvá A, Huguet ET, Murguiondo MZ, Bart PA, Mazza-Stalder J, D'Ambrosio L, Kamolwat P, Bakko F, Barnacle J, Bird S, Brown A, Chandran S, Killington K, Man K, Papineni P, Ritchie F, Tiberi S, Utjesanovic N, Zenner D, Hearn JL, Heysell S, Young L. Long-term outcomes of the global tuberculosis and COVID-19 co-infection cohort. **Eur Respir J.** **2023** Nov 29;62(5):2300925. doi: 10.1183/13993003.00925-2023. PMID: 37827576; PMCID: PMC10627308.
95. Aiello A, Najafi-Fard S, **Goletti D**. Initial immune response after exposure to Mycobacterium tuberculosis or to SARS-CoV-2: similarities and differences. **Front Immunol.** **2023** Aug 17;14:1244556. doi: 10.3389/fimmu.2023.1244556. PMID: 37662901; PMCID: PMC10470049.
96. Alonzi T, Repele F, **Goletti D**. Research tests for the diagnosis of tuberculosis infection. **Expert Rev Mol Diagn.** **2023** Jul-Dec;23(9):783-795. doi: 10.1080/14737159.2023.2240230. Epub 2023 Aug 10. PMID: 37561602.
97. Romagnoli A, Di Rienzo M, Petruccioli E, Fusco C, Palucci I, Micale L, Mazza T, Delogu G, Merla G, **Goletti D**, Piacentini M, Fimia GM. The ubiquitin ligase TRIM32 promotes the autophagic response to Mycobacterium tuberculosis infection in macrophages. **Cell Death Dis.** **2023** Aug 5;14(8):505. doi: 10.1038/s41419-023-06026-1. PMID: 37543647; PMCID: PMC10404268.
98. Petrone L, Sette A, de Vries RD, **Goletti D**. The Importance of Measuring SARS-CoV-2-Specific T-Cell Responses in an Ongoing Pandemic. **Pathogens.** **2023** Jun 22;12(7):862. doi: 10.3390/pathogens12070862. PMID: 37513709; PMCID: PMC10385870.
99. Niewold P, Dijkstra DJ, Cai Y, **Goletti D**, Palmieri F, van Meijgaarden KE, Verreck FAW, Akkerman OW, Hofland RW, Delemarre EM, Nierkens S, Verheul MK, Pollard AJ, van Dissel JT, Ottenhoff THM, Trouw LA, Joosten SA. Identification of circulating monocytes as producers of tuberculosis disease biomarker C1q. **Sci Rep.** **2023** Jul 18;13(1):11617. doi: 10.1038/s41598-023-38889-x. PMID: 37464009; PMCID: PMC10354225.
100. Kontsevaya I, Cabibbe AM, Cirillo DM, DiNardo AR, Frahm N, Gillespie SH, Holtzman D, Meiwees L, Petruccioli E, Reimann M, Ruhwald M, Sabiiti W, Saluzzo F, Tagliani E, **Goletti D**. Update on the diagnosis of tuberculosis. **Clin Microbiol Infect.** **2023** Jul 23:S1198-743X(23)00340-3. doi: 10.1016/j.cmi.2023.07.014. Epub ahead of print. PMID: 37490968.

101. Carlini V, Noonan DM, Abdalalem E, **Goletti D**, Sansone C, Calabrone L, Albini A. The multifaceted nature of IL-10: regulation, role in immunological homeostasis and its relevance to cancer, COVID-19 and post-COVID conditions. **Front Immunol.** **2023** Jun 8;14:1161067. doi: 10.3389/fimmu.2023.1161067. PMID: 37359549; PMCID: PMC10287165.
102. Grifoni A, Alonzi T, Alter G, Noonan DM, Landay AL, Albini A, **Goletti D**. Impact of aging on immunity in the context of COVID-19, HIV, and tuberculosis. **Front Immunol.** **2023** May 24;14:1146704. doi: 10.3389/fimmu.2023.1146704. PMID: 37292210; PMCID: PMC10246744.
103. Ruggieri S, Aiello A, Tortorella C, Navarra A, Vanini V, Meschi S, Lapa D, Haggiag S, Prosperini L, Cuzzi G, Salmi A, Quartuccio ME, Altera AMG, Garbuglia AR, Ascoli Bartoli T, Galgani S, Notari S, Agrati C, Puro V, Nicastrì E, Gasperini C, **Goletti D**. Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster Dose. **Int J Mol Sci.** **2023** May 10;24(10):8525. doi: 10.3390/ijms24108525. PMID: 37239872; PMCID: PMC10218688.
104. Santoro A, Capri A, Petrone D, Colavita F, Meschi S, Matusali G, Mizzoni K, Notari S, Agrati C, **Goletti D**, Pezzotti P, Puro V. SARS-CoV-2 Breakthrough Infections According to the Immune Response Elicited after mRNA Third Dose Vaccination in COVID-19-Naïve Hospital Personnel. **Biomedicines.** **2023** Apr 23;11(5):1247. doi: 10.3390/biomedicines11051247. PMID: 37238918; PMCID: PMC10215853.
105. Batisti Biffignandi G, Vola A, Sasserà D, Najafi-Fard S, Gomez Morales MA, Brunetti E, Teggi A, **Goletti D**, Petrone L, Tamarozzi F. Antigen discovery by bioinformatics analysis and peptide microarray for the diagnosis of cystic echinococcosis. **PLoS Negl Trop Dis.** **2023** Apr 12;17(4):e0011210. doi: 10.1371/journal.pntd.0011210. PMID: 37043489; PMCID: PMC10096192.
106. **Goletti D**, Pisapia R, Fusco FM, Aiello A, Van Crevel R. Epidemiology, pathogenesis, clinical presentation and management of TB in patients with HIV and diabetes. **Int J Tuberc Lung Dis.** **2023** Apr 1;27(4):284-290. doi: 10.5588/ijtld.22.0685. PMID: 37035976; PMCID: PMC10094052.
107. **Goletti D**, Al-Abri S, Migliori GB, Coler R, Ong C, Esposito S, Tadolin M, Matteelli A, Cirillo D, Nemes E, Zumla A, Petersen E. World TB Day 2023 Theme "Yes! We Can End TB!". **Int J Infect Dis.** **2023** Apr 6:S1201-9712(23)00137-6. doi: 10.1016/j.ijid.2023.04.006. Epub ahead of print. PMID: 37031772.
108. Petersen E, Hui DS, Nachega JB, Ntouni F, **Goletti D**, Akillu E, Sharma A, Nyirenda T, Yeboah-Manu D, Satta G, da Costa C, Azhar EI, Bockarie M, Al-Abri S, McHugh TD, Rodriguez-Morales AJ, Varghese GM, Zumla A. End of the Bedaquiline patent - a crucial development for moving forward affordable drugs, diagnostics, and vaccines for infectious diseases in low- and middle-income countries. **Int J Infect Dis.** **2023** Apr 6:S1201-9712(23)00517-9. doi: 10.1016/j.ijid.2023.04.386. Epub ahead of print. PMID: 37030652.
109. Picchianti Diamanti A, Navarra A, Cuzzi G, Aiello A, Salemi S, Di Rosa R, De Lorenzo C, Vio D, Sebastiani G, Ferraioli M, Benucci M, Li Gobbi F, Cantini F, Polidori V, Simmaco M, Cialdi E, Scolieri P, Bruzzese V, Nicastrì E, D'Amelio R, Laganà B, **Goletti D**. The Third Dose of BNT162b2 COVID-19 Vaccine Does Not "Boost" Disease Flares and Adverse Events in Patients with Rheumatoid Arthritis. **Biomedicines.** **2023** Feb 23;11(3):687. doi: 10.3390/biomedicines11030687. PMID: 36979666; PMCID: PMC10045021.
110. Najafi-Fard S, Aiello A, Navarra A, Cuzzi G, Vanini V, Migliori GB, Gualano G, Cerva C, Grifoni A, Sette A, Vaia F, Palmieri F, **Goletti D**. Characterization of the immune impairment of patients with tuberculosis and COVID-19 coinfection. **Int J Infect Dis.** **2023** Mar 21:S1201-9712(23)00099-1. doi: 10.1016/j.ijid.2023.03.021. Epub ahead of print. PMID: 36944383; PMCID: PMC10027657.
111. Nalunjogi J, Mucching-Toscano S, Sibomana JP, Centis R, D'Ambrosio L, Alfenaar JW, Denholm J, Blanc FX, Borisov S, Danila E, Duarte R, García-García JM, **Goletti D**, Ong CWM, Rendon A, Thomas TA, Tiberi S, van den Boom M, Sotgiu G, Migliori GB; Global Tuberculosis Network. Impact of COVID-19 on diagnosis of TB, MDR-TB and on mortality in 11 countries in Europe, Northern America and Australia. A Global Tuberculosis Network study. **Int J Infect Dis.** **2023** Mar 7:S1201-9712(23)00076-0. doi: 10.1016/j.ijid.2023.02.025. Epub ahead of print. PMID: 36893943; PMCID: PMC9991328.
112. Rescigno M, Agrati C, Salvarani C, Giannarelli D, Costantini M, Mantovani A, Massafra R, Zinzani PL, Morrone A, Notari S, Matusali G, Pinter GL, Uccelli A, Ciliberto G, Baldanti F, Locatelli F, Silvestris N, Sinno V, Turolo E, Lupo- Stanghellini MT, Apolone G; VAX4FRAIL study Group. Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters. **Front Immunol.** **2023** Jan 27;14:1104124. doi: 10.3389/fimmu.2023.1104124.
113. Palucci I, Salustri A, De Maio F, Pereyra Boza MDC, Paglione F, Sali M, Occhigrossi L, D'Eletto M, Rossin F, **Goletti D**, Sanguinetti M, Piacentini M, Delogu G. Cysteamine/Cystamine Exert Anti-Mycobacterium abscessus Activity Alone or in Combination with Amikacin. **Int J Mol Sci.** **2023** Jan 7;24(2):1203. doi: 10.3390/ijms24021203. PMID: 36674717; PMCID: PMC9866335
114. Pierneef L, van Hooij A, de Jong D, Tjon Kon Fat EM, van Meijgaarden KE, Petruccioli E, Vanini V, Roukens AHE, **Goletti D**, Corstjens PLAM, Joosten SA, Geluk A; BEAT-COVID study group. Host biomarker-based quantitative rapid tests for detection and treatment monitoring of tuberculosis and COVID-19. **iScience.** **2023** Jan 20;26(1):105873. doi: 10.1016/j.isci.2022.105873. Epub 2022 Dec 26. PMID: 36590898; PMCID: PMC9791715.
115. Centofanti F, Alonzi T, Latini A, Spitalieri P, Murdocca M, Chen X, Cui W, Shang Q, **Goletti D**, Shi Y, Duranti A, Tomino C, Biancolella M, Sangiuolo F, Capobianchi MR, Jain S, Novelli G, Pandolfi PP. Indole-3-carbinol in vitro antiviral activity against SARS-Cov-2 virus and in vivo toxicity. **Cell Death Discov.** **2022** Dec 15;8(1):491. doi: 10.1038/s41420-022-01280-2. PMID: 36522315; PMCID: PMC9751508.
116. Aiello A, Coppola A, Ruggieri S, Farroni C, Altera AMG, Salmi A, Vanini V, Cuzzi G, Petrone L, Meschi S, Lapa D, Bettini A, Haggiag S, Prosperini L, Galgani S, Quartuccio ME, Bevilacqua N, Garbuglia AR, Agrati C, Puro V, Tortorella C, Gasperini C, Nicastrì E, **Goletti D**. Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies. **J Neurol Neurosurg Psychiatry.** **2022** Dec 15:jnnp-2022-330175. doi: 10.1136/jnnp-2022-330175. Epub ahead of print. PMID: 36522154.
117. Buonsenso D, Mariani F, Biala JS, **Goletti D**. COVID-19 effect on tuberculosis care in Sierra Leone: Are we in the recovery phase? **Pulmonology.** **2022** Oct 31:S2531-0437(22)00255-0. doi: 10.1016/j.pulmoe.2022.10.008. Epub ahead of print. PMID: 36473827; PMCID: PMC9618437.

118. Fornaro M, Stano S, **Goletti D**, Semeraro A, Cantatore FP, Maruotti N, Colella S, Abbruzzese A, Santo L, Praino E, Iannone F. Prevalence and management of tuberculosis infection in Apulian rheumatologic patients treated with biologics: an observational cohort 10-year study from the BIOPURE registry. **Eur J Clin Invest.** 2022 Nov 27:e13913. doi: 10.1111/eci.13913. Epub ahead of print. PMID: 36435984
119. Farroni C, Aiello A, Picchianti-Diamanti A, Laganà B, Petruccioli E, Agrati C, Garbuglia AR, Meschi S, Lapa D, Cuzzi G, Petrone L, Vanini V, Salmi A, Altera AMG, Repele F, Grassi G, Bettini A, Vita S, Mariano A, Damiani A, Infantino M, Grossi V, Manfredi M, Niccoli L, Puro V, Rosa RD, Salemi S, Sesti G, Scolieri P, Bruzzese V, Benucci M, Cantini F, Nicastrì E, **Goletti D**. Booster dose of SARS-CoV-2 messenger RNA vaccines strengthens the specific immune response of patients with rheumatoid arthritis: A prospective multicenter longitudinal study. **Int J Infect Dis.** 2022 Nov 1;125:195-208. doi: 10.1016/j.ijid.2022.10.035. Epub ahead of print. PMID: 36328289; PMCID: PMC9622025.
120. Migliori GB, Matteelli A, Zenner D, **Goletti D**, Ong CWM. Reply to Furin et al.: Clinical standards that are appropriate for all settings. **Int J Tuberc Lung Dis.** 2022 Nov 1;26(11):1093-1094. doi: 10.5588/ijtld.22.0452. PMID: 36281054.
121. Najafi-Fard S, Petruccioli E, Farroni C, Petrone L, Vanini V, Cuzzi G, Salmi A, Altera AMG, Navarra A, Alonzi T, Nicastrì E, Palmieri F, Gualano G, Carlini V, Noonan DM, Albini A, **Goletti D**. Evaluation of the immunomodulatory effects of interleukin-10 on peripheral blood immune cells of COVID-19 patients: Implication for COVID-19 therapy. **Front Immunol.** 2022 Sep 6;13:984098. doi: 10.3389/fimmu.2022.984098. PMID: 36148228; PMCID: PMC9486547.
122. Canetti D, Antonello RM, Sadari L, Giro M, **Goletti D**, Sarmati L, Rodari P, Bocchino M, Schirò M, Riccardi N, Sotgiu G. Impact of SARS-CoV-2 infection on tuberculosis outcome and follow-up in Italy during the first COVID-19 pandemic wave: a nationwide online survey. **Infez Med.** 2022 Sep 1;30(3):418-426. doi: 10.53854/liim-3003-10. PMID: 36148161; PMCID: PMC9448321.
123. Ruibal P, Franken KLMC, van Meijgaarden KE, van Wolfswinkel M, Derksen I, Scheeren FA, Janssen GMC, van Veelen PA, Sarfas C, White AD, Sharpe SA, Palmieri F, Petrone L, **Goletti D**, Abeel T, Ottenhoff THM, Joosten SA. Identification of HLA-E Binding Mycobacterium tuberculosis-Derived Epitopes through Improved Prediction Models. **J Immunol.** 2022 Sep 12;2200122. doi: 10.4049/jimmunol.2200122. Epub ahead of print. PMID: 36096642.
124. Compagno M, Navarra A, Campogiani L, Coppola L, Rossi B, Iannetta M, Malagnino V, Parisi SG, Mariotti B, Cerretti R, Arcese W, **Goletti D**, Andreoni M, Sarmati L. Latent Tuberculosis Infection in Haematopoietic Stem Cell Transplant Recipients: A Retrospective Italian Cohort Study in Tor Vergata University Hospital, Rome. **Int J Environ Res Public Health.** 2022 Aug 27;19(17):10693. doi: 10.3390/ijerph191710693. PMID: 36078409; PMCID: PMC9518118.
125. García-García JM, Blanc FX, Buonsenso D, Centis R, Codecasa LR, D'Ambrosio L, **Goletti D**, Gualano G, Kunst H, Pontali E, Tadolini M, Tiberi S, Ong CWM, Sotgiu G, Migliori GB; Global Tuberculosis Network. COVID-19 Hampered Diagnosis of TB Infection in France, Italy, Spain and the United Kingdom. **Arch Bronconeumol.** 2022 Aug 13:S0300-2896(22)00503-8. doi: 10.1016/j.arbres.2022.07.013. Epub ahead of print. PMID: 36064681; PMCID: PMC9393764.
126. Vita S, Rosati S, Ascoli Bartoli T, Beccacece A, D'Abramo A, Mariano A, Scorzoloni L, **Goletti D**, Nicastrì E. Monoclonal Antibodies for Pre- and Postexposure Prophylaxis of COVID-19: Review of the Literature. **Pathogens.** 2022 Aug 5;11(8):882. doi: 10.3390/pathogens11080882. PMID: 36015003; PMCID: PMC9412407.
127. Aiello A, Grossi A, Meschi S, Meledandri M, Vanini V, Petrone L, Casetti R, Cuzzi G, Salmi A, Altera AM, Pierelli L, Gualano G, Ascoli Bartoli T, Castilletti C, Agrati C, Girardi E, Palmieri F, Nicastrì E, Di Rosa E, **Goletti D**. Coordinated innate and T-cell immune responses in mild COVID-19 patients from household contacts of COVID-19 cases during the first pandemic wave. **Front Immunol.** 2022 Jul 27;13:920227. doi: 10.3389/fimmu.2022.920227. PMID: 35967321; PMCID: PMC9364317.
128. Aiello A, Coppola A, Vanini V, Petrone L, Cuzzi G, Salmi A, Altera AMG, Tortorella C, Gualano G, Gasperini C, Scolieri P, Beccacece A, Vita S, Bruzzese V, Lorenzetti R, Palmieri F, Nicastrì E, **Goletti D**. Accuracy of QuantiFERON SARS-CoV-2 RUO assay and characterization of the CD4+ and CD8+ T-cell-SARS-CoV-2 response: comparison with a homemade IFN-γ release assay. **Int J Infect Dis.** 2022 Jul 22;122:841-9. doi: 10.1016/j.ijid.2022.07.049. Epub ahead of print. PMID: 35878802; PMCID: PMC9307287.
129. Petrone L, Tortorella C, Aiello A, Farroni C, Ruggieri S, Castilletti C, Meschi S, Cuzzi G, Vanini V, Palmieri F, Prosperini L, Haggiag S, Galgani S, Grifoni A, Sette A, Gasperini C, Nicastrì E, **Goletti D**. Humoral and Cellular Response to Spike of Delta SARS-CoV-2 Variant in Vaccinated Patients With Multiple Sclerosis. **Front Neurol.** 2022 May 31;13:881988. doi: 10.3389/fneur.2022.881988. PMID: 35711277; PMCID: PMC9194677.
130. Alonzi T, Aiello A, Repele F, Falasca L, Francalancia M, Garbuglia AR, Delogu G, Nicastrì E, Piacentini M, **Goletti D**. Cysteamine exerts in vitro antiviral activity against the SARS-CoV-2 Delta and Omicron variants. **Cell Death Discov.** 2022 Jun 15;8(1):288. doi: 10.1038/s41420-022-01080-8. PMID: 35705564; PMCID: PMC9199336.
131. Bergeron A, Mikulska M, De Greef J, Bondeelle L, Franquet T, Hermann JL, Lange C, Spriet I, Akova M, Donnelly JP, Maertens J, Maschmeyer G, Rovira M, **Goletti D**, de la Camara R; European Conference on Infections in Leukaemia group. Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplants: guidelines from the 8th European Conference on Infections in Leukaemia. **Lancet Infect Dis.** 2022 May 27:S1473-3099(22)00227-4. doi: 10.1016/S1473-3099(22)00227-4. Epub ahead of print. PMID: 35636446.
132. Guglielmetti L, Günther G, Leu C, Cirillo D, Duarte R, Garcia-Basteiro AL, **Goletti D**, Jankovic M, Kuksa L, Maurer FP, Méchai F, Tiberi S, van Leth F, Veziris N, Lange C; Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS) and; Tuberculosis Network European Trials group (TBnet). Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. **Eur Respir J.** 2022 May 19;59(5):2200388. doi: 10.1183/13993003.00388-2022. Print 2022 May. PMID: 35589114 Free PMC article.
133. Migliori GB, Thong PM, Alfenaar JW, Denholm J, Tadolini M, Alyaqubi F, Al-Abri S, Blanc FX, Buonsenso D, Chakaya J, Cho JG, Codecasa LR, Danila E, Duarte R, Dukpa R, García-García JM, Gualano G, Kurhasani X, Manika K, Mello FCQ, Pahl K, Rendon A, Sotgiu G, Souleymane MB,

- Thomas TA, Tiberi S, Kunst H, Udwadia ZF, **Goletti D**, Centis R, D'Ambrosio L, Silva DR. Country-specific lockdown measures in response to the COVID-19 pandemic and its impact on tuberculosis control: a global study. **J Bras Pneumol.** 2022 Apr 20;48(2):e20220087. English, Portuguese. doi: 10.36416/1806-3756/e20220087. PMID: 35475873.
134. Petrone L, Picchianti-Diamanti A, Sebastiani GD, Aiello A, Laganà B, Cuzzi G, Vanini V, Gualano G, Grifoni A, Ferraioli M, Castilletti C, Meschi S, Vaia F, Nicastri E, Sette A, **Goletti D**. Humoral and cellular responses to spike of δ SARS-CoV-2 variant in vaccinated patients with Immune Mediated Inflammatory Diseases. **Int J Infect Dis.** 2022 Apr 21:S1201-9712(22)00229-6. doi: 10.1016/j.ijid.2022.04.027. Epub ahead of print. PMID: 35462039; PMCID: PMC9023365.
 135. Agrati C, Castilletti C, **Goletti D**, Sacchi A, Bordoni V, Mariotti D, Notari S, Matusali G, Meschi S, Petrone L, Aiello A, Najafi Fard S, Farroni C, Colavita F, Lapa D, Leone S, Agresta A, Capobianchi M, Ippolito G, Vaia F, Puro V; INMI COVID-19 Vaccine Study Group. Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine. **Sci Rep.** 2022 Apr 23;12(1):6687. doi: 10.1038/s41598-022-07741-z. PMID: 35461335; PMCID: PMC9034067.
 136. Shu Q, Liu S, Alonzi T, LaCourse SM, Singh DK, Bao D, Wamalwa D, Jiang L, Lyon CJ, John-Stewart G, Kaushal D, **Goletti D**, Hu T. Assay design for unambiguous identification and quantification of circulating pathogen-derived peptide biomarkers. **Theranostics.** 2022 Mar 21;12(6):2948-2962. doi: 10.7150/thno.70373. PMID: 35401822; PMCID: PMC8965485.
 137. Chedid C, Andrieu T, Kokhrezidze E, Tukvadze N, Biswas S, Ather MF, Uddin MKM, Banu S, De Maio F, Delogu G, Endtz H, **Goletti D**, Vocanson M, Dumitrescu O, Hoffmann J, Ader F. In-Depth Immunophenotyping With Mass Cytometry During TB Treatment Reveals New T-Cell Subsets Associated With Culture Conversion. **Front Immunol.** 2022 Mar 22;13:853572. doi: 10.3389/fimmu.2022.853572. PMID: 35392094; PMCID: PMC8980213.
 138. Dahl VN, Tiberi S, **Goletti D**, Wejse C. Armed conflict and human displacement may lead to an increase in the burden of tuberculosis in Europe. **Int J Infect Dis.** 2022 Mar 29:S1201-9712(22)00180-1. doi: 10.1016/j.ijid.2022.03.040. Epub ahead of print. PMID: 35364284.
 139. La Manna MP, Orlando V, Badami GD, Tamburini B, Azgomi MS, Presti EL, Del Nonno F, Petrone L, Belmonte B, Falasca L, Carlo PD, Dieli F, **Goletti D**, Caccamo N. Platelets accumulate in lung lesions of tuberculosis patients and inhibit T-cell responses and Mycobacterium tuberculosis replication in macrophages. **Eur J Immunol.** 2022 Mar 26. doi: 10.1002/eji.202149549. Epub ahead of print. PMID: 35338775.
 140. Margineanu I, Rustage K, Noori T, Zenner D, Greenaway C, Pareek M, Akkerman O, Hayward S, Friedland JS, **Goletti D**, Stienstra Y, Hargreaves S; ESGITM/ESGMYC Study Groups. Country-specific approaches to latent tuberculosis screening targeting migrants in EU/EEA* countries: A survey of national experts, September 2019 to February 2020. **Euro Surveill.** 2022 Mar;27(12). doi: 10.2807/1560-7917.ES.2022.27.12.2002070. PMID: 35332865.
 141. Migliori GB, Falzon D, Marks GB, **Goletti D**, Kasaeva T, Esposito S, Humbert M. Commemorating World Tuberculosis Day 2022: recent ERJ articles of critical relevance to ending TB and saving lives. **Eur Respir J.** 2022 Mar 24;59(3):2200149. doi: 10.1183/13993003.00149-2022. PMID: 35332091.
 142. Di Bari V, Gualano G, Musso M, Libertone R, Nisii C, Ianniello S, Mosti S, Mastrobattista A, Cerva C, Bevilacqua N, Iacomi F, Mondì A, Topino S, **Goletti D**, Girardi E, Palmieri F, On Behalf Of The Tb-Inmi Working Group. Increased Association of Pulmonary Thromboembolism and Tuberculosis during COVID-19 Pandemic: Data from an Italian Infectious Disease Referral Hospital. **Antibiotics (Basel).** 2022 Mar 16;11(3):398. doi: 10.3390/antibiotics11030398. PMID: 35326861; PMCID: PMC8944753.
 143. Farroni C, Picchianti-Diamanti A, Aiello A, Nicastri E, Laganà B, Agrati C, Castilletti C, Meschi S, Colavita F, Cuzzi G, Casetti R, Grassi G, Petrone L, Vanini V, Salmi A, Repele F, Altera AMG, Maffongelli G, Corpolongo A, Salemi S, Di Rosa R, Nalli G, Sesti G, Vaia F, Puro V, **Goletti D**. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis. **Front Immunol.** 2022 Feb 28;13:846753. doi: 10.3389/fimmu.2022.846753. PMID: 35309297; PMCID: PMC8924958.
 144. Tunesi S, Dû DL, Gualano G, Millet JP, Skrahin A, Bothamley G, Casas X, **Goletti D**, Lange C, Musso M, Palmieri F, Pourcher V, Rioux C, Skrahina A, Veziris N, Viatushka D, Jachym-Fréchet M, Guglielmetti L; TBnet, The ESGMYC, and The French MDR-TB Group. Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: A TBnet and ESGMYC study. **J Infect.** 2022 Mar 7:S0163-4453(22)00130-X. doi: 10.1016/j.jinf.2022.03.004. Epub ahead of print. PMID: 35271917.
 145. Melkie ST, Arias L, Farroni C, Jankovic Makek M, **Goletti D**, Vilaplana C. The role of antibodies in tuberculosis diagnosis, prophylaxis and therapy: a review from the ESGMYC study group. **Eur Respir Rev.** 2022 Mar 9;31(163):210218. doi: 10.1183/16000617.0218-2021. PMID: 35264411.
 146. **Goletti D**, Delogu G, Matteelli A, Migliori GB. The role of IGRA in the diagnosis of tuberculosis infection, differentiating from active tuberculosis, and decision making for initiating treatment or preventive therapy of tuberculosis infection. **Int J Infect Dis.** 2022 Mar 4:S1201-9712(22)00126-6. doi: 10.1016/j.ijid.2022.02.047. Epub ahead of print. PMID: 35257904.
 147. Petersen E, Al-Abri S, Chakaya J, **Goletti D**, Parolina L, Wejse C, Mucheleng'anga LA, Khalili SA, Yeboah-Manu D, Chanda-Kapata P, Nasiri MJ, Lungu PS, Maeurer M, Tiberi S, Ntumi F, Battista-Migliori G, Zumla A. World TB Day 2022: Revamping and Reshaping Global TB Control Programs by Advancing Lessons learnt from the COVID-19 pandemic. **Int J Infect Dis.** 2022 Mar 3:S1201-9712(22)00138-2. doi: 10.1016/j.ijid.2022.02.057. Epub ahead of print. PMID: 35248715; PMCID: PMC8894685.
 148. Migliori GB, Wu SJ, Matteelli A, Zenner D, **Goletti D**, Ahmedov S, Al-Abri S, Allen DM, Balcells ME, Garcia-Basteiro AL, Cambau E, Chaisson RE, Chee CBE, Dalcolmo MP, Denholm JT, Erkens C, Esposito S, Farnia P, Friedland JS, Graham S, Hamada Y, Harries AD, Kay AW, Kritski A, Manga S, Marais BJ, Menzies D, Ng D, Petrone L, Rendon A, Silva DR, Schaaf HS, Skrahina A, Sotgiu G, Thwaites G, Tiberi S, Tukvadze N, Zellweger JP, D'Ambrosio L, Centis R, Ong CWM. Clinical standards for the diagnosis, treatment and prevention of TB infection. **Int J Tuberc Lung Dis.** 2022 Mar 1;26(3):190-205. doi: 10.5588/ijtld.21.0753. PMID: 35197159; PMCID: PMC8886963.
 149. Margineanu I, Akkerman O, Cattaneo D, **Goletti D**, Marriott DJE, Migliori GB, Mirzayev F, Peloquin CA, Stienstra Y, Alffenaar JW. Practices of therapeutic drug monitoring in tuberculosis - an international survey. **Eur Respir J.** 2022 Jan 27:2102787. doi: 10.1183/13993003.02787-2021.

- Epub ahead of print. PMID: 35086830.
150. Ferraccioli G, Gremese E, **Goletti D**, Petrone L, Cantini F, Ugel S, Canè S, Bronte V. Immune-guided therapy of COVID-19. *Cancer Immunol Res.* 2022 Jan 24;canimm.0675.2021. doi: 10.1158/2326-6066.CIR-21-0675. Epub ahead of print. PMID: 35074758.
 151. Migliori GB, Ong CWM, Petrone L, D'Ambrosio L, Centis R, **Goletti D**. The definition of tuberculosis infection based on the spectrum of tuberculosis disease. *Breathe (Sheff).* 2021 Sep;17(3):210079. doi: 10.1183/20734735.0079-2021. PMID: 35035549; PMCID: PMC8753649.
 152. Alonzi T, Aiello A, Petrone L, Najafi Fard S, D'Eletto M, Falasca L, Nardacci R, Rossin F, Delogu G, Castilletti C, Capobianchi MR, Ippolito G, Piacentini M, **Goletti D**. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy. *Cells.* 2021 Dec 24;11(1):52. doi: 10.3390/cells11010052. PMID: 35011614; PMCID: PMC8750154.
 153. Petruccioli E, Farroni C, Cuzzi G, Vanini V, Palmieri F, Vittozzi P, **Goletti D**. VIDAS® TB-IGRA reagents induce a CD4+ and CD8+ T-cell IFN-γ response for both TB infection and active TB. *Int J Tuberc Lung Dis.* 2022 Jan 1;26(1):65-68. doi: 10.5588/ijtld.21.0478. PMID: 34969431; PMCID: PMC8734189.
 154. Cantini F, **Goletti D**, Benucci M, Foti R, Damiani A, Niccoli L. Tailored first-line biologic and targeted synthetic disease modifying anti-rheumatic drugs therapy in patients with rheumatoid arthritis: 2021 updated ITABIO statements. *Expert Opin Drug Saf.* 2021 Dec 29:1-11. doi: 10.1080/14740338.2022.2020247. Epub ahead of print. PMID: 34937466.
 155. Montaldo C, Messina F, Abbate I, Antonioli M, Bordon V, Aiello A, Ciccocanti F, Colavita F, Farroni C, Najafi Fard S, Giombini E, **Goletti D**, Matusali G, Rozera G, Rueca M, Sacchi A, Piacentini M, Agrati C, Firnia GM, Capobianchi MR, Lauria FN, Ippolito G. Multi-omics approach to COVID-19: a domain-based literature review. *J Transl Med.* 2021 Dec 7;19(1):501. doi: 10.1186/s12967-021-03168-8. PMID: 34876157; PMCID: PMC8649311.
 156. Tortorella C, Aiello A, Gasperini C, Agrati C, Castilletti C, Ruggieri S, Meschi S, Matusali G, Colavita F, Farroni C, Cuzzi G, Cimmini E, Tartaglia E, Vanini V, Prosperini L, Haggiag S, Galgani S, Quartuccio ME, Salmi A, Repele F, Gerarda Altera AM, Cristofanelli F, D'Abramo A, Bevilacqua N, Corpolongo A, Puro V, Vaia F, Capobianchi MR, Ippolito G, Nicastri E, **Goletti D**; INMI COVID-19 Vaccine Study Group. Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies. *Neurology.* 2021 Nov 22;10.1212/WNL.0000000000013108. doi: 10.1212/WNL.0000000000013108. Epub ahead of print. PMID: 34810244.
 157. Opota O, Mazza-Stalder J, Viveiros M, Cambau E, Santin M, **Goletti D**. Editorial: Tuberculosis and Non-tuberculous Mycobacteria Infections: Control, Diagnosis and Treatment. *Front Public Health.* 2021 Oct 28;9:666187. doi: 10.3389/fpubh.2021.666187. PMID: 34778160; PMCID: PMC8581263.
 158. TB/COVID-19 Global Study Group. Tuberculosis and COVID-19 co-infection: description of the global cohort. *Eur Respir J.* 2021 Nov 11:2102538. doi: 10.1183/13993003.02538-2021. Epub ahead of print. PMID: 34764184; PMCID: PMC8588566.
 159. Miotto P, **Goletti D**, Petrone L. Making IGRA testing easier: First performance report of QIArearch QFT for tuberculosis infection diagnosis. *Pulmonology.* 2022 Jan-Feb;28(1):4-5. doi: 10.1016/j.pulmoe.2021.07.010. Epub 2021 Oct 28. PMID: 34756692.
 160. Pérez-Recio S, Pallarès N, Grijota-Camino MD, Sánchez-Montalvá A, Barcia L, Campos-Gutiérrez S, Pomar V, Rabuñal-Rey R, Balcells ME, Gazel D, Montiel N, Vicente D, Goić-Barišić I, Schön T, Paus J, Mareković I, Cacho-Calvo J, Barac A, **Goletti D**, García-Gasalla M, Barcala JM, Tórtola MT, Anibarro L, Suárez-Toste I, Moga E, Gude-Gonzalez MJ, Naves R, Karşılıgı T, Martín-Peñaranda T, Stevanovic G, Trigo M, Rubio V, Karaoglan I, Bayram N, Alcaide F, Tebé C, Santin M; ESCMID Study Group for Mycobacterial Infections (ESGMYC) and the Mycobacteria Study Group (GEIM) of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC). Identification of Recent Tuberculosis Exposure Using QuantiFERON-TB Gold Plus, a Multicenter Study. *Microbiol Spectr.* 2021 Dec 22;9(3):e0097221. doi: 10.1128/Spectrum.00972-21. Epub 2021 Nov 10. PMID: 34756079; PMCID: PMC8579846.
 161. D'Offici G, Agrati C, Visco-Comandini U, Castilletti C, Puro V, Piccolo P, Montalbano M, Meschi S, Tartaglia E, Sorace C, Leone S, Lapa D, Grassi G, **Goletti D**, Ippolito G, Vaia F, Ettore GM, Lionetti R. Coordinated cellular and humoral immune responses after two-dose SARS-CoV2 mRNA vaccination in liver transplant recipients. *Liver Int.* 2022 Jan;42(1):180-186. doi: 10.1111/liv.15089. Epub 2021 Nov 17. PMID: 34719107; PMCID: PMC8662049.
 162. Delemarre EM, van Hoom L, Bossink AWJ, Drylewicz J, Joosten SA, Ottenhoff THM, Akkerman OW, **Goletti D**, Petruccioli E, Navarra A, van den Broek BTA, Paardekooper SPA, van Haeften I, Koenderman L, Lammers JJ, Thijsen SFT, Hofland RW, Nierkens S. Serum Biomarker Profile Including CCL1, CXCL10, VEGF, and Adenosine Deaminase Activity Distinguishes Active From Remotely Acquired Latent Tuberculosis. *Front Immunol.* 2021 Oct 7;12:725447. doi: 10.3389/fimmu.2021.725447. PMID: 34691031; PMCID: PMC8529994.
 163. Picchianti-Diamanti A, Aiello A, Laganà B, Agrati C, Castilletti C, Meschi S, Farroni C, Lapa D, Najafi Fard S, Cuzzi G, Cimmini E, Grassi G, Vanini V, Di Rosa R, Salemi S, Nalli G, Salmi A, Repele F, Altera AMG, Maffongelli G, Palazzolo C, Vita S, Leone S, Puro V, Capobianchi MR, Ippolito G, Nicastri E, **Goletti D**. Immunosuppressive Therapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients. *Front Immunol.* 2021 Sep 14;12:740249. doi: 10.3389/fimmu.2021.740249. PMID: 34594343; PMCID: PMC8477040.
 164. Petruccioli E, Petrone L, Chiacchio T, Farroni C, Cuzzi G, Navarra A, Vanini V, Massafra U, Lo Pizzo M, Guggino G, Caccamo N, Cantini F, Palmieri F, **Goletti D**. Mycobacterium tuberculosis Immune Response in Patients With Immune-Mediated Inflammatory Disease. *Front Immunol.* 2021 Aug 10;12:716857. doi: 10.3389/fimmu.2021.716857. PMID: 34447382; PMCID: PMC8382688.
 165. Migliori GB, Thong PM, Alfenaar JW, Denholm J, Tadolini M, Alyaqubi F, Blanc FX, Buonsenso D, Cho JG, Ruffo Codecasa L, Danila E, Duarte R, García-García JM, Gualano G, Rendon A, Rossato Silva D, Souleymane MB, Tham SM, Thomas TA, Tiberi S, Udwadia ZF, **Goletti D**, Centis R, D'Ambrosio L, Sotgiu G, Ong CWM; Global Tuberculosis Network. Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study. *Eur Respir J.* 2021 Aug 26:2101786. doi: 10.1183/13993003.01786-2021. Epub ahead of print. PMID: 34446465.
 166. Petrone L, Tamarozzi F, Vola A, Gomez Morales MA, Ludovisi A, Najafi Fard S, Mariconti M, Brunetti E, **Goletti D**. Accuracy of an experimental whole-blood test for detecting reactivation of echinococcal cysts. *PLoS Negl Trop Dis.* 2021 Aug 20;15(8):e0009648. doi:

- 10.1371/journal.pntd.0009648. PMID: 34415898; PMCID: PMC8378729.
167. Rustage K, Lobe J, Hayward SE, Kristensen KL, Margineanu I, Stienstra Y, **Goletti D**, Zenner D, Noori T, Pareek M, Greenaway C, Friedland JS, Nellums LB, Hargreaves S; ESGITM and ESGMYC study groups. Initiation and completion of treatment for latent tuberculosis infection in migrants globally: a systematic review and meta-analysis. **Lancet Infect Dis.** 2021 Aug 4:S1473-3099(21)00052-9. doi: 10.1016/S1473-3099(21)00052-9. Epub ahead of print. PMID: 34363771.
168. Minardi ML, Fato I, Di Gennaro F, Mosti S, Mastrobattista A, Cerva C, Libertone R, Saracino A, **Goletti D**, Girardi E, Andreoni M, Palmieri F, Gualano G. Common and Rare Hematological Manifestations and Adverse Drug Events during Treatment of Active TB: A State of Art. **Microorganisms.** 2021 Jul 9;9(7):1477. doi: 10.3390/microorganisms9071477. PMID: 34361913; PMCID: PMC8304680.
169. Bohrer AC, Castro E, Hu Z, Queiroz ATL, Tocheny CE, Assmann M, Sakai S, Nelson C, Baker PJ, Ma H, Wang L, Zilu W, du Bruyn E, Riou C, Kauffman KD; Tuberculosis Imaging Program, Moore IN, Del Nonno F, Petrone L, **Goletti D**, Martineau AR, Lowe DM, Cronan MR, Wilkinson RJ, Barry CE, Via LE, Barber DL, Klion AD, Andrade BB, Song Y, Wong KW, Mayer-Barber KD. Eosinophils are part of the granulocyte response in tuberculosis and promote host resistance in mice. **J Exp Med.** 2021 Oct 4;218(10):e20210469. doi: 10.1084/jem.20210469. Epub 2021 Aug 4. PMID: 34347010; PMCID: PMC8348215.
170. Grace PS, Dolatshahi S, Lu LL, Cain A, Palmieri F, Petrone L, Fortune SM, Ottenhoff THM, Lauffenburger DA, **Goletti D**, Joosten SA, Alter G. Antibody Subclass and Glycosylation Shift Following Effective TB Treatment. **Front Immunol.** 2021 Jul 5;12:679973. doi: 10.3389/fimmu.2021.679973. PMID: 34290702; PMCID: PMC8287567.
171. **Goletti D**, Petrone L, Manissero D, Bertoletti A, Rao S, Ndunda N, Sette A, Nikolayevskyy V. The potential clinical utility of measuring SARS-CoV-2-specific T-cell responses. **Clin Microbiol Infect.** 2021 Jul 10:S1198-743X(21)00378-5. doi: 10.1016/j.cmi.2021.07.005. Epub ahead of print. PMID: 34256141; PMCID: PMC8272618.
172. Najafi Fard S, Petrone L, Petruccioli E, Alonzi T, Matusali G, Colavita F, Castilletti C, Capobianchi MR, **Goletti D**. In Vitro Models for Studying Entry, Tissue Tropism, and Therapeutic Approaches of Highly Pathogenic Coronaviruses. **Biomed Res Int.** 2021 Jun 21;2021:8856018. doi: 10.1155/2021/8856018. PMID: 34239932; PMCID: PMC8221881.
173. Bayaa R, Ndiaye MDB, Chedid C, Kokhraidze E, Tukvadze N, Banu S, Uddin MKM, Biswas S, Nasrin R, Ranaivomanana P, Raheerindrana AH, Rakotonirina J, Rasolofo V, Delogu G, De Maio F, **Goletti D**, Endtz H, Ader F, Hamze M, Ismail MB, Pouzol S, Rakotosamimanana N, Hoffmann J; HINTT working group within the GABRIEL network. Multi-country evaluation of RISK6, a 6-gene blood transcriptomic signature, for tuberculosis diagnosis and treatment monitoring. **Sci Rep.** 2021 Jul 1;11(1):13646. doi: 10.1038/s41598-021-93059-1. PMID: 34211042; PMCID: PMC8249600.
174. Agrati C, Castilletti C, **Goletti D**, Meschi S, Sacchi A, Matusali G, Bordoni V, Petrone L, Lapa D, Notari S, Vanini V, Colavita F, Aiello A, Agresta A, Farroni C, Grassi G, Leone S, Vaia F, Capobianchi MR, Ippolito G, Puro V, On Behalf Of The Inmi Covid-Vaccine Study Group. Coordinate Induction of Humoral and Spike Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2 mRNA Vaccine. **Microorganisms.** 2021 Jun 16;9(6):1315. doi: 10.3390/microorganisms9061315. PMID: 34208751; PMCID: PMC8235087.
175. Puro V, Castilletti C, Agrati C, **Goletti D**, Leone S, Agresta A, Cimini E, Tartaglia E, Casetti R, Colavita F, Meschi S, Matusali G, Lapa D, Najafi Fard S, Aiello A, Farrone C, Galli P, Capobianchi MR, Ippolito G, On Behalf Of The Inmi Covid-Vaccine Study Group. Impact of Prior Influenza and Pneumococcal Vaccines on Humoral and Cellular Response to SARS-CoV-2 BNT162b2 Vaccination. **Vaccines (Basel).** 2021 Jun 8;9(6):615. doi: 10.3390/vaccines9060615. PMID: 34201065; PMCID: PMC8229609.
176. Petruccioli E, Najafi Fard S, Navarra A, Petrone L, Vanini V, Cuzzi G, Gualano G, Pierelli L, Bertoletti A, Nicastrì E, Palmieri F, Ippolito G, **Goletti D**. Exploratory analysis to identify the best antigen and the best immune biomarkers to study SARS-CoV-2 infection. **J Transl Med.** 2021 Jun 26;19(1):272. doi: 10.1186/s12967-021-02938-8. PMID: 34174875; PMCID: PMC8235902.
177. Belleudi V, Rosa AC, Poggi FR, Armuzzi A, Nicastrì E, **Goletti D**, Diamanti AP, Davoli M, Agabiti N, Addis A. Direct and Indirect Impact of COVID-19 for Patients with Immune-Mediated Inflammatory Diseases: A Retrospective Cohort Study. **J Clin Med.** 2021 May 28;10(11):2388. doi: 10.3390/jcm10112388. PMID: 34071452; PMCID: PMC8197915.
178. Grassi G, Vanini V, De Santis F, Romagnoli A, Aiello A, Casetti R, Cimini E, Bordoni V, Notari S, Cuzzi G, Mosti S, Gualano G, Palmieri F, Fraziano M, **Goletti D**, Agrati C, Sacchi A. PMN-MDSC Frequency Discriminates Active Versus Latent Tuberculosis and Could Play a Role in Counteracting the Immune-Mediated Lung Damage in Active Disease. **Front Immunol.** 2021 Apr 26;12:594376. doi: 10.3389/fimmu.2021.594376. PMID: 33981297; PMCID: PMC8107479.
179. Occhigrossi L, Rossin F, D'Eletto M, Farrace MG, Ciccossanti F, Petrone L, Sacchi A, Nardacci R, Falasca L, Del Nonno F, Palucci I, Smimov E, Barlev N, Agrati C, **Goletti D**, Delogu G, Fimia GM, Piacentini M. Transglutaminase 2 Regulates Innate Immunity by Modulating the STING/TBK1/IRF3 Axis. **J Immunol.** 2021 May 15;206(10):2420-2429. doi: 10.4049/jimmunol.2001122. Epub 2021 May 3. PMID: 33941660.
180. D'Abramo A, Vita S, Maffongelli G, Mariano A, Agrati C, Castilletti C, **Goletti D**, Ippolito G, Nicastrì E; Spallanzani COVID-19 Case Investigation Team. Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: A tailored approach. **Int J Infect Dis.** 2021 Apr 24;107:247-250. doi: 10.1016/j.ijid.2021.04.068. Epub ahead of print. PMID: 33901654; PMCID: PMC8065233.
181. Aiello A, Najafi Fard S, Petruccioli E, Petrone L, Vanini V, Farroni C, Cuzzi G, Navarra A, Gualano G, Mosti S, Pierelli L, Nicastrì E, **Goletti D**. Spike is the most recognized antigen in the whole-blood platform in both acute and convalescent COVID-19 patients. **Int J Infect Dis.** 2021 May;106:338-347. doi: 10.1016/j.ijid.2021.04.034. Epub 2021 Apr 14. PMID: 33864921; PMCID: PMC8045417.
182. Di Gennaro F, Gualano G, Timelli L, Vittozzi P, Di Bari V, Libertone R, Cerva C, Pinnarelli L, Nisii C, Ianniello S, Mosti S, Bevilacqua N, Iacomì F, Mondì A, Topino S, **Goletti D**, Vaia F, Ippolito G, Girardi E, Palmieri F. Increase in Tuberculosis Diagnostic Delay during First Wave of the COVID-19 Pandemic: Data from an Italian Infectious Disease Referral Hospital. **Antibiotics (Basel).** 2021 Mar 8;10(3):272. doi: 10.3390/antibiotics10030272. PMID: 33800406; PMCID: PMC7998965.

183. Novelli G, Liu J, Biancolella M, Alonzi T, Novelli A, Patten JJ, Cocciadiferro D, Agolini E, Colona VL, Rizzacasa B, Giannini R, Bigio B, **Goletti D**, Capobianchi MR, Grelli S, Mann J, McKee TD, Cheng K, Amanat F, Krammer F, Guaracino A, Pepe G, Tomino C, Tandjaoui-Lambiotte Y, Uzunhan Y, Tubiana S, Ghosn J; COVID Human Genetic Effort; French COVID Cohort Study Group; CoV- Contact Cohort, Notarangelo LD, Su HC, Abel L, Cobat A, Elhanan G, Grzymiski JJ, Latini A, Sidhu SS, Jain S, Davey RA, Casanova JL, Wei W, Pandolfi PP. Inhibition of HECT E3 ligases as potential therapy for COVID-19. **Cell Death Dis.** 2021 Mar 24;12(4):310. doi: 10.1038/s41419-021-03513-1. PMID: 33762578; PMCID: PMC7987752.
184. Zumla A, Chakaya J, Khan M, Fatima R, Wejse C, Al-Abri S, Fox GJ, Nachega J, Kapata N, Knipper M, Orcutt M, Goscé L, Abubakar I, Nagu TJ, Mugusi F, Gordon AK, Shanmugam S, Bachmann NL, Lam C, Sintchenko V, Rudolf F, Amanullah F, Kock R, Haider N, Lipman M, King M, Maeurer M, **Goletti D**, Petrone L, Yaqoob A, Tiberi S, Ditiu L, Sahu S, Marais B, Issayeva AM, Petersen E. World Tuberculosis Day 2021 Theme - 'The Clock is Ticking' - and the world is running out of time to deliver the United Nations General Assembly commitments to End TB due to the COVID-19 pandemic. **Int J Infect Dis.** 2021 Mar 18:S1201-9712(21)00264-2. doi: 10.1016/j.ijid.2021.03.046. Epub ahead of print. PMID: 33746094.
185. Petrone L, Petruccioli E, Vanini V, Cuzzi G, Gualano G, Vittozzi P, Nicastrì E, Maffongelli G, Grifoni A, Sette A, Ippolito G, Migliori GB, Palmieri F, **Goletti D**. Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2. **Int J Infect Dis.** 2021 Mar 10:S1201-9712(21)00176-4. doi: 10.1016/j.ijid.2021.02.090. Epub ahead of print. PMID: 33713816; PMCID: PMC7944764.
186. **Goletti D**, Cantini F. Baricitinib Therapy in Covid-19 Pneumonia - An Unmet Need Fulfilled. **N Engl J Med.** 2021 Mar 4;384(9):867-869. doi: 10.1056/NEJMe2034982. PMID: 33657299; PMCID: PMC7944951.
187. Petrone L, Petruccioli E, Alonzi T, Vanini V, Cuzzi G, Najafi Fard S, Castilletti C, Palmieri F, Gualano G, Vittozzi P, Nicastrì E, Lepore L, Grifoni A, Antinori A, Vergori A, Ippolito G, Cantini F, **Goletti D**. In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy. **J Infect.** 2021 Apr;82(4):58-66. doi: 10.1016/j.jinf.2021.02.023. Epub 2021 Feb 25. PMID: 33639176; PMCID: PMC7904476.
188. Chedid C, Kokhraidze E, Tukvadze N, Banu S, Uddin MKM, Biswas S, Russomando G, Acosta CCD, Arenas R, Ranaivomanana PP, Razafimahatratra C, Herindrainy P, Rakotonirina J, Raheirinandrasana AH, Rakotosamimanana N, Hamze M, Ismail MB, Bayaa R, Berland JL, De Maio F, Delogu G, Endtz H, Ader F, **Goletti D**, Hoffmann J. Relevance of QuantiFERON-TB Gold Plus and Heparin-Binding Hemagglutinin Interferon-γ Release Assays for Monitoring of Pulmonary Tuberculosis Clearance: A Multicentered Study. **Front Immunol.** 2021 Feb 2;11:616450. doi: 10.3389/fimmu.2020.616450. PMID: 33603746; PMCID: PMC7885528.
189. Visca D, Ong CWM, Tiberi S, Centis R, D'Ambrosio L, Chen B, Mueller J, Muel ler P, Duarte R, Dalcolmo M, Sotgiu G, Migliori GB, **Goletti D**. Tuberculosis and COVID 19 interaction: A review of biological, clinical and public health effects. **Pulmonology.** 2021 Jan 22:S25310437(21)00004 0. doi: 10.1016/j.pulmoe.2020.12.012. Epub ahead of print. PMID: 33547029; PMCID: PMC7825946.
190. Musso M, Di Gennaro F, Gualano G, Mosti S, Cerva C, Fard SN, Libertone R, Di Bari V, Cristofaro M, Tonnarini R, Castilletti C, **Goletti D**, Palmieri F. Concurrent cavitary pulmonary tuberculosis and COVID 19 pneumonia with in vitro immune cell anergy. **Infection.** 2021 Jan 17:1doi: 10.1007/s15010 021 01576 y. Epub ahead of print. PMID: 33454928; PMCID: PMC7811686.
191. Vita S, Di Bari V, Corpolongo A, **Goletti D**, Espinosa J, Petraccia S, Palmieri F, Nicastrì E; INMI COVID 19 study groups. Down Syndrome patients with COVID 19 pneumonia: A high risk category for unfavourable outcome. **Int J Infect Dis.** 2021 Feb;103:607 610. doi: 10.1016/j.ijid.2020.11.188. Epub 2020 Nov 30. PMID: 33271290; PMCID: PMC7703224.
192. Stebbing J, Sánchez Nieves G, Falcone M, Youhanna S, Richardson P, Ottaviani S, Shen JX, Sommerauer C, Tiseo G, Ghiadoni L, Virdis A, Monzani F, Rizo LR, Forfori F, Avendaño Céspedes A, De Marco S, Carrozzi L, Lena F, Sánchez Jurado PM, Lacerenza LG, Cesira N, Caldev illa Bernardo D, Perrella A, Niccoli L, Méndez LS, Matarrese D, **Goletti D**, Tan YJ, Monteil V, Dranitsaris G, Cantini F, Farcomeni A, Dutta S, Burley SK, Zhang H, Pistello M, Li W, Romero MM, Andrés Pretel F, Simón Talero RS, García Molina R, Kutter C, Felc e JH, Nizami ZF, Miklosi AG, Penninger JM, Menichetti F, Mirazimi A, Abizanda P, Lauschke VM. JAK inhibition reduces SARS CoV 2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. **Sci Adv.** 2021 Jan 1;7(1):eabe4724. doi : 10.1126/sciadv.abe4724. PMID: 33187978; PMCID: PMC7775747.
193. Cantini F, **Goletti D**, Petrone L, Najafi Fard S, Niccoli L, Foti R. Immune Therapy, or Antiviral Therapy, or Both for COVID 19: A Systematic Review. **Drugs.** 2020 Dec;80(18):1929 1946. doi: 10.1007/s40265 020 01421 w. PMID: 33068263; PMCID: PMC7568461.
194. Petrone L, Petruccioli E, Vanini V, Cuzzi G, Fard SN, Alonzi T, Castilletti C, Palmieri F, Gualano G, Vittozzi P, Nicastrì E, Lepore L, Antinori A, Vergori A, Caccamo N, Cantini F, Girardi E, Ippolit o G, Grifoni A, **Goletti D**. A whole blood test to measure SARS CoV 2 specific response in COVID 19 patients. **Clin Microbiol Infect.** 2020 Oct 10:S1198 743X(20)30605 4. doi: 10.1016/j.cmi.2020.09.051. Epub ahead of print.
195. Cantini F, **Goletti D**, Petrone L, Najafi Fard S, Niccoli L, Foti R. Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review. **Drugs.** 2020 Oct 17:1-18. doi: 10.1007/s40265-020-01421-w.
196. Petrone L, Petruccioli E, Vanini V, Cuzzi G, Fard SN, Alonzi T, Castilletti C, Palmieri F, Gualano G, Vittozzi P, Nicastrì E, Lepore L, Antinori A, Vergori A, Caccamo N, Cantini F, Girardi E, Ippolito G, Grifoni A, **Goletti D**. A whole blood test to measure SARS-CoV-2 specific response in COVID-19 patients. **Clin Microbiol Infect.** 2020 Oct 10:S1198-743X(20)30605-4. doi: 10.1016/j.cmi.2020.09.051. Epub ahead of print. PMID: 33045370.
197. Sala C, Benjak A, **Goletti D**, Banu S, Mazza-Stadler J, Jatón K, Busso P, Remm S, Leleu M, Rougemont J, Palmieri F, Cuzzi G, Butera O, Vanini V, Kabir S, Rahman SMM, Nicod L, Cole ST. Multicenter analysis of sputum microbiota in tuberculosis patients. **PLoS One.** 2020 Oct 12;15(10):e0240250. doi: 10.1371/journal.pone.0240250. PMID: 33044973.
198. Méchai F, Cordel H, Guglielmetti L, Aubry A, Jankovic M, Viveiros M, Santin M, **Goletti D**, Cambau E. Management of Tuberculosis: Are the Practices Homogeneous in High-Income Countries? **Front Public Health.** 2020 Sep 4;8:443. doi: 10.3389/fpubh.2020.00443. PMID: 33014963; PMCID: PMC7509453.
199. Chedid C, Kokhraidze E, Tukvadze N, Banu S, Uddin MKM, Biswas S, Russomando G, Acosta CCD, Arenas R, Ranaivomanana PP,

- Razafimahatratra C, Herindrainy P, Rakotosamimanana N, Hamze M, Ismail MB, Bayaa R, Berland JL, Delogu G, Endtz H, Ader F, **Goletti D**, Hoffmann J; HINTT working group within the GABRIEL network. Association of baseline white blood cell counts with tuberculosis treatment outcome: a prospective multicentered cohort study. *Int J Infect Dis.* 2020 Sep 10;100:199-206. doi: 10.1016/j.ijid.2020.09.017. Epub ahead of print. PMID: 32920230.
200. Migliori GB, Thong PM, Akkerman O, Alffenaar JW, Álvarez-Navascués F, Assao- Neino MM, Bernard PV, Biala JS, Blanc FX, Bogorodskaya EM, Borisov S, Buonsenso D, Calnan M, Castellotti PF, Centis R, Chakaya JM, Cho JG, Codecasa LR, D'Ambrosio L, Denholm J, Enwerem M, Ferrarese M, Galvão T, García-Clemente M, García-García JM, Gualano G, Gullón-Blanco JA, Inwentarz S, Ippolito G, Kunst H, Maryandyshev A, Melazzini M, de Queiroz Mello FC, Muñoz-Torrico M, Njung'iyini PB, Palmero DJ, Palmieri F, Piccioni P, Piubello A, Rendon A, Sabriá J, Saporiti M, Scognamiglio P, Sharma S, Silva DR, Souleymane MB, Spanevello A, Tabernero E, Tadolini M, Tchangou ME, Thornton ABY, Tiberi S, Udwadia ZF, Sotgiu G, Ong CWM, **Goletti D**. Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January-April 2020. *Emerg Infect Dis.* 2020 Sep 11;26(11). doi: 10.3201/eid2611.203163. Epub ahead of print. PMID: 32917293.
201. Falasca L, Nardacci R, Colombo D, Lalle E, Di Caro A, Nicastri E, Antinori A, Petrosillo N, Marchioni L, Biava G, D'Offizi G, Palmieri F, **Goletti D**, Zumla A, Ippolito G, Piacentini M, Del Nonno F. Post-Mortem Findings in Italian Patients with COVID-19 - a Descriptive Full Autopsy Study of cases with and without co- morbidities. *J Infect Dis.* 2020 Sep 11;jiaa578. doi: 10.1093/infdis/jiaa578. Epub ahead of print. PMID: 32914853; PMCID: PMC7543426.
202. Schön T, Köser CU, Werngren J, Viveiros M, Georgiou S, Kahlmeter G, Giske C, Maurer F, Lina G, Turnidge J, van Ingen J, Jankovic M, **Goletti D**, Cirillo DM, Santin M, Cambau E; ESGMYC. What is the role of the EUCAST reference method for MIC testing of the Mycobacterium tuberculosis complex? *Clin Microbiol Infect.* 2020 Aug 6:S1198-743X(20)30445-6. doi: 10.1016/j.cmi.2020.07.037. Epub ahead of print. PMID: 32768492.
203. Cantini F, Niccoli L, Nannini C, Matarrese D, Natale MED, Lotti P, Aquilini D, Landini G, Cimolati B, Pietro MAD, Trezzi M, Stobbione P, Frausini G, Navarra A, Nicastri E, Sotgiu G, **Goletti D**. Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study. *J Infect.* 2020 Jun 24:S0163-4453(20)30433-3. doi: 10.1016/j.jinf.2020.06.052. Online ahead of print. PMID: 32592703 Free PMC article.
204. Tadolini M, García-García JM, Blanc FX, Borisov S, **Goletti D**, Motta I, Codecasa LR, Tiberi S, Sotgiu G, Migliori GB; GTN TB/COVID group. On Tuberculosis and COVID-19 co-infection. *Eur Respir J.* 2020 Jun 25:2002328. doi: 10.1183/13993003.02328-2020. Online ahead of print. PMID: 32586888 Free PMC article.
205. Ong Catherine Wei Min, Giovanni Battista Migliori, Mario Raviglione, Gavin MacGregor-Skinner, Giovanni Sotgiu, Jan-Willem Alffenaar, Simon Tiberi, Cornelia Adlhoeh, Tonino Alonzi, Sophia Archuleta, Sergio Brusin, Emmanuelle Cambau, Maria Rosaria Capobianchi, Concetta Castilletti, Rosella Centis, Daniela M. Cirillo, Lia D'Ambrosio, Masoud Dara, Giovanni Delogu, Susanna M.R. Esposito, Jose Figueroa, Jon S. Friedland, Benjamin Ho Choon Heng, Giuseppe Ippolito, Tauhidul Islam A.B.M, Mateja Jankovic, Hannah Yejin Kim, Senia Rosales Klintz, Csaba Ködmön, Eleonora Lalle, Yee Sin Leo, Chi-Chiu Leung, Anne-Grete Mårtson, Mario Melazzini, Saeid Najafi Fard, Pasi Penttinen, Linda Petrone, Elisa Petruccioli, Emanuele Pontali, Laura Saderi, Miguel Santin, Antonio Spanevello, Reinout van Crevel, Martin van den Boom, Marieke J. van der Werf, Dina Visca, Miguel Viveiros, Jean Pierre Zellweger, Alimuddin Zumla, **Delia Goletti**. Epidemic and pandemic viral infections: impact on tuberculosis and the lung. A consensus by the World Association for Infectious Diseases and Immunological Disorders (WAIID), Global Tuberculosis Network (GTN) and members# of ESCMID Study Group for Mycobacterial Infections (ESGMYC). *Eur Respir J.* 2020 Oct 1;56(4):2001727. doi: 10.1183/13993003.01727-2020. PMID: 32586885; PMCID: PMC7527651.
206. Buonsenso D, Iodice F, Sorba J, Biala M, **Goletti D**. COVID-19 effects on Tuberculosis care in Sierra Leone, *Pulmonology*, 2021 Jan-Feb;27(1):67-69. doi: 10.1016/j.pulmoe.2020.05.013. Epub 2020 Jun 6. PMID: 32561353; PMCID: PMC7275172.
207. Messina F, Giombini E, Agrati C, Vairo F, Ascoli Bartoli T, Al Moghazi S, Piacentini M, Locatelli F, Kobinger G, Maeurer M, Zumla A, Capobianchi MR, Lauria FN, Ippolito G. COVID-19: viral-host interactome analyzed by network based-approach model to study pathogenesis of SARS-CoV-2 infection. *J Transl Med.* 2020 Jun 10;18(1):233. doi: 10.1186/s12967-020-02405-w. PubMed PMID: 32522207.
208. Tadolini M, Codecasa LR, García-García JM, Blanc FX, Borisov S, Alffenaar JW, Andréjak C, Bachez P, Bart PA, Belilovski E, Cardoso-Landivar J, Centis R, D'Ambrosio L, De Souza-Galvão ML, Dominguez-Castellano A, Dourmane S, Jachym MF, Froissart A, Giacomet V, **Goletti D**, Grard S, Gualano G, Izadifar A, Le Du D, Royo MM, Mazza-Stalder J, Motta I, Ong CWM, Palmieri F, Rivière F, Rodrigo T, Rossato Silva D, Sánchez-Montalvá A, Saporiti M, Scarpellini P, Schlemmer F, Spanevello A, Sumarokova E, Tabernero E, Tambyah PA, Tiberi S, Torre A, Visca D, Murguiondo MZ, Sotgiu G, Migliori GB. Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. *Eur Respir J.* 2020 May 26;. doi: 10.1183/13993003.01398-2020.
209. Motta I, Centis R, D'Ambrosio L, García-García JM, **Goletti D**, Gualano G, Lipani F, Palmieri F, Sánchez-Montalvá A, Pontali E, Sotgiu G, Spanevello A, Stochino C, Tabernero E, Tadolini M, van den Boom M, Villa S, Visca D, Migliori GB. Tuberculosis, COVID-19 and migrants: preliminary analysis of deaths occurring in 69 patients from two cohorts. *Pulmonology.* 2020 May 14;. doi: 10.1016/j.pulmoe.2020.05.002. [Epub ahead of print] PubMed PMID: 32411943; PubMed Central PMCID: PMC7221402.
210. Petruccioli E, Chiacchio T, Navarra A, Vanini V, Cuzzi G, Cimaglia C, Codecasa LR, Pinnetti C, Riccardi N, Palmieri F, Antinori A, **Goletti D**. Effect of HIV-infection on QuantiFERON-plus accuracy in patients with active tuberculosis and latent infection. *J Infect.* 2020 May;80(5):536-546. doi: 10.1016/j.jinf.2020.02.009. Epub 2020 Feb 22. PubMed PMID: 32097688.
211. Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, **Goletti D**. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. *J Infect.* 2020 Apr 23:S0163-4453(20)30228-0. doi: 10.1016/j.jinf.2020.04.017.
212. Ong CWM, **Goletti D**. Impact of the global COVID-19 outbreak on the management of other communicable diseases. *Int J Tuberc Lung Dis.* 2020 May 1;24(5):547-548. doi: 10.5588/ijtld.20.0140.

213. Lubbers R, Sutherland JS, **Goletti D**, de Paus RA, Dijkstra DJ, van Moorsel CHM, Veltkamp M, Vestjens SMT, Bos WJW, Petrone L, Malherbe ST, Walz G, Gelderman KA, Groeneveld GH, Geluk A, Ottenhoff THM, Joosten SA, Trouw LA. Expression and production of the SERPING1-encoded endogenous complement regulator C1-inhibitor in multiple cohorts of tuberculosis patients. **Mol Immunol.** 2020 Apr;**120**:187-195. doi: 10.1016/j.molimm.2020.02.006. Epub 2020 Mar 13. PubMed PMID: 32179338.
214. Esmail H, Cobelens F, **Goletti D**. Transcriptional biomarkers for predicting development of tuberculosis: progress and clinical considerations. **Eur Respir J.** 2020 Mar;**55**(3). doi: 10.1183/13993003.01957-2019.
215. Tiberi S, Migliori GB, Muhwa Chakaya J, Kaesava T, Salem Al Abri S, Wejse C, **Goletti D**, Kapata N, Sotgiu G, Bomanji J, Zellweger JP, Hasan R, Irfan M, Ahmed I, Pshenichnaya N, Vasilieva I, Yeboah-Manu D, Alffenaar JW, Yejin Kim H, Centis R, Cirillo DM, Alagna R, D'Ambrosio L, Maeurer M, Cui X, Cao B, Harries AD, Abri SA, Raviglione M, Zumla A, Petersen E, Ippolito G. Cover Editorial- IJID World TB Day 2020 Theme Series. **Int J Infect Dis.** 2020 Mar 4. pii: S1201-9712(20)30120-X. doi: 10.1016/j.ijid.2020.03.001. Al Abri S, Kasaeva T, Migliori GB, **Goletti D**, Zenner D, Denholm J, Al Maani A, Cirillo DM, Schön T, Lillebæk T, Al-Jardani A, Go UY, Dias HM, Tiberi S, Al Yaqubi F, Khamis FA, Kurup P, Wilson M, Memish Z, Al Maqali A, Akhtar M, Wejse C, Petersen E. Tools to implement the WHO End TB Strategy: Addressing common challenges in high and low endemic countries. **Int J Infect Dis.** 2020 Feb 27.
216. Petruccioli E, Chiacchio T, Navarra A, Vanini V, Cuzzi G, Cimaglia C, Codecasa LR, Pinnetti C, Riccardi N, Palmieri F, Antinori A, **Goletti D**. Effect of HIV-infection on QuantiFERON-plus accuracy in patients with active tuberculosis and latent infection. **J Infect.** 2020 Feb 22.
217. Palucci I, Maulucci G, De Maio F, Sali M, Romagnoli A, Petrone L, Fimia GM, Sanguinetti M, **Goletti D**, De Spirito M, Piacentini M, Delogu G. Inhibition of Transglutaminase 2 as a Potential Host-Directed Therapy Against Mycobacterium tuberculosis. **Front Immunol.** 2020 Jan **24**:10:3042.
218. **Goletti D**, Navarra A, Petruccioli E, Cimaglia C, Compagno M, Cuzzi G, De Carli G, Fondaco L, Franzetti F, Giannetti A, Gori A, Lapadula G, Lichtner M, Mastroianni CM, Mazzotta V, Orchi N, Pavone P, Piacentini D, Pirriatore V, Pontali E, Sarmati L, Spolti A, Tacconelli E, Galli M, Antinori A, Calcagno A, Girardi E. Latent tuberculosis infection screening in persons newly-diagnosed with HIV infection in Italy: a multicentre study promoted by the Italian Society of Infectious and Tropical Diseases. **Int J Infect Dis.** 2019 Dec 27. pii:S1201-9712(19)30504-1. doi: 10.1016/j.ijid.2019.12.031. PubMed PMID: 31887456.
219. Petrone L, Albrich WC, Tamarozzi F, Frischknecht M, Gomez-Morales MA, Teggi A, Hoffmann M, **Goletti D**. Species-specificity preliminary evaluation of an IL-4 based test for the differential diagnosis of human echinococcosis. **Parasite Immunol.** 2019 Dec 29:e12695. doi: 10.1111/pim.12695. [Epub ahead of print] PubMed PMID: 31884696.
220. Zabotti A, **Goletti D**, Lubrano E, Cantini F. The impact of the interleukin 12/23 inhibitor ustekinumab on the risk of infections in patients with psoriatic arthritis. **Expert Opin Drug Saf.** 2020 Jan;**19**(1):69-82. doi: 10.1080/14740338.2020.1703946. Epub 2019 Dec 19. PubMed PMID: 31847608.
221. Larsen ES, Joensen UN, Poulsen AM, **Goletti D**, Johansen IS. Bacillus Calmette-Guérin immunotherapy for bladder cancer: A review of immunological aspects, clinical effects and BCG infections. **APMIS.** 2019 Nov 22. doi: 10.1111/apm.13011. [Epub ahead of print] Review. PubMed PMID: 31755155.
222. Musso M, Mosti S, Gualano G, Mencarini P, Urso R, Ghirga P, Rianda A, Del Nonno F, **Goletti D**, Palmieri F. Hepatitis C virus infection: a challenge in the complex management of two cases of multidrug-resistant tuberculosis. **BMC Infect Dis.** 2019 Oct 22;**19**(1):882. doi: 10.1186/s12879-019-4494-1. PubMed PMID: 31640579; PubMed Central PMCID: PMC6806539.
223. Sotgiu G, **Goletti D**, Matteelli A. Global tuberculosis prevention: should we start from the beginning? **Eur Respir J.** 2019 Sep 12;**54**(3).
224. Sotgiu G, Saderi L, Petruccioli E, Aliberti S, Piana A, Petrone L, **Goletti D**. QuantiFERON TB Gold Plus for the diagnosis of tuberculosis: a systematic review and meta-analysis. **J Infect.** 2019 Aug 29. pii: S0163-4453(19)30258-0.
225. Alonzi T, Petruccioli E, Vanini V, Fimia GM, **Goletti D**. Optimization of the autophagy measurement in a human cell line and primary cells by flow cytometry. **Eur J Histochem.** 2019 Jun **26**;63(2). doi: 10.4081/ejh.2019.3044. PubMed PMID: 31243942
- 226.
227. Palucci I, Battah B, Salustri A, De Maio F, Petrone L, Ciccocanti F, Sali M, Bondet V, Duffy D, Fimia GM, **Goletti D**, Delogu G. IP-10 contributes to the inhibition of mycobacterial growth in an ex vivo whole blood assay. **Int J Med Microbiol.** 2019 May 22. pii: S1438-4221(19)30097-9. doi:10.1016/j.jimm.2019.05.005.
228. Cantini F, Niccoli L, Capone A, Petrone L, **Goletti D**. Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice. **Expert Opin Drug Saf.** 2019 May **8**:1-11.
229. Chiacchio T, Petruccioli E, Vanini V, Cuzzi G, Massafra U, Baldi G, Navarra A, Scrivo R, Mastroianni C, Sauzullo I, Esposito C, Palmieri F, Cantini F, **Goletti D**. Characterization of QuantiFERON-TB-Plus results in latent tuberculosis infected patients with or without immune-mediated inflammatory diseases. **J Infect.** 2019
230. Gualano G, Mencarini P, Musso M, Mosti S, Santangelo L, Murachelli S, Cannas A, Di Caro A, Navarra A, **Goletti D**, Girardi E, Palmieri F. Putting in harm to cure: Drug related adverse events do not affect outcome of patients receiving treatment for multidrug-resistant Tuberculosis. Experience from a tertiary hospital in Italy. **PLoS One.** 2019 Feb **28**;14(2):e0212948.
231. Santos VS, **Goletti D**, Kontogianni K, Adams ER, Molina-Moya B, Dominguez J, Crudu V, Martins-Filho PRS, Ruhwald M, Lawson L, Bimba JS, Garcia-Basteiro AL, Petrone L, Kabeer BS, Reither K, Cuevas LE. Acute phase proteins and IP-10 as triage tests for the diagnosis of tuberculosis: systematic review and meta-analysis. **Clin Microbiol Infect.** 2019 Feb;**25**(2):169-177.
232. Coluzzi F, Meniconi RL, Caruso D, Rivosecchi F, Petrone L, **Goletti D**, Ettore GM. Severe chest allodynia as an unusual first presentation of hydatid disease: a case report. **BMC Infect Dis.** 2019 Jan 9;**19**(1):37. doi: 10.1186/s12879-019-3670-7.
233. De Maio F, Battah B, Palmieri V, Petrone L, Corrente F, Salustri A, Palucci I, Bellesi S, Papi M, Rubino S, Sali M, **Goletti D**, Sanguinetti M,

- Manganelli R, De Spirito M, Delogu G. PE_PGRS3 of Mycobacterium tuberculosis is specifically expressed at low phosphate concentration, and its arginine-rich C-terminal domain mediates adhesion and persistence in host tissues when expressed in Mycobacterium smegmatis. *Cell Microbiol.* 2018 Dec;20(12):e12952. doi: 10.1111/cmi.12952. Epub 2018 Sep 26. PubMed PMID: 30192424.
234. Goletti D, Lindestam Arlehamn CS, Scriba TJ, Anthony R, Cirillo DM, Alonzi T, Denking CM, Cobelens F. Can we predict tuberculosis cure? What tools are available? *Eur Respir J.* 2018 Nov 8;52(5). pii: 1801089. doi: 10.1183/13993003.01089-2018. Print 2018 Nov. Review. PubMed PMID: 30361242.
235. De Maio F, Squeglia F, Goletti D, Delogu G. The Mycobacterial HBHA Protein: a Promising Biomarker for Tuberculosis. *Curr Med Chem.* 2018 Oct 29. doi: 10.2174/0929867325666181029165805. [Epub ahead of print] PubMed PMID: 30378481.
236. Sali M, Buonsenso D, D'Alfonso P, De Maio F, Ceccarelli M, Battah B, Palucci I, Chiacchio T, Goletti D, Sanguinetti M, Valentini P, Delogu G. Combined use of Quantiferon and HBHA-based IGRA supports tuberculosis diagnosis and therapy management in children. *J Infect.* 2018 Sep 26. pii: S0163-4453(18)30284-6.
237. De Maio F, Battah B, Palmieri V, Petrone L, Corrente F, Salustri A, Palucci I, Bellesi S, Papi M, Rubino S, Sali M, Goletti D, Sanguinetti M, Manganelli R, De Spirito M, Delogu G. PE_PGRS3 of Mycobacterium tuberculosis is specifically expressed at low phosphate concentration, and its arginine-rich C-terminal domain mediates adhesion and persistence in host tissues when expressed in Mycobacterium smegmatis. *Cell Microbiol.* 2018 Sep 7:e12952.
238. Petrone L, Bondet V, Vanini V, Cuzzi G, Palmieri F, Palucci I, Delogu G, Ciccocanti F, Fimia GM, Blauenfeldt T, Ruhwald M, Duffy D, Goletti D. First description of agonist and antagonist IP-10 in urine of patients with active TB. *Int J Infect Dis.* 2018 Sep 7. pii: S1201-9712(18)34513-2.
239. Kik SV, Schumacher S, Maria Cirillo D, Churchyard G, Boehme C, Goletti D, Rangaka MX, Denking CM, Lienhardt C, Gilpin C, Matteelli A, Cobelens F. An evaluation framework for new tests that predict progression from tuberculosis infection to clinical disease. *Eur Respir J.* 2018
240. Santos VS, Goletti D, Kontogianni K, Adams ER, Molina-Moya B, Dominguez J, Crudu V, Martins-Filho PRS, Ruhwald M, Lawson L, Bimba JS, Garcia-Basteiro AL, Petrone L, Kabeer BS, Reither K, Cuevas LE. Acute phase proteins and IP-10 as triage tests for the diagnosis of tuberculosis: systematic review and meta-analysis. *Clin Microbiol Infect.* 2018 Aug 2. pii: S1198-743X(18)30535-4.
241. Blauenfeldt T, Petrone L, Del Nonno F, Baiocchi A, Falasca L, Chiacchio T, Bondet V, Vanini V, Palmieri F, Galluccio G, Casrouge A, Eugen-Olsen J, Albert ML, Goletti D, Duffy D, Ruhwald M. Interplay of DDP4 and IP-10 as a Potential Mechanism for Cell Recruitment to Tuberculosis Lesions. *Front Immunol.* 2018 Jul 5;9:1456. doi: 10.3389/fimmu.2018.01456. eCollection 2018. PubMed PMID: 30026741; PubMed Central PMCID: PMC6041415.
242. Petrone L, Vanini V, Chiacchio T, Petruccioli E, Cuzzi G, Schinà V, Palmieri F, Ippolito G, Goletti D. Evaluation of IP-10 in Quantiferon-Plus as biomarker for the diagnosis of latent tuberculosis infection. *Tuberculosis (Edinb).* 2018 Jul;111:147-153. doi: 10.1016/j.tube.2018.06.005. Epub 2018 Jun 12. PubMed PMID: 30029901.
243. Andrade JM, Custódio L, Romagnoli A, Reis CP, Rodrigues MJ, Garcia C, Petruccioli E, Goletti D, Faustino C, Fimia GM, Rijo P. Antitubercular and anti-inflammatory properties screening of natural products from Plectranthus species. *Future Med Chem.* 2018 Jun 29.
244. Schinà V, Albarello F, Cristofaro M, Di Stefano F, Fusco N, Cuzzi G, Arend SM, Goletti D, Busi Rizzi E. Diagnostic imaging of hepatic tuberculosis: case series. *Int J Tuberc Lung Dis.* 2018 Jul 1;22(7):779-787.
245. Orlando V, La Manna MP, Goletti D, Palmieri F, Lo Presti E, Joosten SA, La Mendola C, Buccheri S, Ottenhoff THM, Dieli F, Caccamo N. Human CD4 T-Cells With a Naive Phenotype Produce Multiple Cytokines During Mycobacterium Tuberculosis Infection and Correlate With Active Disease. *Front Immunol.* 2018 May 23;9:1119.
246. Goletti D, Petrone L, Ippolito G, Niccoli L, Nannini C, Cantini F. Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs. *Expert Rev Anti Infect Ther.* 2018 Jun 12:1-12.
247. Romagnoli A, Petruccioli E, Palucci I, Camassa S, Carata E, Petrone L, Mariano S, Sali M, Dini L, Girardi E, Delogu G, Goletti D, Fimia GM. Clinical isolates of the modern Mycobacterium tuberculosis lineage 4 evade host defense in human macrophages through eluding IL-1 β -induced autophagy. *Cell Death Dis.* 2018 May 24;9(6):624.
248. Chiacchio T, Petruccioli E, Vanini V, Cuzzi G, Manna MP, Orlando V, Pinetti C, Sampaoli A, Antinori A, Caccamo N, Goletti D. Impact of antiretroviral and tuberculosis therapies on CD4(+) and CD8(+) HIV/M. tuberculosis-specific T-cell in co-infected subjects. *Immunol Lett.* 2018 Apr 7.
249. Goletti D, Montesano C, Mattei M, Migliori GB. Professor Massimo Amicosante, 1968-2017. *Int J Tuberc Lung Dis.* 2018 Feb 1;22(2):236. doi: 10.5588/ijtld.17.0772.
250. Carvalho I, Goletti D, Manga S, Silva DR, Manissero D, Migliori G. Managing latent tuberculosis infection and tuberculosis in children. *Pulmonology.* 2018 Mar - Apr;24(2):106-114. doi: 10.1016/j.rppnen.2017.10.007.
251. Baddley JW, Cantini F, Goletti D, Gómez-Reino JJ, Mylonakis E, San-Juan R, Fernández-Ruiz M, Torre-Cisneros J. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumour necrosis factor- α agents). *Clin Microbiol Infect.* 2018 Feb 6. pii: S1198-743X(18)30030-2. doi: 10.1016/j.cmi.2017.12.025.
252. Goletti D, Lee MR, Wang JY, Walter N, Ottenhoff THM. Update on tuberculosis biomarkers: From correlates of risk, to correlates of active disease and of cure from disease. *Respirology.* 2018 Feb 18. doi: 10.1111/resp.13272.
253. Paolino M, Brindisi M, Vallone A, Butini S, Campiani G, Nannicini C, Giuliani G, Anzini M, Lamponi S, Giorgi G, Sbardella D, Ferraris DM, Marini S, Coletta M, Palucci I, Minerva M, Delogu G, Peponi I, Goletti D, Cappelli A, Gemma S, Brogi S. Development of Potent Inhibitors of the Mycobacterium tuberculosis Virulence Factor Zmp1 and Evaluation of Their Effect on Mycobacterial Survival inside Macrophages. *ChemMedChem.* 2018 Mar 6;13(5):422-430. doi: 10.1002/cmdc.201700759. Epub 2018 Feb 14. PubMed PMID: 29334428.

254. Parlato S, Chiacchio T, Salerno D, Petrone L, Castiello L, Romagnoli G, Canini I, **Goletti D**, Gabriele L. Impaired IFN- α -mediated signal in dendritic cells differentiates active from latent tuberculosis. **PLoS One**. 2018 Jan 10;13(1):e0189477. doi: 10.1371/journal.pone.0189477. eCollection 2018.h
255. Palucci I, Matic I, Falasca L, Minerva M, Maulucci G, De Spirito M, Petruccioli E, **Goletti D**, Rossin F, Piacentini M, Delogu G. Transglutaminase type 2 plays a key role in the pathogenesis of Mycobacterium tuberculosis infection. **J Intern Med**. 2017 Dec 4. doi: 10.1111/joim.12714.
256. Linda Petrone, Valentina Vanini, Massimo Amicosante, Angela Corpolongo, Maria Angeles Gomez Morales, Alessandra Ludovisi, Giuseppe Ippolito, Edoardo Pozio, Antonella Teggi, **Delia Goletti**. **Parasite Immunology**, 2017
257. Kaufmann SHE, Dockrell HM, Drager N, Ho MM, McShane H, Neyrolles O, Ottenhoff THM, Patel B, Roordink D, Spertini F, Stenger S, Thole J, Verreck FAW, Williams A; **TBAC2020 Consortium**. **TBAC2020**: Advancing Tuberculosis Vaccines from Discovery to Clinical Development. **Front Immunol**. 2017 Oct 4;8:1203.
258. Chiacchio T, Delogu G, Vanini V, Cuzzi G, De Maio F, Pinnetti C, Sampaulesi A, Antinori A, **Goletti D**. Immune characterization of the HBHA-specific response in Mycobacterium tuberculosis-infected patients with or without HIV infection. **PLoS One**. 2017 Aug 24;12(8):e0183846.
259. Jones A, Pitts M, Al Dulayymi JR, Gibbons J, Ramsay A, **Goletti D**, Gwenin CD, Baird MS. New synthetic lipid antigens for rapid serological diagnosis of tuberculosis. **PLoS One**. 2017 Aug 14;12(8):e0181414.
260. Petruccioli E, Vanini V, Chiacchio T, Cuzzi G, Cirillo DM, Palmieri F, Ippolito G, **Goletti D**. Analytical evaluation of QuantiFERON- Plus and QuantiFERON- Gold In-tube assays in subjects with or without tuberculosis. **Tuberculosis (Edinb)**. 2017 Sep;106:38-43.
261. Scriba TJ, Carpenter C, Carrasco Pro S, Sidney J, Musvosvi M, Rozot V, Seumois G, Rosales SL, Vijayanand P, **Goletti D**, Makgotlo E, Hanekom W, Hatherill M, Peters B, Sette A, Lindestam Arlehamn CS. Differential Recognition of Mtb-specific Epitopes as a Function of Tuberculosis Disease History. **Am J Respir Crit Care Med**. 2017 Jul 31. doi: 10.1164/rccm.201706-1208OC.
262. Cantini F, Nannini C, Niccoli L, Petrone L, Ippolito G, **Goletti D**. Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics. **Mediators Inflamm**. 2017;2017:8909834.
263. Bénet T, Sánchez Picot V, Messaoudi M, Chou M, Eap T, Wang J, Shen K, Pape JW, Rouzier V, Awasthi S, Pandey N, Bavdekar A, Sanghavi S, Robinson A, Rakoto-Andrianarivelo M, Sylla M, Diallo S, Nymadawa P, Naranbat N, Russomando G, Basualdo W, Komurian-Pradel F, Endtz H, Vanhems P, Paranhos-Baccalà G; Global Approach to Biological Research, Infectious diseases and Epidemics in Low-income countries (GABRIEL) Network. Microorganisms Associated With Pneumonia in Children <5 Years of Age in Developing and Emerging Countries: The GABRIEL Pneumonia Multicenter, Prospective, Case-Control Study. **Clin Infect Dis**. 2017
264. Solovic I, Abubakar I, Sotgiu G, Dara M, **Goletti D**, Duarte R, Aliberti S, de Benedictis FM, Ward B, Teixeira V, Gratzou C, Migliori GB. Standard operating procedures for tuberculosis care. **Eur Respir J**. 2017 Jun 1;49(6). pii: 1700515.
265. Petruccioli E, Scriba TJ, Petrone L, Hatherill M, Cirillo DM, Joosten SA, Codecasa LR, Ottenhoff TH, Denkiner CM, **Goletti D**. Long-lasting tuberculous pleurisy. **Eur Respir J**. 2017 May 25;49(5). pii: 1700356.
266. Camassa S, Palucci I, Iantomasi R, Cubeddu T, Minerva M, De Maio F, Jouny S, Petruccioli E, **Goletti D**, Ria F, Sali M, Sanguinetti M, Manganelli R, Rocca S, Brodin P, Delogu G. Impact of pe_pgrs33 Gene Polymorphisms on Mycobacterium tuberculosis Infection and Pathogenesis. **Front Cell Infect Microbiol**. 2017 Apr 21;7:137. doi: 10.3389/fcimb.2017.00137. eCollection 2017. Cantini F, Niccoli L, Nannini C, Cassarà E, Kaloudi O, Giulio Favalli E, Becciolini A, Benucci M, Gobbi FL, Guiducci S, Foti R, Mosca M, **Goletti D**. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. **Semin Arthritis Rheum**. 2017 Mar 22.
267. La Manna MP, Orlando V, Dieli F, Di Carlo P, Cascio A, Cuzzi G, Palmieri F, **Goletti D**, Caccamo N. Quantitative and qualitative profiles of circulating monocytes may help identifying tuberculosis infection and disease stages. **PLoS One**. 2017 Feb 16;12(2):e0171358.
268. Girardi E, Sañé Schepisi M, **Goletti D**, Bates M, Mwaba P, Yeboah-Manu D, Ntoumi F, Palmieri F, Maeurer M, Zumla A, Ippolito G. The global dynamics of diabetes and tuberculosis: the impact of migration and policy implications. **Int J Infect Dis**. 2017 Mar;56:45-53.
269. Petruccioli E, Chiacchio T, Pepponi I, Vanini V, Urso R, Cuzzi G, Barcellini L, Palmieri F, Cirillo DM, Ippolito G, **Goletti D**. Characterization of the CD4 and CD8 T-cell response in the QuantiFERON-TB Gold Plus kit. **Int J Mycobacteriol**. 2016 Dec;5 Suppl 1:S25-S26.
270. Petruccioli E, Vanini V, Chiacchio T, Cirillo DM, Palmieri F, Ippolito G, **Goletti D**. Modulation of interferon-gamma response to QuantiFERON-TB-plus detected by enzyme-linked immunosorbent assay in patients with active and latent tuberculosis infection. **Int J Mycobacteriol**. 2016 Dec;5 Suppl 1:S143-S144.
271. Chiacchio T, Petruccioli E, Pepponi I, Vanini V, Gualano G, Cirillo D, Palmieri F, Ippolito G, **Goletti D**. Modulation of CD4 and CD8 response to QuantiFERON-TB Plus in patients with active tuberculosis and latent tuberculosis infection followed over time during treatment. **Int J Mycobacteriol**. 2016 Dec;5 Suppl 1:S141-S142.
272. Matucci A, Cammelli D, Cantini F, **Goletti D**, Marino V, Milano GM, Scarpa R, Tocci G, Maggi E, Vultaggio A. Influence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative review. **Expert Opin Drug Saf**. 2016 Dec;15(sup1):3-10. PubMed PMID: 27924646.
273. Tocci G, **Goletti D**, Marino V, Matucci A, Milano GM, Cantini F, Scarpa R. Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis. **Expert Opin Drug Saf**. 2016 Dec;15(sup1):55-61. PubMed PMID: 27924645.
274. Bonovas S, Minozzi S, Lytras T, González-Lorenzo M, Pecoraro V, Colombo S, Polloni I, Moja L, Cinquini M, Marino V, **Goletti D**, Matucci A, Tocci G, Milano GM, Scarpa R, Cantini F. Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. **Expert Opin Drug Saf**. 2016 Dec;15(sup1):35-54. PubMed PMID: 27924644.
275. Minozzi S, Bonovas S, Lytras T, Pecoraro V, González-Lorenzo M, Bastiampillai AJ, Gabrielli EM, Lonati AC, Moja L, Cinquini M, Marino V, Matucci A, Milano GM, Tocci G, Scarpa R, **Goletti D**, Cantini F. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. **Expert Opin Drug Saf**. 2016 Dec;15(sup1):11-34. PubMed PMID: 27924643.

276. Petruccioli E, Scriba TJ, Petrone L, Hatherill M, Cirillo DM, Joosten SA, Ottenhoff TH, Denkinger CM, **Goletti D**. Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis. *Eur Respir J*. 2016 Nov 11. pii: ERJ-01012-2016. doi: 10.1183/13993003.01012-2016.
277. Barcellini L, Borroni E, Brown J, Brunetti E, Campisi D, Castellotti PF, Codecasa LR, Cugnata F, Di Serio C, Ferrarese M, **Goletti D**, Lipman M, Rancoita PM, Russo G, Tadolini M, Vanino E, Cirillo DM. First evaluation of QuantiFERON-TB Gold Plus performance in contact screening. *Eur Respir J*. 2016 Nov;48(5):1411-1419.
278. Petrone L, Cannas A, Vanini V, Cuzzi G, Aloï F, Nsubuga M, Sserunkuma J, Nazziwa RA, Jugheli L, Lukindo T, Girardi E, Antinori A, Pucci L, Reither K, **Goletti D**. Blood and urine inducible protein 10 as potential markers of disease activity. *Int J Tuberc Lung Dis*. 2016 Nov;20(11):1554-1561.
279. Polverino E, Bothamley GH, **Goletti D**, Heyckendorf J, Sotgiu G, Aliberti S. The best of respiratory infections from the 2015 European Respiratory Society International Congress. *ERJ Open Res*. 2016 Jul
280. Petruccioli E, Chiacchio T, Peponi I, Vanini V, Urso R, Cuzzi G, Barcellini L, Cirillo DM, Palmieri F, Ippolito G, **Goletti D**. First characterization of the CD4 and CD8 T-cell responses to QuantiFERON-TB Plus. *J Infect*. 2016
281. Delogu G, Vanini V, Cuzzi G, Chiacchio T, De Maio F, Battah B, Pinnetti C, Sampaioles A, Antinori A, **Goletti D**. Lack of response to HBHA in HIV-infected patients with latent tuberculosis infection. *Scand J Immunol*. 2016
282. Cirillo DM, Barcellini L, **Goletti D**. Preliminary data on precision of QuantiFERON-TB Plus performance. *Eur Respir J*. 2016 Sep;48(3):955-6.
283. Dara M, Solovic I, Sotgiu G, D'Ambrosio L, Centis R, Tran R, **Goletti D**, Duarte R, Aliberti S, de Benedictis FM, Bothamley G, Schaberg T, Abubakar I, Teixeira V, Ward B, Gratzou C, Migliori GB. Tuberculosis care among refugees arriving in Europe: a ERS/WHO Europe Region survey of current practices. *Eur Respir J*. 2016
284. Petruccioli E, Navarra A, Petrone L, Vanini V, Cuzzi G, Gualano G, Palmieri F, Girardi E, **Goletti D**. Use of several immunological markers to model the probability of active tuberculosis. *Diagn Microbiol Infect Dis*. 2016 Jun 14.
285. **Goletti D**, Petruccioli E, Joosten SA, Ottenhoff TH. Tuberculosis Biomarkers: From Diagnosis to Protection. *Infect Dis Rep*. 2016 Jun 24;8(2):6568.
286. Barcellini L, Borroni E, Brown J, Brunetti E, Campisi D, Castellotti PF, Codecasa LR, Cugnata F, Di Serio C, Ferrarese M, **Goletti D**, Lipman M, Rancoita PM, Russo G, Tadolini M, Vanino E, Cirillo DM. First evaluation of QuantiFERON-TB Gold Plus performance in contact screening. *Eur Respir J*. 2016 Jul 7.
287. Dara M, Solovic I, **Goletti D**, Sotgiu G, Centis R, D'Ambrosio L, Ward B, Teixeira V, Gratzou C, Migliori GB. Preventing and controlling tuberculosis among refugees in Europe: more is needed. *Eur Respir J*. 2016 Jul;48(1):272-4.
288. Joosten SA, van Meijgaarden KE, Del Nonno F, Baiocchi A, Petrone L, Vanini V, Smits HH, Palmieri F, **Goletti D**, Ottenhoff TH. Patients with Tuberculosis Have a Dysfunctional Circulating B-Cell Compartment, Which Normalizes following Successful Treatment. *PLoS Pathog*. 2016 Jun 15;12(6):e1005687.
289. Vennarecci G, Manfredelli S, Guglielmo N, Laurenzi A, **Goletti D**, Ettore GM. Major liver resection for recurrent hydatid cyst of the liver after suboptimal treatment. *Updates Surg*. 2016 Apr 28.
290. Dara M, Solovic I, Sotgiu G, D'Ambrosio L, Centis R, **Goletti D**, Duarte R, Aliberti S, de Benedictis FM, Bothamley G, Schaberg T, Abubakar I, Ward B, Teixeira V, Gratzou C, Migliori GB. Call for urgent actions to ensure access to early diagnosis and care of tuberculosis among refugees: Statement of the European Respiratory Society and the European Region of the International Union Against Tuberculosis and Lung Disease. *Eur Respir J*. 2016 May;47(5):1345-7.
291. Barcellini L, Borroni E, Brown J, Brunetti E, Codecasa L, Cugnata F, Dal Monte P, Di Serio C, **Goletti D**, Lombardi G, Lipman M, Rancoita PM, Tadolini M, Cirillo DM. First independent evaluation of QuantiFERON-TB Plus performance. *Eur Respir J*. 2016 Feb 11.
292. Klionsky DJ, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy*. 2016 Jan 2;12(1):1-222. PubMed PMID: 26799652.
293. Boer MC, van Meijgaarden KE, **Goletti D**, Vanini V, Prins C, Ottenhoff TH, Joosten SA. KLRG1 and PD-1 expression are increased on T-cells following tuberculosis-treatment and identify cells with different proliferative capacities in BCG-vaccinated adults. *Tuberculosis (Edinb)*. 2016 Mar;97:163-71.
294. Cantini F, Niccoli L, Nannini C, Cassarà E, Kaloudi O, Giulio Favalli E, Becciolini A, Biggioggero M, Benucci M, Li Gobbi F, Grossi V, Infantino M, Meacci F, Manfredi M, Guiducci S, Bellando-Randone S, Matucci-Cerinic M, Foti R, Di Gangi M, Mosca M, Tani C, Palmieri F, **Goletti D**; Italian board for the Tailored BIOlogic therapy (ITABIO). Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. *Semin Arthritis Rheum*. 2015 Oct 22. pii: S0049-0172(15)00241-3.
295. Petrone L, Vanini V, Petruccioli E, Ettore GM, Schinina V, Busi Rizzi E, Ludovisi A, Corpolongo A, Ippolito G, Pozio E, Teggi A, **Goletti D**. Polyfunctional Specific Response to Echinococcus Granulosus Associates to the Biological Activity of the Cysts. *PLoS Negl Trop Dis*. 2015 Nov 17;9(11):e0004209.
296. Sali M, Buonsenso D, **Goletti D**, D'Alfonso P, Zumbo A, Fadda G, Sanguinetti M, Delogu G, Valentini P. Accuracy of QuantiFERON-TB Gold Test for Tuberculosis Diagnosis in Children. *PLoS One*. 2015 Oct 6;10(10):e0138952.
297. Petrone L, Cannas A, Aloï F, Nsubuga M, Sserunkuma J, Nazziwa RA, Jugheli L, Lukindo T, Girardi E, Reither K, **Goletti D**. Blood or Urine IP-10 Cannot Discriminate between Active Tuberculosis and Respiratory Diseases Different from Tuberculosis in Children. *Biomed Res Int*. 2015;2015:589471.
298. Carpenter C, Sidney J, Kolla R, Nayak K, Tomiyama H, Tomiyama C, Padilla OA, Rozot V, Ahamed SF, Ponte C, Rolla V, Antas PR, Chande A, Kenneth J, Laxmi S, Makgutho E, Vanini V, Ippolito G, Kazanova AS, Panteleev AV, Hanekom W, Mayanja-Kizza H, Lewinsohn D, Saito M,

- McElrath MJ, Boom WH, **Goletti D**, Gilman R, Lyadova IV, Scriba TJ, Kallas EG, Murali-Krishna K, Sette A, Lindestam Arlehamn CS. A side-by-side comparison of T cell reactivity to fifty-nine Mycobacterium tuberculosis antigens in diverse populations from five continents. **Tuberculosis (Edinb)**. 2015 Aug 1.
299. Petruccioli E, Petrone L, Vanini V, Cuzzi G, Navarra A, Gualano G, Palmieri F, Girardi E, **Goletti D**. Assessment of CD27 expression as a tool for active and latent tuberculosis diagnosis. **J Infect**. 2015 Aug 5.
300. Spinicci M, Mencarini J, **Goletti D**, Mantella A, Della Malva N, Bartoloni A, Bartalesi F. Discordance between the QuantiFERON-TB Gold In-Tube and Tuberculin Skin Test: need for a further step? **Eur Respir J**. 2015 Jul 23. pii: ERJ-00403-2015. doi: 10.1183/13993003.00403-2015.
301. Guggino G, Orlando V, Cutrera S, La Manna MP, Di Liberto D, Vanini V, Petruccioli E, Dieli F, **Goletti D**, Caccamo N. Granzyme A as a potential biomarker of Mycobacterium tuberculosis infection and disease. **Immunol Lett**. 2015 Aug;166(2):87-91. doi: 10.1016/j.imlet.2015.05.019.
302. El Daker S, Sacchi A, Tempestilli M, Carducci C, **Goletti D**, Vanini V, Colizzi V, Lauria FN, Martini F, Martino A. Granulocytic Myeloid Derived Suppressor Cells Expansion during Active Pulmonary Tuberculosis Is Associated with High Nitric Oxide Plasma Level. **PLoS One**. 2015 Apr 16;10(4):e0123772
303. Xia H, Wang X, Li F, Longuet C, Vernet G, **Goletti D**, Zhao Y, Lagrange PH. Diagnostic Values of the QuantiFERON-TB Gold In-Tube Assay Carried out in China for Diagnosing Pulmonary Tuberculosis. **PLoS One**. 2015 Apr 13;10(4):e0121021.
304. Lönnroth K, Migliori GB, Abubakar I, D'Ambrosio L, de Vries G, Diel R, Douglas P, Falzon D, Gaudreau MA, **Goletti D**, González Ochoa ER, LoBue P, Matteelli A, Njoo H, Solovic I, Story A, Tayeb T, van der Werf MJ, Weil D, Zellweger JP, Abdel Aziz M, Al Lawati MR, Aliberti S, Arrazola de Oñate W, Barreira D, Bhatia V, Blasi F, Bloom A, Bruchfeld J, Castelli F, Centis R, Chernob D, Cirillo DM, Colorado A, Dadu A, Dahle UR, De Paoli L, Dias HM, Duarte R, Fattorini L, Gaga M, Getahun H, Glaziou P, Gogvadze L, Del Granado M, Haas W, Järvinen A, Kwon GY, Mosca D, Nahid P, Nishikiori N, Nogueira I, O'Donnell J, Pace-Asciak A, Pompa MG, Popescu GG, Robalo Cordeiro C, Rønning K, Ruhwald M, Sculier JP, Simunović A, Smith-Palmer A, Sotgiu G, Sulis G, A Torres-Duque C, Umeki K, Uplekar M, van Weezenbeek C, Vasankari T, Vitillo RJ, Voniatos C, Wanlin M, Raviglione MC. Towards tuberculosis elimination: an action framework for low-incidence countries. **Eur Respir J**. 2015.
305. Zellweger JP, Sotgiu G, Block M, Dore S, Altet N, Blunski R, Bogyi M, Bothamley G, Bothe C, Codecasa L, Costa P, Dominguez J, Duarte R, Fløe A, Fresard I, García-García JM, **Goletti D**, Halm P, Hellwig D, Henninger E, Heykes-Uden H, Horn L, Kruczak K, Latorre I, Pache G, Rath H, Ringshausen FC, Seminario Ruiz A, Solovic I, de Souza-Galvão ML, Widmer U, Witte P, Lange C; TBNET. Risk Assessment of Tuberculosis in Contacts by Interferon-γ Release Assays (IGRAs). A TBNET Study. **Am J Respir Crit Care Med**. 2015
306. Sañé Schepisi M, Parracino MP, Mammone A, Bellagamba R, Pinnetti C, Cicalini S, Sampaolesi A, Ammassari A, **Goletti D**, Girardi E. Immune Status and Serial Quantiferon-TB Gold In-Tube Screening for Latent Mycobacterium tuberculosis Infection Among HIV-Infected Persons in a Country With a Low Tuberculosis Incidence. **J Infect Dis**. 2015 Jan 26.
307. Cantini F, Nannini C, Niccoli L, Iannone F, Delogu G, Garlaschi G, Sanduzzi A, Matucci A, Prignano F, Conversano M, **Goletti D**; on behalf of SAFEBO (Italian multidisciplinary task force for screening of tuberculosis before and during biologic therapy). Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. **Autoimmun Rev**. 2015 Jan 21. pii: S1568-9972(15)00026-9.
308. Petrone L, Vanini V, Petruccioli E, Ettore GM, Busi Rizzi E, Schinà V, Girardi E, Ludovisi A, Gómez-Morales MA, Pozio E, Teggi A, **Goletti D**. IL-4 specific-response in whole blood associates with human Cystic Echinococcosis and cyst activity. **J Infect**. 2014 Oct 22.
309. Rozot V, Patrizia A, Viganò S, Mazza-Stalder J, Idrizi E, Day CL, Perreau M, Lazor-Blanchet C, Ohmiti K, **Goletti D**, Bart PA, Hanekom W, Scriba TJ, Nicod L, Pantaleo G, Harari A. Combined Use of Mycobacterium tuberculosis-Specific CD4 and CD8 T-Cell Responses Is a Powerful Diagnostic Tool of Active Tuberculosis. **Clin Infect Dis**. 2014 Oct 31. pii: ciu795.
310. De Visser V, Sotgiu G, Lange C, Aabye MG, Bakker M, Bartalesi F, Brat K, Chee CB, Dheda K, Dominguez J, Eyuboglu F, Ghanem M, **Goletti D**, Dilektasli AG, Guglielmetti L, Koh WJ, Latorre I, Losi M, Polanova M, Ravn P, Ringshausen FC, Rumetshofer R, de Souza-Galvão ML, Thijsen S, Bothamley G, Bossink A; for the TBNET. False-negative interferon-γ release assay results in active tuberculosis: a TBNET study. **Eur Respir J**. 2014 Oct 30.
311. Sester M, van Leth F, Bruchfeld J, Bumbacea D, Cirillo DM, Dilektasli AG, Domínguez J, Duarte R, Ernst M, Eyuboglu FO, Gerogianni I, Girardi E, **Goletti D**, Janssens JP, Julander I, Lange B, Latorre I, Losi M, Markova R, Matteelli A, Milburn H, Ravn P, Scholman T, Soccia PM, Straub M, Wagner D, Wolf T, Yalcin A, Lange C; TBNET. Risk Assessment of Tuberculosis in Immunocompromised Patients. A TBNET Study. **Am J Respir Crit Care Med**. 2014 Nov 15;190(10):1168-76.
312. Cantini F, Boccia S, **Goletti D**, Iannone F, Leoncini E, Panic N, Prignano F, Gaeta GB. HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF-α) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis. **Int J Rheumatol**. 2014;2014:926836.
313. Chiacchio T, Petruccioli E, Vanini V, Cuzzi G, Pinnetti C, Sampaolesi A, Antinori A, Girardi E, **Goletti D**. Polyfunctional T-cells and effector memory phenotype are associated with active TB in HIV-infected patients. **J Infect**. 2014 Dec;69(6):533-45.
314. Lagrange PH, Thangaraj SK, Dayal R, Deshpande A, Ganguly NK, Girardi E, Joshi B, Katoch K, Katoch VM, Kumar M, Lakshmi V, Leportier M, Longuet C, Malladi SV, Mukerjee D, Nair D, Raja A, Raman B, Rodrigues C, Sharma P, Singh A, Singh S, Sodha A, Kabeer BS, Vernet G, **Goletti D**. A toolbox for tuberculosis (TB) diagnosis: an Indian multi-centric study (2006-2008); evaluation of serological assays based on PGL-Tb1 and ESAT-6/CFP10 antigens for TB diagnosis. **PLoS One**. 2014 May 5;9(5):e96367.
315. Cantini F, Boccia S, **Goletti D**, Iannone F, Leoncini E, Panic N, Prignano F, Gaeta GB. HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF-α) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis. **Int J Rheumatol**. 2014
316. Lagrange PH, Thangaraj SK, Dayal R, Deshpande A, Ganguly NK, Girardi E, Joshi B, Katoch K, Katoch VM, Kumar M, Lakshmi V, Leportier M, Longuet C, Malladi SV, Mukerjee D, Nair D, Raja A, Raman B, Rodrigues C, Sharma P, Singh A, Singh S, Sodha A, Kabeer BS, Vernet G,

- Goletti D.** A Toolbox for Tuberculosis (TB) Diagnosis: An Indian Multi-Centric Study (2006-2008); Evaluation of Serological Assays Based on PGL-Tb1 and ESAT-6/CFP10 Antigens for TB Diagnosis. **PLoS One.** 2014 May 5;9(5):e96367.
317. Cantini F, Prignano F, **Goletti D.** Restarting biologics and management of patients with flares of inflammatory rheumatic disorders or psoriasis during active tuberculosis treatment. **J Rheumatol Suppl.** 2014 May;91:78-82.
 318. Cantini F, Niccoli L, **Goletti D.** Tuberculosis Risk in Patients Treated with Non-Anti-Tumor Necrosis Factor- α (TNF- α) Targeted Biologics and Recently Licensed TNF- α Inhibitors: Data from Clinical Trials and National Registries. **J Rheumatol Suppl.** 2014 May;91:56-64.
 319. Cantini F, Niccoli L, **Goletti D.** Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. **J Rheumatol Suppl.** 2014 May;91:47-55.
 320. **Goletti D,** Sanduzzi A, Delogu G. Performance of the Tuberculin Skin Test and Interferon- γ Release Assays: An Update on the Accuracy, Cutoff Stratification, and New Potential Immune-based Approaches. **J Rheumatol Suppl.** 2014 May;91:24-31.
 321. Delogu G, **Goletti D.** The spectrum of tuberculosis infection: new perspectives in the era of biologics. **J Rheumatol Suppl.** 2014 May;91:11-6.
 322. Cantini F, **Goletti D.** Biologics and tuberculosis risk: the rise and fall of an old disease and its new resurgence. **J Rheumatol Suppl.** 2014 May;91:1-3.
 323. Lange C, Abubakar I, Alffenaar JW, Bothamley G, Caminero JA, Carvalho AC, Chang KC, Codecassa L, Correia A, Crudu V, Davies P, Dedicoat M, Drobniewski F, Duarte R, Ehlers C, Erkens C, **Goletti D,** Günther G, Ibraim E, Kampmann B, Kuksa L, de Lange W, van Leth F, van Lunzen J, Matteelli A, Menzies D, Monedero I, Richter E, Rüscher-Gerdes S, Sandgren A, Scardigli A, Skrahina A, Tortoli E, Volchenkov G, Wagner D, van der Werf MJ, Williams B, Yew WW, Zellweger JP, Cirillo DM; for the TBNET. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. **Eur Respir J.** 2014 Mar 23.
 324. Petrone L, Chiacchio T, Vanini V, Petruccioli E, Cuzzi G, Di Giacomo C, Pucci L, Montalbano M, Lionetti R, Testa A, Lapa D, Navarra A, Visco-Comandini U, **Goletti D.** High urine IP-10 levels associate with chronic HCV infection. **J Infect.** 2014 Feb 26. pii: S0163-4453(14)00044-9. doi: 10.1016/j.jinf.2014.02.008.
 325. Miotto P, Mwangoka G, Valente IC, Norbis L, Sotgiu G, Bosu R, Ambrosi A, Codecassa LR, **Goletti D,** Matteelli A, Ntinginya EN, Aloï F, Heinrich N, Reither K, Cirillo DM. miRNA Signatures in Sera of Patients with Active Pulmonary Tuberculosis. **PLoS One.** 2013 Nov 21;8(11):e80149.
 326. Petrone L, Cuzzi G, Colace L, Ettore GM, Busi-Rizzi E, Schinina V, Pucillo L, Angeletti C, Pane S, Di Caro A, Bordini E, Girardi E, Pozio E, Corpolongo A, Teggi A, Brunetti E, **Goletti D.** Cystic echinococcosis in a single tertiary care center in Rome, Italy. **Biomed Res Int.** 2013;2013:978146.
 327. Dorhoi A, Iannaccone M, Farinacci M, Faé KC, Schreiber J, Moura-Alves P, Nouailles G, Mollenkopf HJ, Oberbeck-Müller D, Jörg S, Heinemann E, Hahnke K, Löwe D, Del Nonno F, **Goletti D,** Capparelli R, Kaufmann SH. MicroRNA-223 controls susceptibility to tuberculosis by regulating lung neutrophil recruitment. **J Clin Invest.** 2013 Oct 1.
 328. Lagrange PH, Thangaraj SK, Dayal R, Deshpande A, Ganguly NK, Girardi E, Joshi B, Katoch K, Katoch VM, Kumar M, Lakshmi V, Leportier M, Longuet C, Malladi SV, Mukerjee D, Nair D, Raja A, Raman B, Rodrigues C, Sharma P, Singh A, Singh S, Sodha A, Kabeer BS, Vernet G, **Goletti D.** A Toolbox for Tuberculosis (TB) Diagnosis: An Indian Multicentric Study (2006-2008). Evaluation of QuantiFERON-TB Gold in Tube for TB Diagnosis. **PLoS One.** 2013 Sep 6;8(9):e73579.
 329. Petruccioli E, Petrone L, Vanini V, Sampaioles A, Gualano G, Girardi E, Palmieri F, **Goletti D.** IFN γ /TNF α specific-cells and effector memory phenotype associate with active tuberculosis. **J Infect.** 2013 Feb 24. doi:pii: S0163-4453(13)00028-5. 10.1016/j.jinf.2013.02.004.
 330. Rozot V, Vigano S, Mazza-Stalder J, Idrizi E, Day CL, Perreau M, Lazor-Blanchet C, Petruccioli E, Hanekom W, **Goletti D,** Bart PA, Nicod L, Pantaleo G, Harari A. Mycobacterium tuberculosis-specific CD8(+) T cells are functionally and phenotypically different between latent infection and active disease. **Eur J Immunol.** 2013 Mar 4. doi: 10.1002/eji.201243262.
 331. **Goletti D,** Petruccioli E, Romagnoli A, Piacentini M, Fimia GM. Autophagy in Mycobacterium tuberculosis infection: A passepartout to flush the intruder out? **Cytokine Growth Factor Rev.** 2013 Feb 7. doi:pii: S1359-6101(13)00003-8. 10.1016/j.cytogfr.2013.01.002. [Epub ahead of print] PubMed PMID: 23395260.
 332. Podlekareva DN, Grint D, Post FA, Mocroft A, Panteleev AM, Miller RF, Miro JM, Bruyand M, Furrer H, Riekstina V, Girardi E, Losso MH, Caylá JA, Malashenkov EA, Obel N, Skrahina AM, Lundgren JD, Kirk O; HIV-TB Study Group. Health care index score and risk of death following tuberculosis diagnosis in HIV-positive patients. **Int J Tuberc Lung Dis.** 2013 Feb;17(2):198-206. doi: 10.5588/ijtld.12.0224. PubMed PMID: 23317955.
 333. Giehl C, Lange C, Duarte R, Bothamley G, Gerlach C, Cirillo DM, Wagner D, Kampmann B, **Goletti D,** Juers T and Sester M. TBNET – COLLABORATIVE RESEARCH ON TUBERCULOSIS IN EUROPE. **European Journal of Microbiology and Immunology** 2012. 4, pp. 264–274. DOI: 10.1556/EuJMI.2.2012.4.4
 334. Bartalesi F, **Goletti D,** Spinicci M, Cavallo A, Attala L, Mencarini J, Fiori G, Li Gobbi F, Mantella A, Benucci M, Prignano F, Pimpinelli N, Matucci Cerinic M, Girardi E, Bartoloni A. Serial QuantiFERON TB-Gold in-tube testing during LTBI therapy in candidates for TNFi treatment. **J Infect.** 2012 Oct 24. doi:pii: S0163-4453(12)00303-9. 10.1016/j.jinf.2012.10.017.
 335. Lagrange PH, Thangaraj SK, Dayal R, Deshpande A, Ganguly NK, Girardi E, Joshi B, Katoch K, Katoch VM, Kumar M, Lakshmi V, Leportier M, Longuet C, Malladi SV, Mukerjee D, Nair D, Raja A, Raman B, Rodrigues C, Sharma P, Singh A, Singh S, Sodha A, Kabeer BS, Vernet G, **Goletti D.** A toolbox for tuberculosis diagnosis: an Indian multicentric study (2006-2008): microbiological results. **PLoS One.** 2012;7(8):e43739. Epub 2012 Aug 24.
 336. Romagnoli A, Etna MP, Giacomini E, Pardini M, Remoli ME, Corazzari M, Falasca L, **Goletti D,** Gafa V, Simeone R, Delogu G, Piacentini M, Brosch R, Fimia GM, Coccia EM. ESX-1 dependent impairment of autophagic flux by Mycobacterium tuberculosis in human dendritic cells. **Autophagy.** 2012 Sep 1;8(9):1357-70.

337. Greco E, Quintiliani G, Santucci MB, Serafino A, Ciccaglione AR, Marcantonio C, Papi M, Maulucci G, Delogu G, Martino A, **Goletti D**, Sarmati L, Andreoni M, Altieri A, Alma M, Caccamo N, Di Liberto D, De Spirito M, Savage ND, Nisini R, Dieli F, Ottenhoff TH, Fraziano M. Janus-faced liposomes enhance antimicrobial innate immune response in Mycobacterium tuberculosis infection. **Proc Natl Acad Sci U S A.** 2012 May 22;109(21):E1360-8.
338. Bumbacea D, Arend SM, Eyuboglu F, Fishman JA, **Goletti D**, Ison MG, Jones CE, Kampmann B, Kotton CN, Lange C, Ljungman P, Milburn H, Morris MI, Muller E, Muñoz P, Nellore A, Rieder HL, Sester U, Theodoropoulos N, Wagner D, Sester M. The risk of tuberculosis in transplant candidates and recipients: A TBNET consensus statement. **Eur Respir J.** 2012 Apr 10.
339. **Goletti D**, Sester M. Screening for latent infection with Mycobacterium tuberculosis: a plea for targeted testing in low endemic regions. **Expert Rev Mol Diagn.** 2012 Apr;12(3):231-4.
340. Vanini V, Petruccioli E, Gioia C, Cuzzi G, Orchi N, Rianda A, Alba L, Giancola ML, Conte A, Schinina V, Busi Rizzi E, Girardi E, **Goletti D**. IP-10 is an additional marker for tuberculosis (TB) detection in HIV-infected persons in a low-TB endemic country. **J Infect.** 2012 Jul;65(1):49-59.
341. Petruccioli E, Romagnoli A, Corazzari M, Coccia EM, Butera O, Delogu G, Piacentini M, Girardi E, Fimia GM, **Goletti D**. Specific T cells restore the autophagic flux inhibited by Mycobacterium tuberculosis in human primary macrophages. **J Infect Dis.** 2012 May;205(9):1425-35.
342. Laurenti P, Bruno S, Quaranta G, La Torre G, Cairo AG, Nardella P, Delogu G, Fadda G, Pirroni T, Geraci S, Pelargonio S, Lauria FN, **Goletti D**, Ricciardi G. Tuberculosis in sheltered homeless population of Rome: an integrated model of recruitment for risk management. **Scientific World Journal.** 2012;2012:396302.
343. Cingolani A, Cozzi Lepri A, Castagna A, **Goletti D**, De Luca A, Scarpellini P, Fanti I, Antinori A, d'Aminio Monforte A, Girardi E. Impaired CD4 T-cell count response to combined antiretroviral therapy in antiretroviral-naïve HIV-infected patients presenting with tuberculosis as AIDS-defining condition. **Clin Infect Dis.** 2012 Mar;54(6):853-61.
344. Chiacchio T, Petruccioli E, Vanini V, Butera O, Cuzzi G, Petrone L, Matteucci G, Lauria FN, Franken KL, Girardi E, Ottenhoff TH, **Goletti D**. Higher Frequency of T-Cell Response to *M. tuberculosis* Latency Antigen Rv2628 at the Site of Active Tuberculosis Disease than in Peripheral Blood. **PLoS One.** 2011;6(11):e27539.
345. Diel R, **Goletti D**, Lange C, Manissero D. Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection. **Eur Respir J.** 2011 Nov;38(5):1238-9.
346. Borgia P, Cambieri A, Chini F, Coltella L, Delogu G, Di Rosa E, Fadda G, Giorgi Rossi P, Girardi E, **Goletti D**, Guasticchi G, Morrone A, Pezzotti P, Romagnoli C, Sacerdote M, Russo C, Villani A, Zarelli L. Suspected transmission of tuberculosis in a maternity ward from a smear-positive nurse: preliminary results of clinical evaluations and testing of neonates potentially exposed, Rome, Italy, 1 January to 28 July 2011. **Euro Surveill.** 2011 Oct 6;16(40).
347. Busi Rizzi E, Schinina V, Cristofaro M, **Goletti D**, Palmieri F, Bevilacqua N, Lauria FN, Girardi E, Bibbolino C. Detection of Pulmonary tuberculosis: comparing MR imaging with HRCT. **BMC Infect Dis.** 2011 Sep 16;11:243.
348. Syed Ahamed Kabeer B, Raja A, Raman B, Thangaraj S, Leportier M, Ippolito G, Girardi E, Lagrange PH, **Goletti D**. IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy. **BMC Infect Dis.** 2011 May 19;11(1):135.
349. Delogu G, Chiacchio T, Vanini V, Butera O, Cuzzi G, Bua , Molicotti P, Zanetti S, Lauria FN, Grisetti S, Magnavita N, Fadda G, Girardi E, **Goletti D**. Methylated HBHA Produced in *M. smegmatis* Discriminates between Active and Non-Active Tuberculosis Disease among RD1-Responders. **PLoS ONE** 6(3): e18315, 2011.
350. Ruhwald M, Dominguez J, Latorre I, Losi M, Richeldi L, Pasticcini MB, Mazzolla R, **Goletti D**, Butera O, Bruchfeld J, Gaines H, Gerogianni I, Tuuminen T, Ferrara G, Eugen-Olsen J, Ravn P; on behalf of TBNET. A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with *M. tuberculosis*. **Tuberculosis.** 2011 May;91(3):260-267.
351. Cannas A, Calvo L, Chiacchio T, Cuzzi G, Vanini V, Lauria FN, Pucci L, Girardi E, **Goletti D**. IP-10 detection in urine is associated with lung diseases. **BMC Infect Dis.** 2010 Nov 22;10:333.
352. Diel R, **Goletti D**, Ferrara G, Bothamley G, Cirillo D, Kampmann B, Lange C, Losi M, Markova R, Migliori GB, Nienhaus A, Ruhwald M, Wagner D, Zellweger JP, Huitric E, Sandgren A, Manissero D. Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. **Eur Respir J.** 2011 Jan;37(1):88-99.
353. Girardi E, **Goletti D**. Do IFN-γ-release assays predict the risk of TB? New evidence from a study on patients with silicosis. **Expert Rev Anti Infect Ther** 2010 Oct;8(10):1105-8.
354. **Goletti D**, Raja A, Syed Ahamed Kabeer B, Rodrigues C, Sodha A, Carrara S, Vernet G, Longuet C, Ippolito G, Thangaraj S, Leportier M, Girardi E, Lagrange PH. Is IP-10 an accurate marker for detecting *M. tuberculosis*-specific response in HIV-infected persons? **PLoS One.** 2010 Sep 7;5(9):e12577.
355. Lange C, Bossink A, Eberhardt R, **Goletti D**, Jafari C, Latorre I, Kirsten D, Losi M, Migliori GB, Sotgiu G. Bronchoalveolar lavage immunodiagnosis for tuberculosis suspects in Europe and Africa. **Thorax.** 2010 Sep;65(9):842; author reply 842-3.
356. Sotgiu G, Centis R, D'ambrosio L, De Lorenzo S, D'arcy Richardson M, Lange C, Manissero D, Migliori GB; TBNET MDR-TB project. Development of a standardized tool to survey MDR-/XDR-TB case management in Europe. **Eur Respir J.** 2010 Jul;36(1):208-11.
357. Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, Kampmann B, Hellmich B, Groves R, Schreiber S, Wallis RS, Sotgiu G, Schölvinc EH, **Goletti D**, Zellweger JP, Diel R, Carmona L, Bartalesi F, Ravn P, Bossink A, Duarte R, Erkens C, Clark J, Migliori GB, Lange C. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. **Eur Respir J.** 2010 Nov;36(5):1185-206.
358. **Goletti D**, Raja A, Ahamed Kabeer BS, Rodrigues C, Sodha A, Butera O, Carrara S, Vernet G, Longuet C, Ippolito G, Thangaraj S, Leportier M, Girardi E, Lagrange PH. IFNγ, but not IP10, MCP2 or IL2 response to RD1 selected peptides associates to active tuberculosis. **J Infect.** 2010 May 11.

359. Butera O, Chiacchio T, Carrara S, Casetti R, Vanini V, Meraviglia S, Guggino G, Dieli F, Vecchi M, Lauria FN, Marruchella A, Laurenti P, Singh M, Caccamo N, Girardi E, **Goletti D**. New tools for detecting latent tuberculosis infection: evaluation of RD1-specific long-term response. **BMC Infect Dis.** 2009 Nov 21;9:182.
360. **Goletti D**, Butera O, Vanini V, Lauria FN, Lange C, Franken KL, Angeletti C, Ottenhoff TH, Girardi E. Response to Rv2628 latency antigen associates with cured tuberculosis and remote infection. **Eur Respir J.** 2009 Nov 19.
361. Podlekareva DN, Mocroft A, Post FA, Riekstina V, Miro JM, Furrer H, Bruyand M, Panteleev AM, Rakhmanova AG, Girardi E, Losso MH, Toibaro JJ, Caylá J, Miller RF, Obel N, Skrahina A, Chentsova N, Lundgren JD, Kirk O; HIV/TB Study Writing Group. Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina. **AIDS.** 2009 Nov 27;23(18):2485-95. **Multicenter study.**
362. Biselli R, Mariotti S, Sargentini V, Sauzullo I, Lastilla M, Mengoni F, Vanini V, Girardi E, **Goletti D**, D'Amelio R, Nisini R. Detection of IL-2 in addition to IFN-gamma discriminates active tuberculosis patients, latently infected individuals and controls. **Clin Microbiol Infect.** 2010 Aug;16(8):1282-4.
363. Girardi E, Angeletti C, Puro V, Sorrentino R, Magnavita N, Vincenti D, Carrara S, Butera O, Ciufoli AM, Squarcione S, Ippolito G, **Goletti D**. Estimating diagnostic accuracy of tests for latent tuberculosis infection without a gold standard among healthcare workers. **Euro Surveill.** 2009 Oct 29;14(43).
364. Leidl L, Mayanja-Kizza H, Sotgiu G, Baseke J, Ernst M, Hirsch C, **Goletti D**, Toossi Z, Lange C. Relationship of immunodiagnostic assays for tuberculosis and numbers of circulating CD4+ T-cells in HIV-infection. **Eur Respir J.** 2010 Mar;35(3):619-26.
365. Jafari C, Thijsen S, Sotgiu G, **Goletti D**, Benítez JA, Losi M, Eberhardt R, Kirsten D, Kalsdorf B, Bossink A, Latorre I, Migliori GB, Strassburg A, Winteroll S, Greinert U, Richeldi L, Ernst M, Lange C; Tuberculosis Network European Trialsgroup. Bronchoalveolar lavage enzyme-linked immunospot for a rapid diagnosis of tuberculosis: a Tuberculosis Network European Trialsgroup study. **Am J Respir Crit Care Med.** 2009 Oct 1;180(7):666-73. Sargentini V, Mariotti S, Carrara S, Gagliardi MC, Teloni R, **Goletti D**, Nisini R. Cytometric detection of antigen-specific IFN-gamma/IL-2 secreting cells in the diagnosis of tuberculosis. **BMC Infect Dis.** 2009 Jun 23;9:99.
366. Chiacchio T, Casetti R, Butera O, Vanini V, Carrara S, Girardi E, Di Mitri D, Battistini L, Martini F, Borsellino G, **Goletti D**. Characterization of regulatory T cells identified as CD4(+)CD25(high)CD39(+) in patients with active tuberculosis. **Clin Exp Immunol.** 2009 Jun;156(3):463-70. **nn**
367. Mack U, Migliori GB, Sester M, Rieder HL, Ehlers S, **Goletti D**, Bossink A, Magdorf K, Hölscher C, Kampmann B, Arend SM, Detjen A, Bothamley G, Zellweger JP, Milburn H, Diel R, Ravn P, Cobelens F, Cardona PJ, Kan B, Solovic I, Duarte R, Cirillo DM; C. Lange; TBNET. LTBI: latent tuberculosis infection or lasting immune responses to *M. tuberculosis*? A TBNET consensus statement. **Eur Respir J.** 2009 ay;33(5):956-73.
368. Bartalesi F, Vicidomini S, **Goletti D**, Fiorelli C, Fiori G, Melchiorre D, Tortoli E, Mantella A, Benucci M, Girardi E, Cerinic MM, Bartoloni A. QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. **Eur Respir J.** 2009 Mar;33(3):586-93. **Epub 2008**
369. Casetti R, Martino A, Sacchi A, Agrati C, **Goletti D**, Martini F. Do human gammadelta T cells respond to M tuberculosis protein antigens? **Blood.** 2008 Dec 1;112(12):4776-7; **author reply 4777**. **Goletti D** and GB Migliori. Respiratory Society. **Expert Reviews in Respiratory research,** 2008 Dec 1;2(6):707-711.
370. Casetti R, Martino A, Sacchi A, Agrati C, **Goletti D**, Martini F. Do human gammadelta T cells respond to M tuberculosis protein antigens? **Blood.** 2008 Dec 1;112(12):4776-7.
371. **Goletti D**, Stefania C, Butera O, Amicosante M, Ernst M, Sauzullo I, Vullo V, Cirillo D, Borroni E, Markova R, Drenska R, Dominguez J, Latorre I, Angeletti C, Navarra A, Petrosillo N, Lauria FN, Ippolito G, Migliori GB, Lange C, Girardi E. Accuracy of immunodiagnostic tests for active tuberculosis using single and combined results: a multicenter TBNET-Study. **PLoS ONE.** 2008;3(10):e3417.
372. Cannas A, **Goletti D**, Girardi E, Chiacchio T, Calvo L, Cuzzi G, Piacentini M, Melkonyan H, Umansky SR, Lauria FN, Ippolito G, Tomei LD. Mycobacterium tuberculosis DNA detection in soluble fraction of urine from pulmonary tuberculosis patients. **Int J Tuberc Lung Dis.** 2008; 12:146-51 **nnnnnnnnnn**
373. **Goletti D**, Carrara S, Mayanja-Kizza H, Baseke J, Mugerwa MA, Girardi E, Toossi Z. Response to *M. tuberculosis* selected RD1 peptides in Ugandan HIV-infected patients with smear positive pulmonary tuberculosis: a pilot study. **BMC Infectious Diseases** 2008; 8:11
374. **Goletti D**, Carrara s, Vincenti D, Girardi E. T cell responses to commercial *M. tuberculosis*-specific antigens in HIV-infected patients. **Clin Inf Dis** 2007; 45: 1652-54.
375. Palazzo R, Spensieri F, Massari M, Fedele G, Frasca L, Carrara S, **Goletti D**, Ausiello CM. In-house bulk and single cell antigen-specific whole blood Interferon-gamma assays for surveillance of *M. tuberculosis* infection. **Clin Vaccine Immunol,** 2007; 15:327-337.
376. Vincenti D, Carrara S, Butera O, Bizzoni F, Casetti R, Girardi E, **Goletti D**. Response to region of difference 1 (RD1) epitopes in human immunodeficiency virus (HIV)-infected individuals enrolled with suspected active tuberculosis: a pilot study. **Clin Exp Immunol.** 2007;150(1):91-8.
377. Girardi E, Loffredo M, Alessandrini A, Anzidei G, **Goletti D**. A two-step approach for screening contacts of active tuberculosis. **Infection.** 2007; 35(2):122-3.
378. **Goletti D**, Parracino MP, Butera O, Bizzoni F, Casetti R, Dainotto D, Anzidei G, Nisii C, Ippolito G, Poccia F, Girardi E. Isoniazid prophylaxis differently modulates T-cell responses to RD1-epitopes in contacts recently exposed to Mycobacterium tuberculosis: a pilot study. **Respir Res** 2007;8:5.
379. Girardi E, **Goletti D**, Ippolito G. Should individuals who are tuberculin skin test negative and positive to RD1-IFN-gamma assay receive preventive therapy? **Am J Respir Crit Care Med.** 2007 Jan 15;175(2):198-199.
380. **Goletti D**, Macchia I, Leone P, Pace M, Semicola L, Pavone-Cossut MR, Mayrella MT, Cafaro A, Ensoli B, Titti F. Innate anti-viral immunity is associated with the protection elicited by the simian immunodeficiency virus (SIV) live attenuated virus vaccine in cynomolgus monkeys. **Med Sci**

- Monit. 2006 Oct;12(10):BR330-40.**
381. **Goletti D.**, Butera O., Bizzoni F., et al. Selective effector or memory response of RD1-specific CD4+ T cells in patients with different stages of tuberculosis. **J Infect Dis**, 2006, 194:984-992
 382. **Goletti D**, Carrara S, Vincenti D, et al. Accuracy of an immune diagnostic assay based on RD1 selected epitopes for active tuberculosis in a clinical setting: a pilot study. **Clin Microbiol Infect**, 2006, 12:544-550.
 383. **Goletti D**, Vincenti D, Carrara S, et al. Selected RD1 peptides for active tuberculosis diagnosis: comparison of a gamma interferon whole-blood enzyme-linked immunosorbent assay and an enzyme-linked immunospot assay. **Clin Diagn Lab Immunol**. 2005, 12:1311-1316.
 384. Palmieri F, Cicalini S, Froio N, Busi Rizzi E, Macri G, **Goletti D**, Festa A, Petrosillo N. Pulmonary Cryptosporidiosis in an AIDS Patient: successful treatment with paromomycin plus azithromycin. **International Journal of STD&AIDS**, 2005, 189:624-633.
 385. Palmieri F, Petrosillo N, Paglia MG, Conte A, **Goletti D**, Pucillo LP, Menegon M, Sannella A, Severini C, Majori G. Genetic confirmation of quinine-resistant plasmodium falciparum malaria in a traveller from Mozambique, followed by a post-malaria neurological syndrome **Journal of Clinical Microbiology**, 2004, 42:5424-6.
 386. **Goletti D**, Carrara S, Vincenti D, Giacomini E, Fattorini L, Garbuglia AR, Capobianchi MR, Alonzi, Fimia GM, Federico M, Poli G and Coccia E. *Mycobacterium tuberculosis* inhibits Human Immunodeficiency Virus replication in monocyte-derived macrophages. **Journal Infectious Diseases**, 2004, 189:624-33.
 387. Carrara S, Vincenti D, Petrosillo N, Amicosante M, Girardi E, **Goletti D**. Use of a T-cell-based assay for monitoring efficacy of anti-tuberculosis therapy. **Clinical Infectious Diseases**, 2004, 38:754-6.
 388. Gioia C, Agrati C, **Goletti D**, Vincenti D, Carrara S, Amicosante M, Casarini M, Giosue S, Puglisi G, Rossi A, Colizzi V, Pucillo LP, Poccia F. Different cytokine production and effector/memory dynamics of $\alpha\beta$ + or $\gamma\delta$ + T-cell subsets in the peripheral blood of patients with active pulmonary tuberculosis. **Int J Immunopathol Pharmacol**, 2003;16:247-252.
 389. Vincenti D, Carrara S, De Mori P, Pucillo LP, Petrosillo N, Palmieri F, Armignacco O, Ippolito G, Girardi E, Amicosante M, **Goletti D**. Identification of early secretory antigen target-6 epitopes for the immunodiagnosis of active tuberculosis. **Mol Med**, 2003;9:105-11.
 390. Antonucci G, **Goletti D**, Lanini S, Girardi E, Loiacono O. HIV/HCV co-infection: putting the pieces of the puzzle together. **Cell Death Differ**, 2003 Suppl 1:S25-6.
 391. D'Offizi G, Ciapparani V, Gioia C, **Goletti D**, Agrati C, Pucillo LP, Narciso P, Poccia F. The loss of CMV-specific CD27(-) T-cell effectors in a patient with recurrences of CMV retinitis is independent of HIV-1 viremia. **Infection**. 2002;30:323-5.
 392. Martini F, Poccia F, **Goletti D**, Carrara S, Vincenti D, D'Offizi G, Agrati C, Ippolito G, Colizzi V, Pucillo LP, Montesano C. Acute human immunodeficiency virus replication causes a rapid and persistent impairment of Vgamma9Vdelta2 T cells in chronically infected patients undergoing structured treatment interruption. **J Infect Dis**. 2002;186:847-50.
 393. **Goletti D**, Kinter AL, Coccia EM, Battistini A, Petrosillo N, Ippolito G, Poli G. Interleukin (IL)-4 inhibits phorbol-ester induced HIV-1 expression in chronically infected U1 cells independently from the autocrine effect of endogenous tumour necrosis factor-alpha, IL-1beta, and IL-1 receptor antagonist. **Cytokine**. 2002;17:28-35.
 394. Gioia C, Agrati C, Casetti R, Cairo C, Borsellino G, Battistini L, Mancino G, **Goletti D**, Colizzi V, Pucillo LP, Poccia F. Lack of CD27-CD45RA-V gamma 9V delta 2+ T cell effectors in immunocompromised hosts and during active pulmonary tuberculosis. **J Immunol**. 2002;168:1484-9.
 395. Mariani F, **Goletti D**, Ciaramella A, Martino A, Colizzi V, Fraziano M. Macrophage response to *Mycobacterium tuberculosis* during HIV infection: relationships between macrophage activation and apoptosis. **Curr Mol Med**. 2001; 2:209-16.
 396. Andreoni M, **Goletti D**, Pezzotti P, Pozzetto A, Monini P, Sarmati L, Farchi F, Tisone G, Piazza A, Pisani F, Angelico M, Leone P, Citterio F, Ensoli B, Rezza G. Prevalence, incidence and correlates of HHV-8/KSHV infection and Kaposi's sarcoma in renal and liver transplant recipients. **J Infect**. 2001;43:195-9.
 397. Girardi E, **Goletti D**, Antonucci G, Ippolito G. Tuberculosis and HIV: a deadly interaction. **J Biol Regul Homeost Agents**. 2001 Jul-Sep;15:218-23.
 398. Monini P, Sirianni MC, Franco M, Vincenzi L, Topino S, **Goletti D**, Leone P, Leone P, Chiozzini C, Nicastrì E, Andreoni M, Borduagni O, Sgadari C, Rezza G, Stürzl M, Ensoli B. Clearance of human herpesvirus 8 from blood and regression of leukopenia-associated aggressive classic Kaposi's sarcoma during interferon-alpha therapy: a case report. **Clin Infect Dis**. 2001;33:1782-5.
 399. Petrosillo N, Pellicelli AM, Cicalini S, Conte A, **Goletti D**, Palmieri F. Endocarditis caused by *Aspergillus* species in injection drug users. **Clin Infect Dis**. 2001;33:e97-9.
 400. Cafaro A, Titti F, Fracasso C, Mayrella MT, Baroncelli S, Caputo A, **Goletti D**, Borsetti A, Pace M, Fanales-Belasio E, Ridolfi B, Negri DR, Sernicola L, Belli R, Corrias F, Macchia I, Leone P, Michelini Z, ten Haaf P, Butto S, Verani P, Ensoli B. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). **Vaccine**. 2001;19:2862-77.
 401. Cafaro, A. Caputo, C. Fracasso, M.T. Mayrella, **D. Goletti**, S. Baroncelli, M. Pace, L. Semicola, M.L. Koanga-Mogtomo, M. Betti, A. Borsetti, R. Belli, L. Akerblom, F. Corrias, S. Butto, J. Heeney, P. Verani, F. Titti, B. Ensoli. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. **Nat Med** 5:643-50, 1999.
 402. Monini P, Colombini S, Stürzl M, **Goletti D**, Cafaro A, Sgadari C, Buttò S, Franco M, Leone P, Fais S, Leone P, Melucci-Vigo G, Chiozzini C, Carlini F, Ascherl G, Cornali E, Zietz C, Ramazzotti E, Ensoli F, Andreoni M, Pezzotti P, Rezza G, Yarchoan R, Gallo RC, Ensoli B. Reactivation and persistence of human herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in Kaposi's sarcoma. **Blood**. 1999 Jun 15;93(12):4044-58.

403. Monini P, Carlini F, Stürzl M, Rimessi P, Superti F, Franco M, Melucci-Vigo G, Cafaro A, **Goletti D**, Sgadari C, Butto' S, Leone P, Chiozzini C, Barresi C, Tinari A, Bonaccorsi A, Capobianchi MR, Giuliani M, di Carlo A, Andreoni M, Rezza G, Ensoli B. Alpha interferon inhibits human herpesvirus 8 (HHV-8) reactivation in primary effusion lymphoma cells and reduces HHV-8 load in cultured peripheral blood mononuclear cells. **J Virol.** 1999 May;73(5):4029-41.
404. **Goletti D**, Weissman D, Jackson RW, Collins F, Kinter A, Fauci AS. The in vitro induction of human immunodeficiency virus (HIV) replication in purified protein derivative-positive HIV-infected persons by recall antigen response to Mycobacterium tuberculosis is the result of a balance of the effects of endogenous interleukin-2 and proinflammatory and antiinflammatory cytokines. **J Infect Dis.** 1998 May;177(5):1332-8.
405. Ostrowski MA, Stanley SK, Justement JS, Gantt K, **Goletti D**, Fauci AS. Increased in vitro tetanus-induced production of HIV type 1 following in vivo immunization of HIV type 1-infected individuals with tetanus toxoid. **AIDS Res Hum Reoviruses.** 1997 Apr 10;13(6):473-80.
406. Kinter AL, Ostrowski M, **Goletti D**, Oliva A, Weissman D, Gantt K, Hardy E, Jackson R, Ehler L, Fauci AS. HIV replication in CD4+ T cells of HIV-infected individuals is regulated by a balance between the viral suppressive effects of endogenous beta-chemokines and the viral inductive effects of other endogenous cytokines. **Proc Natl Acad Sci U S A.** 1996 Nov 26;93(24):14076-81.
407. **Goletti D**, Weissman D, Jackson RW, Graham NM, Vlahov D, Klein RS, Munsiff SS, Ortona L, Cauda R, Fauci AS. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. **J Immunol.** 1996 Aug 1;157(3):1271-8.
408. **Goletti D**, Kinter AL, Hardy EC, Poli G, Fauci AS. Modulation of endogenous IL-1 beta and IL-1 receptor antagonist results in opposing effects on HIV expression in chronically infected monocytic cells. **J Immunol.** 1996 May 1;156(9):3501-8.
409. Biswas P, Smith CA, **Goletti D**, Hardy EC, Jackson RW, Fauci AS. Cross-linking of CD30 induces HIV expression in chronically infected T cells. **Immunity.** 1995 Jun;2(6):587-96.
410. **Goletti D**, Kinter AL, Biswas P, Bende SM, Poli G, Fauci AS. Effect of cellular differentiation on cytokine-induced expression of human immunodeficiency virus in chronically infected promonocytic cells: dissociation of cellular differentiation and viral expression. **J Virol.** 1995 Apr;69(4):2540-6.
411. Cauda R, **Goletti D**, Lucia MB, Tumbarello M, Rumi C, Orengo AM, Moretta A. Analysis of natural killer (NK) cell subsets defined by the expression of two novel surface antigens (EB6 and GL183) in AIDS and AIDS-related conditions. **Clin Immunol Immunopathol.** 1994 Mar;70(3):198-205.
412. Burastero SE, Lo Pinto G, **Goletti D**, Cutolo M, Burlando L, Falagiani P. Rheumatoid arthritis with monoclonal IgE rheumatoid factor. **J Rheumatol.** 1993 Mar;20(3):489-94.

data 16 08 2026

FIRMA

Autorizzo il trattamento dei dati personali ai sensi dell'art. 13 GDPR (UE 2016/679).

Delia Goletti